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A number of antiretroviral drugs that are currently in use for anti-HIV therapy have extremely poor 
aqueous solubility. This, along with the fact that many of these pharmaceutical compounds possess 
potential hydrogen bond donor and acceptor functionalities, makes them ideal candidates for 
attempted supramolecular derivatisation. The primary objective of this study was to carry out co-
crystal screening and attempt cyclodextrin complexation with nevirapine, efavirenz, lamivudine and 
zidovudine, with a view to identifying and isolating new solid forms of these drugs. Any new forms 
were to be characterised by a variety of analytical techniques, including thermal, spectroscopic and 
X-ray analysis and, where possible, such derivatives would be tested for any enhancements of drug 
solubility. 
Three novel co-crystals of nevirapine with carboxylic acid co-formers were isolated. Each could be 
prepared by a simple, rapid liquid-assisted grinding procedure and single crystals were grown by 
slow evaporation for subsequent X-ray structure elucidation. It was found that upon melting each of 
the co-crystals, the nevi rapine that had been co-crystallised was able to recrystallise as the original, 
anhydrous form. This is a rare phenomenon in co-crystal chemistry. Quite remarkably, the aqueous 
solubility of nevirapine for one of these co-crystals was shown to be five times greater than that of 
the untreated form of the drug. 
During liquid-assisted co-grinding for the purposes of co-crystal screening, efavirenz underwent 
phase transformations in several experiments. Subsequently, a very efficient liquid-assisted grinding 
method was developed for the preparation of a known polymorph of efavirenz. This preparative 
procedure has not been reported hitherto. 
Zidovudine was successfully included in ~-cyclodextrin and the complex characterised fully, both in 
the solid state (by single crystal X-ray diffraction) and in solution (by proton NMR spectroscopy). The 
association constant for the complex in solution was determined and it indicated that the host-guest 
interactions in water are extremely weak. By employing water-assisted kneading and powder X-ray 
diffraction analysis, y-cyclodextrin was also shown to form an inclusion complex with this active 
pharmaceutical ingredient. 
Two pharmaceutical salts and a ~-cyclodextrin inclusion complex of lamivudine were isolated and 
characterised. Furthermore, reaction products of lamivudine with glutaric acid and succinic acid 
were prepared and studied. The ~-cyclodextrin complex was found to crystallise in a unique packing 
arrangement. Both the solution- and solid-state behaviours of this complex were investigated by 
methods that included thermal analysis, X-ray diffraction analysis, isothermal titration calorimetry 
and proton NMR spectroscopy. 
A variety of nine new pharmaceutical salts, co-crystals and cyclodextrin inclusion complexes were 
prepared using the selected antiretroviral drugs. Of these, single crystal X-ray structures were 
determined for seven. A number of interesting novel results presented in this dissertation provide 










Chapter 1: Introduction 
Chapter 1: Introduction 
Supramolecular Modification of Pharmaceuticals 
It was Hermann Emil Fischer who in 1894 pre-empted the importance of supra molecular chemistry 
as a field of study when he used the analogy of a lock and key in describing the enzyme-substrate 
interaction. In 1987 Charles Pedersen, Donald Cram and Jean-Marie Lehn won the Nobel Prize for 
their work on crown ethers and cryptands, which could selectively bind metal cations, and this was a 
milestone that legitimised supramolecular chemistry as an independent field of research. 1 The crown 
ethers are simple cyclic arrays of ether groups, with organic spacers - anything from ethyl chains to 
bulkier groups like cyclohexyl or phenyl rings - and cryptands are effectively three-dimensional 
analogues of these.2 Lehn, who coined the term 'supramolecular chemistry', described the process 
of this research field's development as beginning with the selective binding of alkali metal cations by 
macrocyclic ligands (cryptands and crown ethers) and exploding with the arrival of synthetic 
receptor molecules.3 Some areas within the field rely heavily on large synthetic molecules while in 
other areas, commonly available small molecules are utilised with great success. 
More recently the term 'crystal engineering' has been used to describe the process of designing 
supramolecular assemblies. In an effort to predict and control the properties of a crystal, the 
molecular building blocks and conditions are chosen so that the process of assembly (crystallisation) 
occurs as desired .4 The two main principles are still molecular recognition and supra molecular 
function 1 so crystal engineers make use of their knowledge of hydrogen bond complementarity and 










Figure 1: Some highly prevalent supramolecular synthons. 
Supramolecular modification (or crystal engineering) of active pharmaceutical ingredients (APls) 
entails the harnessing of long-range interactions (particularly hydrogen bonds) for the preparation of 
new, superior solid forms. The motivation lies in the fact that many drugs with poor aqueous 
solubility are currently in development or in use and they are not ideal because of their potentially 
low or unpredictable bioavailability. To overcome such problems, a number of techniques have been 











Chapter 1: Introduction 
cyclodextrins and the preparation of salt forms are widely-employed, reliable strategies, examples of 
which are presented in this dissertation. The formation of pharmaceutical co-crystals is a more novel 
technique that is also exhibited here. There is evidence that through these types of modifications, 
chemists are able to enhance in particular dissolution and solubility - in some cases dramatically - as 
well as modify properties such as thermal stability. This study will refer to polymorphs and solvates 
but will focus on novel results related to co-crystals, salts and cyclodextrin inclusion complexes of 
some antiretroviral drugs. 
John Maddox's famous 1988 assertion that it is a "continuing scandal" that we are not able to 
predict how compounds will pack in the solid state based on their molecular structure6 is still very 
relevant today and partly the inspiration for this and other studies like it. While we are in pursuit 
here of improved physicochemical performance of a selection of antiretroviral drugs, this study 
serves also as an exploration of molecular behaviour, adding to the body of knowledge that will in 
time provide an understanding of how molecules collectively 'choose' a crystal packing arrangement 
and align themselves accordingly. 
Polymorphs and Solvates 
In an article entitled "Pharmaceutical Applications of Polymorphism", Haleblian and McCrone 
defined a polymorph as "a solid crystalline phase of a given compound resulting from the possibility 
of at least two different arrangements of the molecules of that compound in the solid state" . 
Polymorphs of a given molecule would be identical when converted to liquid or gaseous form, which 
distinguishes them from geometric isomers and tautomers.7 
Pharmaceutical polymorphs are of particular interest because different forms often exhibit different 
physicochemical properties, which translate into variations in bioavailability. Differences in thermal 
stability and aqueous solubility of closely-related polymorphs are of particular concern . Often the 
principal weak interactions are preserved between forms, depending on their robustness.s The case 
of the "elusive but predictable" polymorph of aspirin is an important example, where a very 
commonly used drug could exist as a different polymorph that had gone unidentified until 2005.9 
Even more important and relevant to this thesis is the example of ritonavir, where a commercial 
batch failed dissolution testing and was later identified as a conformational polymorph of the known 
form. This newly-discovered Form II was far less water-soluble than Form 1.10 
Joel Bernstein discusses the use of the term pseudopolymorph, which has in the past incorporated 
solvates and hydrates.ll The term solvate refers to a crystal that incorporates molecules of the 
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solvent.12 In most cases the solvent molecules form an integral part of the crystal and their removal 
causes the structure to collapse. The problem is that there are other cases in which the solvent may 
be removed easily and returned to the crystal without disrupting the host packing arrangement. A 
test to distinguish between these and genuine polymorphs is to check for bubbles upon heating, or 
to check for a loss of mass using thermogravimetric analysis.ll Pharmaceutical solvates are 
permissible where the solvent incorporated is not harmful or is present at non-toxic levels. Thus, 
hydrates are permissible and very common, and other potentially acceptable solvents are ethanol 
and acetone.13 
Pharmaceutical Salts 
A salt is usually the product of an acid-base reaction . The salt form of an organic substance has 
different physicochemical properties to those of the neutral compound . Pharmaceutical salts have 
been of interest for many years because of their ability to increase the dissolution and solubility of a 
drug.14 The standard method of pharmaceutical salt preparation is to dissolve the drug and salt 
former in a common solvent and recrystallise the salt product. A solution-based method that is used 
less commonly is salt exchange, where one of the components is already in salt form, while the 
other is still a free acid or base.1s Trask and co-workers demonstrated the effectiveness of neat 
grinding and solvent-drop grinding as alternative methods of salt screening and preparation.16 
A variety of important physicochemical considerations accompanies pharmaceutical salt selection. 
The salt form must preferably have a high degree of crystallinity, low hygroscopicity, and be stable 
under conditions of elevated temperature (40 °C) and high relative humidity (75 %).15 One must be 
sure that the salt will dissociate into its constituent free acid and base, which depends on factors 
such as the intrinsic solubility, solubility product and the pH of maximum solubility. An investigation 
of the effect of common ions is particularly important for basic drugs. 17 
In Serajuddin's consideration of salt forms approved by the FDA during 1995-2006, relatively strong 
acids were used in the salt forms of 77 % of basic APls. It appears that the more common carboxylic 
acids are usually suitable for salt formation of the majority of basic drugs.17 The development of salt 
forms is not always feasible, since the difference in pKa values of the drug and salt former must be, in 











Chapter 1: Introduction 
Pharmaceutical Co-crystals 
Definition 
An official definition of the term co-crystal still eludes us. This is the cause of a great deal of 
confusion, some of which was addressed in a series of letters during 2003-2007, published by 
Desiraju, Dunitz and Bond in CrystEngComm. Desiraju argued that the well-established term 
'molecular complex' is sufficient but that if we retain the term co-crystal, it should at least refer to 
multi-component crystals where some properties of the free components are still evident.18 Dunitz 
stated that the term molecular complex had been used for many years without appropriately 
specific reference to the crystalline state. It encompassed too broad a variety of entities that were 
solid, liquid or even gaseous at room temperature . He believed the term co-crystal (the hyphen 
essential) implied a crystal compriSing more than one component, that the class should encompass 
solvates, clathrates and inclusion compounds, and that the term would in any case "be difficult to 
displace" .19 Bond argued that there is no basis for the assertion that the term should refer to, in 
particular, a complex of which all components are solid at room temperature; that this additional 
burden is attributed to the term is "contrived and inappropriate". He prefers that co-crystal be used 
purely as a synonym for the term 'multi-component molecular crystal,.12 
In their definition of a co-crystal, Shan and Zaworotko have included the stipulation of the 
components being solid at room temperature because of certain practical implications. In particular, 
this detail distinguishes them from solvates (including hydrates), which are often less stable upon 
heating, and addresses the amenability of co-crystals to be discovered and prepared by solid-state 
methods, as will be discussed in a later section of this chapter. 
This thesis deals particularly with the subset of co-crystals called pharmaceutical co-crystals, where 
at least one of the components is a neutral API. Here, a narrowing of the definition is accepted, so 
that it includes the condition that any co-formers must be pharmaceutically acceptable.20 
Furthermore it is accepted to include only co-formers that are solids at room temperature for the 
reasons mentioned by Shan and Zaworotko,2l which are relevant to our co-crystal screening 
procedures. So, importantly, in this thesis the term co-crystal refers to a pharmaceutical co-crystal, 
which is taken to be a molecular complex incorporating a neutral API and at least one other 
component that is pharmaceutically acceptable and a solid at room temperature . 
Often, the components of a co-crystal are co-operatively hydrogen bonded and certainly in the 
engineering of co-crystals, it is usually necessary to make use of hydrogen bond complementarities. 
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(Figure 2) so that the starting components combine rather than separate (homomeric 
recrystallisation). In that sense, recrystallisation is used here in a very different way than in 
purification during molecular synthesis.22 
I ~ 
Figure 2: The difference between homomeric recrystallisation (above) and co-crystallisation (below). 
Utility 
Pharmaceutical co-crystals incorporate APls and non-drug partner molecules that are safe for 
consumption - usually meaning that the substance is on the FDA's list of Generally Regarded as Safe 
(GRAS) substances. This list includes food additives and pharmaceutical excipients. Having 
established that the molecules of a co-crystal must be in neutral, not ionic form, we have identified 
the main difference between these and pharmaceutical salts, since the formation of salts involves 
some kind of charge transfer. In this regard, it is very important, in crystallographic studies, to be 
able to unambiguously identify the position of acidic protons that may have been transferred during 
the preparative procedure. 
One of the main implications for the distinction between co-crystals and salts has been with regard 
to the rational design of new forms. It has been shown that the predictability of the form is reduced 
when proton transfer takes place. In other words, when a salt is formed, the resulting structure is 
often more complex than in similar cases where there has been no proton transfer. It may result in 
an obscure stoichiometry, the inclusion of solvent molecules and complex patterns of hydrogen 
bonding. One rationalisation has been the tendency of carboxylates to bond with multiple 
acceptors.23 
Regarding their usefulness, both salts and co-crystals provide new forms with potentially more 
desirable properties than the parent API. The main difference lies in the vastly greater possibilities 











compared with the unpredictability of salts. Importantly also, when compared with pharmaceutical 
salts, the number of possible co-crystals is vastly greater than the number of potential salt forms. 
This is because the primary requirement for obtaining a salt, is that the two starting components 
must engage in an acid-base reaction, and this is not a requirement for co-crystal formation. Thus, 
where the possibility of salt formation is limited for drugs that are not readily ionisable, this factor 
does not limit co-crysallisation formation at all. Also, the number of suitable co-formers often 
exceeds the number of potential salt formers for a given API.24 
Examples 
The majority of studies in co-crystallisation - even those involving APls - have not specifically 
involved pharmaceutically acceptable partner molecules.5 However, the realisation of their utility in 
producing superior formulations has resulted in studies with a more specific focus on discovering 
pharmaceutically viable co-crystals. Perhaps the first examples of crystal engineering of a 
pharmaceutically relevant organic compound were the studies on substituted barbituric acid 
conducted by ZerkowskL25 By varying the barbituric acid substituents and incorporating different 
melamine derivatives, over 60 different co-crystals were constructed with linear tape, crinkle tape 
and rosette tape motifs. The research demonstrated how relatively minor changes in the structure 
of self-assembling molecular building blocks affected the crystal architecture. 
In terms of strategy for the rational design of co-crystals, carbamazepine is an interesting example. 
Crystal engineers have used two approaches. The first was to engage the 'peripheral' groups with 
hydrogen bonding potential Le. to make use of available hydrogen bonding potential without 
disrupting the primary hydrogen bonding motif of the free drug. An example of how this was 
achieved with saccharin is shown in Figure 3. The second strategy was to compete directly with the 
amide-amide self-association of carbamazepine.21 Fleischman and co-workers reported a set of 13 
new mUlti-component crystalline phases of carbamazepine using this strategy. Most importantly, the 
group showed it was possible to produce a great variety of new forms with existing, commonly 
available compounds, where the greatest challenge was not to invent and synthesise but to choose 
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Figure 3: Carbamazepine-saccharin co-crystal reported by Fleischman et 01. 26 
Itraconazole was modified by co-crystallisation with dicarboxylic acids that belong to the FDA's list of 
GRAS compounds. The drug formed 2:1 complexes with similar hydrogen bonding motifs in the six 
co-crystals reported by Remenar's group.27 Importantly, the groups found that solvent-drug 
interactions played an important role in determining the success of co-crystallisation. The aqueous 
dissolution of the co-crystals was tested and it was found that the dissolution profiles were more 
similar to those of an amorphous form of the drug- than the crystalline form of itraconazole. For the 
co-crystals, the itraconazole solubility was enhanced 4-20 fold over that of the free crystalline form. 
Intellectual property 
The increasing prominence of pharmaceutical co-crystal research is also driven by the implications 
for intellectual property protection. For an invention to be considered worthy of patenting it must 
be novel, useful and non-obvious. The novelty aspect is no concern because pharmaceutical salts 
have for many years been considered patentable. Co-crystallisation has the potential to improve a 
variety of physicochemical properties and is still highly unpredictable (non-obvious). Thus, co-
crystals satisfy the basic criteria and the implication is that inventors must identify and protect co-
crystals in addition to useful polymorphs, solvates and salts of the drug. This is a mammoth task 
considering the 2000+ compounds that may be potential co-formers. 28 
Co-crystal Screening 
Recent activity in the area of co-crystal screening has incorporated various methods. All of the 
following have been used in varying degrees in high-throughput co-crystal screening. 
Dry co-grinding (or neat co-grinding) of the API and co-former involves combining the two, in a given 
molar ratio, in a mortar and grinding them together lightly for a recorded period of time. The 
process of grinding facilitates the reaction . It is considered an example of green chemistry because 
harmful organic solvents are not required. 












For liquid-assisted co-grinding (LAG), also called solvent-drop grinding or solvent-assisted grinding, a 
few drops of solvent are introduced during the grinding process. The solvent is usually one in which 
at least one of the components is partially soluble. There has been evidence to suggest that the 
solubility of one of the components lends itself to an increase in the rate of the supramolecular 
reaction, while a lack of solubility is less likely to result in a rate increase.29 
Co-precipitation from solution by various methods is most commonly carried out by the well-known 
slow evaporation method. Here a solution containing the API and co-former is allowed to evaporate 
slowly, yielding crystals after a period of hours to weeks. It is the most widely employed method of 
crystal growth and the main method used for co-crystal screening. Slow cooling may also be 
employed and this method is particularly useful for single crystal growth. The solution is prepared at 
high temperature and then slowly allowed to cool - over a period of hours or days - to control the 
recrystallisation. Vapour diffusion and layering are also useful when the above methods fail. 
Reaction co-crystallisation, also called the slurry method or solution-mediated phase transformation, 
is a method claimed to be a highly efficient way of screening for co-crystals.30,31 The difficulty with 
this procedure is that generally larger amounts of starting material are required than for the grinding 
methods and the solvent effect is still not fully accounted for. If the co-crystal is more soluble than 
the components, which it may well be, then this will not be effective. 
There is no protocol accepted to produce the best results for any given API and co-former. Effective 
protocols have been varying combinations of the above methods. In some reported cases, several 
co-crystals have been produced by both grinding and slow evaporation.20 However, there have also 
been reports of co-crystals that could only be prepared by one of the two methods or where 
different co-crystals resulted from grinding and slow evaporation.32,33 Herein, a recent paper 
detailing an industrially relevant protocol was used as a guide for the co-crystal screening of the 
a ntiretrovira Is.34 
For a co-crystal to form, it requires complementarity of the hydrogen bonding groups and 
conformational flexibility of the drug. To illustrate the generally low rates of success with co-crystal 
screening, observe a particularly rewarding example, that of carbamazepine. While the hit rate was 
considered very high, a variety of screening experiments incorporated 50 co-crystal formers (not 
necessarily GRAS) and produced only 10 new co-crystals. Most drugs produce hit rates far lower 












Considerations of pKa 
Predictions of whether the resultant species of reaction between an API and co-former will be a salt 
or a co-crystal have been based on the value of ~pKa where ~pKa= pKa(base) - pKa(acid). It has been 
shown that the outcome is reasonably predictable when ~pKa < a (most likely a co-crystal) or 
~pKa > 3 (most likely a salt), but when a < ~pKa < 3 it is not possible to predict co-crystal or salt 
formation, and there is the added complication that there exists a type of continuum between these 
extremes. The phenomenon of 'shared' protons may result, where the proton is not fully transferred 
but exists at an intermediate position between the acidic and basic components. 35 In other words, 
there may be a statistical distribution within the crystal between the cases of protons transferred 
and retained. 
Cyclodextrin Inclusion 
Cyclodextrins (CDs) are macrocyclic oligosaccharides derived from an enzymatic process involving 
cyclodextrin glucosyl transferase. These compounds were first described by A. Villiers in 1891 after 
he isolated them from starch, calling them 'cellulosine' .36 However, it is Franz Schardinger who is 
widely regarded as having laid the foundation for cyclodextrin chemistry by demonstrating that the 
occurrence of what he called tla and ~ dextrin" in the bacterial digest of Bacillus macerans was 
largely independent of the type of starch substrate used. During the period 1935-1954, the 
combined work of Freudenberg, Jacobi and Cramer (among others) served to identify the three main 
naturally occurring cyclodextrins and to fully characterise their physicochemical properties and 
molecular structure. Chemists also became aware of the ability of cyclodextrins to both stabilise and 
destabilise chemically labile compounds, solubilise lipophilic compounds and to complex organic 
guest molecules.37 
Structural features and properties 
CDs are made up D-glucopyranoside units, linked by a-l,4-glycosidic bonds (Figure 4). The group of 
a-, ~- and y-CD occur naturally and are referred to as the native, parent or first-generation 
cyclodextrins. They are made up of six, seven and eight glucopyranoside units, respectively. There 
are also derivatised forms. A number of modified cyclodextrins have also been synthetically 
produced. Most commonly, they have been derivatised by substitution at the hydroxyl groups. The 
ones of interest in this study are dimethylated ~-CD (DIMEB), trimethylated ~-CD (TRIMEB), 
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b 
Figure 4: (a) I3-CO with seven glucose units, (b) the truncated cone shape. Reproduced from reference 42. 
The cyclodextrins are often represented as a truncated cones (Figure 4). The primary rim is the 
narrow end of the torus, where the -CH 20H groups are located . The wider secondary rim is made up 
of secondary hydroxyl groups. These engage in intramolecular O-H" 'O hydrogen bonding to form a 
'belt' that stabilises the shape of the cyclodextrin, which would otherwise be far less rigid.38 The 
positioning of these hydroxyl groups at both surfaces is responsible for the fact that the outer 
portion is hydrophilic and the cavity of the CD is hydrophobic. It is this feature in particular that 
makes them well-suited to inclusion complexation of hydrophobic molecules or large molecules with 
a hydrophobic portion. Figure 5 is a molecular structure of a glucopyranoside unit with conventional 
labelling. The hydroxyl groups of the primary rim are referred to the OH6 hydroxyls and those of the 
secondary rim the OH2 and OH3 groups. The oxygen atom of the glycosidic linker is 04 and the one 













Figure 5: Glucopyranoside unit with carbon atoms labelled conventionally. The index n is equal to 6, 7 or 8 for a-, 13- and 
y-CO, respectively. 
Properties of the cyclodextrins used in this study are provided in Table 1. Of particular relevance is 
the difference in aqueous solubility. The reason that ~-CD has a much lower solubility than both a-
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the aqueous solvent cage because of its even number of hydrogen bond donors and acceptors. Also, 
the hydrogen bonding belt at the secondary rim limits the hydroxyl-water interactions, whereas for 
a- and V-CD, this belt of hydrogen bonds is incomplete so the hydroxyl groups are more accessible. 
Herein also lies the main reason why the derivatised ~-CDs have particularly high aqueous solubility 
- on average > 500 mg cm-3 at 25 0c.39 The derivatised CDs become less soluble at elevated 
temperature, so co-precipitation experiments with these are usually conducted at 60°C. 
Table 1: Properties of the native cyclodextrins. 36,40 
Property a-CD (3-CD V-CD 
Molecular mass (g morl ) 972 1135 1297 
Aqueous solubility at 25 ·C (mg cm-3) 145 18.5 232 
Diameter of cavity (A) 4.7-5.3 6.0-6.5 7.5-8.3 
Outer diameter (A) 14.6 15.4 17.5 
Cavity Volume (A3) 174 262 472 
Mean K for 1:1 complexes 130(8) 490(8) 350(9) 
Inclusion complexes 
An inclusion complex involves a host molecule and a smaller guest molecule, where the guest is 
included within the host cavity by non-covalent forces.4l For a cyclodextrin inclusion complex to 
form, the cavity must of course be large enough to accommodate the guest but it is possible for 
larger molecules to form complexes by insertion of certain groups or side chains. Important also is 
the polarity of the guest molecule. Hydrophobic molecules usually form more stable complexes, 
while polar molecules that are highly water-soluble are less amenable to inclusion. Similarly it has 
been shown that ionic forms of a guest form weaker complexes than the neutral molecule.42 
Interestingly these inclusion complexes may form stereoselectively and chemically unstable 
compounds may be stabilised against photosensitivity or oxidation by complexation. Cyclodextrins 
have also been useful in masking bad smells and tastes, and increasing the aqueous solubility of 
hydrophobic compounds.43 
Cyclodextrin complexes may be prepared by a variety of methods including dry kneading, water-
assisted kneading, co-precipitation by slow cooling and co-precipitation at elevated temperature . 
The dry kneading method is exactly the same as was described for co-crystals, where the 
cyclodextrin and guest compounds are simply ground together so that the powdered materials are 
mixed intimately. Water may be added to facil itate the inclusion reaction . Depending on the nature 
of the guest and the quantities used, the complex formation may be complete after a few minutes or 
as many as several hours of kneading. The slow cooling method is particularly useful when 
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obtained by normal slow evaporation are often very small, while slow cooling tends to yield large, 
single crystals more frequently. 
Crystal packing 
Two major patterns of cyclodextrin crystal packing have been recognised and examples of both are 
illustrated in Figure 6. The cage type pattern has the cyclodextrin cavities shut off from one another. 
In these crystals, a guest molecule in one cavity is not able to interact with guests in other cavities. 
The two typical examples of cage type packing are the herringbone arrangement and brickwork 
arrangements. 
The channel type patterns are broadly divided into head-to-head or head-to-tail arrangements. The 
head-to-head arrangements form dimeric pairs. Within the channel type packing arrangements 
there are several variations, including the helical channel, screw channel and intermediate channel 
types. The formation of these channels often allows guest molecules to be positioned in multiple 
orientations along the length of the channel. 
Herringbone Brickwork 
Channel (head-to-head) Channel (head-to-tail) 











Chapter 1: J ntroduction 
The herringbone and layer type structures above are typical examples of monomeric packing 
arrangements. Dimeric structures like the head-to-head channel type are common for ~-CD inclusion 
complexes. The dimer is stabilised by hydrogen bonding between the hydroxyls of one secondary 
rim and the other. Other examples are the screw channel and chessboard packing arrangements, 







Figure 7: Examples of dimeric packing - the screw channel and chessboard arrangements. 
An important concept related to cyclodextrin packing arrangements is that of isostructurality. Two 
crystals are said to be isostructural when they are of the same crystal system, Bravais lattice and 
space group. Surveys have been conducted and the known inclusion complexes categorised 
according to isostructurality.44,45 Both Caira and Lubhelwana made extensive use of the Cambridge 
Crystal Structural Database (CSD),46 which is a collection of thousands of reported single-crystal X-ray 
structures. Two examples pertaining to ~-CD that are particularly relevant to this thesis will be 
mentioned here. The series 7 (B1) is the one containing the pure host hydrate as well as other guest 
molecules that do not cause significant changes in the packing arrangement. These crystallise in the 
space group P2 1 with unit cell dimensions a ~ 15 A, b ~ 10 A, c ~ 21 A and ~ ~ 110°. The series of C2 
structures with cell dimensions a ~ 19 A, b ~ 24.5 A, c ~ 16 A and ~ ~ 110°, and classified as series 11 
(B6) includes solvent guests and small organic molecules, including the API ibuprofen . For y-CD, 
there is only one isostructural series of complexes, with tetragonal space group P421 2 and unit cell 
dimensions a = b ~ 24 A and c ~ 23 A. 
An important consequence of this level of categorisation, and indeed the main reason it was carried 
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powder X-ray diffraction (PXRD) analysis. Within a given isostructural series, the PXRD traces of all of 
the inclusion complexes have the same principal features, despite the fact that the guest molecules 
may be very different. Previously, using PXRD analysis to confirm complexation meant comparing 
the pattern of the suspected complex with those of the guest, the free host and a physical mixture of 
the two. By using the CSD to generate reference patterns that are an average of the patterns within 
a given isostructural series, it is possible to unequivocally confirm that complexation has occurred if 
the pattern of the sample matches one of the reference patterns.44 PXRD traces of structures from 
the isostructural series 11 are provided in Figure 8 to demonstrate their similarity. They are labelled 
according to CSD reference codes. The guests are methylparaben (AJUVEG), S-ibuprofen (TUXKUS) 















15 20 25 30 
Figure 8: PXRD traces of representative structures from the isostructural series 11, 
Another utility of isostructural classification relates to the use of isomorphous replacement (formally 
'isostructural replacement' according to IUPAC) as a tool for structure solution, The technique 
involves using the coordinates of the host in a known (solved) structure as the coordinates of the 
host atoms in an unknown structure, where both the known and unknown at least belong to the 
same isostructural series by virtue of a similarity in unit cell dimensions. The technique is based on 
the premise that, particularly in cyclodextrin inclusion complexes, the host framework is both 
dominant in determining the X-ray diffraction pattern and has coordinates that are very similar to 
the coordinates of other host frameworks within the isostructural series to which it belongs. 
Molecular geometry 
Of particular interest in the study of cyclodextrin inclusion complexes is the conformation of the host 
molecule. There are several parameters defined by Saenger47 and Harata43 used to quantify the 
extent to which the guest influences the host geometry. These parameters may be compared with 











Chapter 1: Introduction 
geometrical information is the 04 polygon, which in the case of ~-CO is a pseudo-heptagon whose 
vertices are the 04 oxygen atoms. An idealised version, with important distances and angles, is 
represented in Figure 9. 
_c , , , 
, r , , , , , , 
Figure 9: An idealised 04 polygon with important geometrical parameters indicated. 
For a glucopyranoside residue labelled n, I is the length of the 04(n-1)-04(n) side of the polygon. The 
value r is the centroid-04n distance. The parameters a and <t> are the angle 04(n-1)-04(n)-04(n+1) 
and the torsion angle 04(n-2)-04(n-1)-04(n)-04(n+1) respectively. There are a few parameters not 
represented in the figure. The distance d is the displacement of 04n from the mean plane of all the 
04 atoms and 03 is the distance between consecutive interglucose hydroxyls (03(n)-02(n+1)) of the 
secondary rim . Also important are the tilt angles ' I and ' 2. The first is the angle between the mean 
plane of the ring C1 ~05 for a given residue and the line orthogonal to the 04 mean plane. For the 
residue n, '2 is the angle at which the mean plane of 04(n), C4(n), C1(n) and 04(n+1) intersects the 
04 mean plane. The ' I and '2 angles are expected to be similar. 
Complexes in solution 
It has been said that an understanding of the forces that drive cyclodextrin inclusion is not important 
in the field of cyclodextrin chemistry alone but is of fundamental importance to supramolecular 
chemistry as a whole. The primary factors that contribute to the complex formation with a neutral 
guest are electrostatic interactions, van der Waals interactions, the hydrophobic interaction and 
hydrogen bonding. While the expulsion of water molecules from the cyclodextrin cavity may appear 
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effect - when the high-energy water molecules are released, hydrogen bonding within the complex 
generally lowers their conformational freedom. 48 
Obviously, cyclodextrin molecules are far less rigid in solution but it is important to realise that they 
are able to adopt several very different conformations. In solution, 1:1 stoichiometric ratios are most 
common but other ratios have also been reported .38 Since most complexes are prepared from 
solution - usually aqueous solution - an understanding of the complexation reaction in solution is 
extremely useful. While evidence of strong association in solution implies that solid-state 
complexation is likely, it does not guarantee such a result . The reaction below governs the 
complexation in solution where K is the ratio of the rate of dissociation (kD) and the rate of 
recombination (k R ).49 
K 
CD + G H CD· G 
The measurement of K may be highly dependent on the experimental method employed, 
particularly because the simple model used to describe guest inclusion in solution does not account 
for the multitude of other possible modes of interaction, and this must be considered when drawing 
comparisons between different systems.50 Characterisation of the complexes involves primarily 
determining the stoichiometric ratio, the association constant and the mode of inclusion. The 
characterisation of complexes in solution is achieved by a variety of methods that includes UV /Vis 
spectroscopy, NMR spectroscopy, circular dichroism and isothermal titration calorimetry (ITC).38 
NMR spectroscopy is used in the continuous variation method to determine Job plots from which 
these parameters may be derived . ITC is particularly useful and unique because it allows the direct 
determination of the enthalpy of binding. Curve-fitting and a series of simple calculations allow the 
further determination of other thermodynamic parameters viz. entropy and Gibbs free energy of 
complex formation. Both the continuous variation method and ITC are employed in this study and 
these methods are explained in detail in Chapter 2. 
Pharmaceutical applications 
Lipophilic drugs with low aqueous solubility are particularly good candidates for bioavailability 
improvement through cyclodextrin inclusion. This is because there is evidence that cyclodextrins 
enhance the oral bioavailability of FDA's Class II (poor aqueous solubility, high permeability) drugs. 
On the other hand, cyclodextrin complexes of the Class I (high solubility, high permeability) and Class 
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The utility of a drug complex is highly dependent on the magnitude of K. Generally, higher K values 
are an indication that the complex may be stable enough to isolate in the solid state. Stable 
cyclodextrin-drug complexes have association constants in the range 100-20,000. While there is the 
danger that the complex may be so tightly bound that the drug is not adequately released, even 
highly stable complexes have been shown to dissociate upon dilution. Typically a 1:100 dilution will 
cause a 70 % reduction in the concentration of complexed drug molecules.42 
Recent human trials of a topical microbicide gel incorporating the antiretroviral drug tenofovir52 
produced very promising results. The gel reduced the acquisition of HIV by 39 % overall and for the 
subset with a high rate of adherence, a 54 % reduction was achieved. The experimental 
antiretroviral drug UC78153 was a candidate for use in similar topical formulations. Inclusion 
complexes of this molecule have been formed with ~-CD, RAMEB and HP-~-CD, and tested for 
solubility enhancement and improvements in the inhibition of HIV. Experimental results showed that 
the solubility of UC781 was enhanced in the order ~-CD < RAMEB < HP-~-CD and that the HP-~-CD 
complex yielded a remarkable 30-fold enhancement in inhibition of the virus. This provides strong 
motivation for further attempts at cyclodextrin inclusion of anti-HIV drugs, both for traditional oral 











Chapter 1: Introduction 
The Selected Antiretrovirals 
The antiretrovirals (ARVs) were chosen primarily on the basis of hydrogen bonding capability and 
limited evidence of supra molecular modification in literature. In addition, polymorphism was 
considered an important ind icator of the potential to yield new forms. 
Nevirapine Efavirenz 
Zidovudine Lamivudine 
Figure 10: Molecular structures of the ARVs that were the subject of this study. 
Relevant properties of the drugs are listed in Table 2. Note the particularly low aqueous solubility 
values for nevirapine and efavirenz. All are of relatively low molecular mass and nevirapine is the 
most chemically stable, melting at 247-249 0c. Lamivudine is the only one for which salt forms have 
been reported,54,55 despite the fact that nevirapine is more acidic and should be more readily 
ionised . 
Table 2: Properties of the selected antiretrovirals.56,57 
Property Nevirapine Efavirenz Lamivudine Zidovudine 
Molecular formula C15H14N40 C14HgCIF3N02 CSHllN30 3S ClOH13N50 4 
Molecular mass (g morl ) 266.30 315.68 229.26 267.24 
Solubility at 25 °C (mg cm·3) 0.1 9 70* 25 
pKa 2.8 10.2 4.3 9.7 
Melting point (0C) 247-249 139-141 160-162 106-112 
Known polymorphs 3 several 1 1 













Nevirapine (systematic name 11-cyclopropyl-S,ll-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e] 
diazepin-6-one) is a non-nucleoside reverse transcriptase inhibitor effective against HIV-l. The drug 
is available commercially as Viramune. The anhydrous form is administered as tablets, while the 
hydrate is taken as a suspension.58 Its crystal structure was first reported in 1992, while the drug was 
still in clinical trials.59 Numerous solvates have been produced and recently, two co-crystals have 
emerged.60 There have been limited attempts at cyclodextrin inclusion.61 
Nevirapine is an ideal candidate for supramolecular modification because it is hydrophobic and 
exhibits polymorphic behaviour. An ability to form numerous solvates suggests that the drug can 
accommodate guest molecules and is at least structurally flexible enough to exist in new forms. 
Solute-solvent interactions have been shown to have an observable effect on nevirapine crystal 
habit. It has been shown that the crystal habit of nevirapine is polarity-dependent. More polar 
solvent produced elongated crystals because of stronger interactions with the nevirapine molecules, 
while less polar solvents produced tabular crystals.62 These interactions are an important 
consideration, given that co-crystals and cyclodextrin complexes are usually prepared from solution 
or in the presence of some solvent. 
Efavirenz 
Efavirenz is widely employed in first-line anti-HIV therapy. Marketed under the name Sustiva or 
Stocrin, its systematic name is (4S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-
2H-3,l-benzoxazin-2-one. It is a non-nucleoside HIV-1 reverse transcriptase inhibitor and was 
approved by the FDA in 1998 and the EMEA in 1999.56,63 Recently, it has been administered in a 
single tablet combination that incorporates emtricitabine and tenofovir disoproxil fumarate.64 
There is a report of efavirenz cyclodextrin complexes with ~-CD, randomly methylated ~-CD and 
hydroxypropyl ~_CD.65 The structure of the pure drug and hydrate were known before this study was 
undertaken, and a few pharmaceutically unacceptable solvates and co-crystals had been discovered 
in a study where efavirenz produced a low hit-rate during co-crystal screening.66 As with nevirapine, 
it has been shown to exhibit polymorphism. In fact, there are many existing patents and patent 
applications - representative examples of which are referenced here - that describe several 
polymorphs and different preparative methods.67,68,69 This implied conformational flexibility suggests 
that the hydrogen bonding groups may be sufficiently accessible for supramolecular modification. 
However, a foreseeable problem is that the drug does not crystallise readily and that it has been 
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Zidovudine 
Also known as azidothymidine or AZT, it has the systematic name 3'-azido-3'-deoxythymidine. Sold 
as Retrovir and Retrovis, it is a nucleoside analogue reverse transcriptase inhibitor and was the first 
drug approved for the treatment of AIDS.71 
The single crystal X-ray structure of zidovudine has been determined by a number of research 
groupS.72,73.74 However, there were no solvates or polymorphs of this drug reported at the time of 
writing. Its moderate but acceptable aqueous solubility of 2S mg cmo3 may be the reason it has not 
received as much attention with respect to supra molecular modification as have other more 
hydrophobic drugs. 
The only co-crystals that are known were formed with lamivudine (to be discussed) and (2,4,6)-
triaminopyrimidine. The co-crystal that incorporated lamivudine is actually a ternary co-crystal that 
incorporates water as wel1. 54 This zidovudine-Iamivudine co-crystal hydrate, which forms a one-
dimensional ribbon type packing arrangement as seen in Figure 11, is of particular interest because 
of the fact that the constituent antiretrovirals are often administered as part of a combination 
therapy. The successful incorporation of two drugs in the same solid phase opens the possibility to 
combination therapies where all of the constituents are combined in one stable solid phase, bearing 
in mind that dosage aspects might complicate such formulations. 
Figure 11: Crystal packing of the zidovudine-Iamivudine co-crystal hydrate, reproduced from reference 54. Lamivudine 
molecules make up the lower layer and zidovudine molecules are in the upper layer. 
Lamivudine 
Lamivudine (systematic name (2R-cis)-4-amino-l-[2-(hydroxymethyl)-l,3-oxathiolan-S-yl]-2(lH)-
pyrimidinone) is sold under the t rade name Epivir. It is a chiral drug that is one of the most widely 
employed nucleoside reverse transcriptase inhibitors in the treatment of HIV infection.75 In addition 











This API is ionisable. It has a pKa of 4.3 and has been incorporated into salts with 3,S-dinitrosalicylic 
acid, saccharin and maleic acid.54,54 The saccharinate and maleate crystal packing arrangements are 
practically identical, and the authors of the paper declaring the saccharinate have hailed it as an 
example of rational design. Importantly, they predicted that other similar salts of lamivudine could 
result from similar rational design processes. Lamivudine has been incorporated in an interesting co-
crystal with zidovudine, as mentioned above. In the same paper there is also the report of a co-
crystal with 4-quinoline.54 The drug is known to exist in the crystalline state as an anhydrous form 
(the most thermodynamically stable solid form)77 and as two hydrates; one is a hemihydrate and the 
other incorporates 0.2 molar equivalents of water per mole of lamivudine. Single crystal structures 
have been reported for all three of these forms.78 
Also of importance is a patent that claims a cyclodextrin inclusion complex with ~-CD, where a PXRD 
pattern is provided as the main evidence of complex formation.79 This patent is evidence that there 












The aims of the project described in this dissertation were to prepare new solid forms of the 
selected antiretroviral drugs by supramolecular modification and to investigate the physicochemical 
properties of these. The specific objectives were as follows: 
22 
1. Carry out co-crystal screening with each of the APls 
2. Attempt cyclodextrin inclusion with each of the APls 
3. Where a new form is identified, prepare samples of the co-crystal/salt/inclusion complex for 
analysis 
4. Characterise the new forms by a variety of spectroscopic, thermal and X-ray analytical 
techniques 
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Chapter 2: Experimental 
Materials 
Nevirapine (ClsH14N40) was purchased from Cipla Ltd. (batch 1001003, Mumbai, India), while 
efavirenz (C14HgCIF3N02), lamivudine (CSHllN30 3S) and zidovudine (ClOH13Ns0 4) were supplied by 
Brunei (batches HEVC0870007, 040803 and 040903, respectively; Pretoria, South Africa). The purity 
of all four drug batches was confirmed by proton NMR spectroscopy and DSC analysis. 
~-cyclodextrin (~-CD; C42H7003S), V-cyclodextrin (V-CD; C4sHso040), dimethylated ~-CD (DIMEB; 
CS6Hgs03S) and trimethylated ~-CD (TRIMEB; C63H11203S) were supplied by Cyclolab (Budapest, 
Hungary). Randomly methylated ~-CD (RAMEB; (C42H7o-n03s)(CH3)n*) and hydroxypropyl ~-CD (HP-~­
CD; (C42H7o-n03s)(C3H70)n t) were obtained from Sigma-Aldrich Chemie Gmbh (Steinheim, Germany). 
All cyclodextrins were used as received and it was determined by TGA analysis that the native CDs 
contained "'7 water molecules of crystallisation per CD molecule at room temperature. 
Co-crystal and salt formers were obtained from Sigma-Aldrich Chemie Gmbh (Steinheim, Germany) 
and Acros Organics (New Jersey, USA). The full list of co-formers is provided in the appendix. 
Co-crystal Screening 
A three-stage co-crystal screening protocol similar to the one described by Li et 01. was employed 
here.1 The first two stages involved co-grinding and served as a high-throughput means of 
identifying co-formers that might produce one or more co-crystals with a given active 
pharmaceutical ingredient (API). The third stage involved more time-consuming co-precipitation 
experiments. Importantly, stages one and two informed the choices in stage three of which co-
formers, solvents and molar ratios to prioritise. Where warranted, there were deviations from the 
protocol. 
Stage one of the screening process was dry co-grinding. The experiments involved combining the API 
with one of a selection of co-formers and neat grinding with a pestle and mortar for at least 5 min. 
The resultant material was analysed by PXRD and its trace compared with PXRD traces of the free 
starting reagents. The appearance of new peaks and the disappearance of free component peaks 
served as evidence of possible co-crystallisation. In general the API and co-former were first 
combined in 1:1 molar ratio before other molar ratios were attempted, based on the predicted 
supramolecular synthons of potential co-crystals. 
n = 0.6-0.8 












Solvent-assisted or liquid-assisted co-grinding (LAG) was the next stage. Here, a few drops of solvent 
were added during the grinding process - periodically where necessary - and the resultant paste/gel 
kneaded for at least 5 min. As for the dry co-grinding experiments, the API and co-former were 
mixed according to the predicted stoichiometries of hypothetical co-crystals. 
Co-precipitation experiments followed with co-former candidates that presented favourable results 
in stages one and two. The co-precipitation was achieved by the common method of slow 
evaporation from solution. With a vast number of possible combinations of co-former, solvent and 
molar ratio, it was important to choose carefully. Where LAG produced a phase change for a 
particular co-former-API combination, the solvent that had been used was then also used for slow 
evaporation. Along with this, the information available in literature was considered, particularly 
where various recrystallisation experiments had been reported. In general, the API and co-former 
were combined stoichiometrically - in some cases pre-ground together - and dissolved in an 
appropriate solvent or mixture of solvents at near saturation, while heated to a few degrees below 
the solvent boiling point. The warm solution was carefully filtered through 0.45 11m microfilters and 
allowed to crystallise at ~20 0c. 
Confirmation of quantitative co-crystal formation required: 
1. Confirmation of no component peaks in the PXRD trace 
2. Confirmation of no component melting peaks in the DSC record 
3. Unambiguous evidence that no acid-base reaction had occurred, so that the resultant 
complex may be considered a genuine co-crystal and not a salt 
The typical API mass used for grinding experiments was ~10 mg. Larger masses (~20-30 mg) were 
required for the slow evaporation stage. It must be noted that the co-crystal screening in this study 
cannot be considered comprehensive. In the case of solvent-assisted co-grinding at least one solvent 
was employed; however, different solvents may have produced very different results. Also, not all of 
the products of slow evaporation experiments were analysed. There were simply too many 
experiments so, except in a few select cases, only the unit cells of single crystals were checked on 
the four-circle diffractometer. In the majority of cases, powdered products were not analysed. 
Where single crystals could not be grown for structure determination, FTIR was employed to provide 
some evidence of whether or not there had been proton transfer resulting in a salt and not a co-
crystal. Details of particular co-crystallisation experiments conducted for each of the APls in this 
study are given in the relevant chapters. Comprehensive lists of co-crystal screening experiments 












Inclusion of the selected antiretroviral drugs in cyclodextrins was attempted by well-known kneading 
and co-precipitation methods. For kneading experiments, in general, the API and cyclodextrin were 
mixed in equimolar ratio and kneaded in the presence of a small quantity of water for 30-90 min. In 
some cases, water was replaced with ethanol, methanol, or aqueous solutions of these. 
Co-precipitation experiments with the ~-CD and V-CD were carried out by dissolving the API and 
cyclodextrin in 1-5 cm3 MilliQ2 water, and stirring for 6-24 h depending on the solubility at 40-60 0c. 
Thereafter, the solutions were filtered using 0.45 11m microfilters to remove any undissolved 
material and other debris, and allowed to cool slowly over 2-3 days in a vacuum flask. 
Where derivatised cyclodextrins were used, the guest and drug were combined in 1-5 cm 3 MilliQ 
water. The solution or suspension was maintained at low temperature (ice bath) and stirred for 
approximately 24 h. While still cold, it was filtered as mentioned above and the resultant clear 
solution placed in a 60 °c oven to crystallise. 
To determine whether or not complexes had formed, single crystals were selected for unit cell 
determination and powders were analysed by PXRD. With PXRD it was possible to compare the 
resultant powder patterns with known calculated patterns for various common isostructural 
complexes. Matching a new complex with a known trace from the isostructural series made it 
possible to know the gross packing arrangement of a new complex. 
Thermal Analysis 
The methods employed were Hot Stage Microscopy (HSM), Differential Scanning Calorimetry (DSq 
and Thermogravimetric Analysis (TGA). The three were used in combination to analyse changes in 
the physical state of API forms as a function of temperature. 
Hot stage microscopy 
The hot stage microscopy (HSM) apparatus comprises a microscope coupled with a digital video 
camera. The 'hot stage' is a plate upon which small samples may be subjected to a temperature 
programme, administered via a digital controller. Hot stage microscopy was used to record visible 
changes that occurred as a function of temperature. Samples were placed in silicone oil for the 
purpose of even heat distribution and so that release of vapour was easily observable. In general the 
events of interest were: desolvation (bubbles), melting, recrystallisation and decomposition. The 











A Linkam TP92 manual temperature controller was used in conjunction with a Linkam THMS600 hot 
stage. The samples were monitored and images recorded via a Sony Digital Hyper HAD colour video 
camera fitted to a Nikon stereomicroscope. A heating rate of 10 K min-1 was used for all 
experiments. 
Thermogravimetry and differential scanning calorimetry 
During thermogravimetric analysis (TGA) a thermobalance records minute changes in mass as the 
temperature is varied. The method allows for the observation of mass loss as a result of volatile 
guest loss and decomposition. 
Differential scanning calorimetry (DSC) involves a sample pan and reference pan subjected to a 
controlled temperature programme, during which both pans are maintained at a constant 
temperature. The heat required to maintain this state is monitored and allows the plotting of heat 
flow against temperature, displaying peaks at the occurrence of endothermic and exothermic 
thermal events. 
A TA-Q500 Thermogravimetric Analyzer and DSC-Q200 Differential Scanning Calorimeter, TA 
instruments, with Universal Analysis 2000 software (v4.5A, TA Instruments-Waters LLC), were 
employed. Both TGA and DSC instruments were run at a nitrogen purge gas flow rate of 
50 cm 3 min-1. A heating rate of 10 K min-1 was used for most experiments to be consistent with the 
data collected by HSM; however, the temperature range for each experiment was varied according 
to the nature of the sample. Sample masses were typically 0.5-2 mg. 
Spectroscopic Studies 
FTIR spectroscopy 
Fourier Transform Infrared (FTIR) Spectroscopy is used routinely to identify and analyse chemical 
bonds by their natural frequencies of vibration. In the present study, the technique was used to 
investigate whether or not proton transfer had taken place between the API and co-former by 
inspecting changes in the characteristic absorption bands of the acidic and basic groups. Spectra 
were collected on a Perkin Elmer 983 spectrophotometer. Samples were prepared using the Nujol 










Proton NMR spectroscopy 
Routine proton NMR experiments were carried out with a Varian-VXR 300 (300 MHz), Varian-Unity 
400 (400 MHz) or Bruker AMX 400 (400 MHz) spectrometer. The experiments were generally 
conducted to determine or confirm the stoichiometry of salts, co-crystals and inclusion complexes. 
All samples were dissolved in an appropriate deuterated solvent - either COCI3, d6-OMSO or 020. 
The data were analysed using the program Topspin3 or MestRe-C.4 
The NMR spectrometer for continuous variation experiments was a Bruker AVANCE III 500 MHz 
spectrophotometer fitted with a 'broad band observe' probehead. Samples were dissolved in 0 20 
where possible and OMSO in the cases of very low aqueous solubility. Typical conditions were as 
follows: temperature at 298 K; 32 K data points; 16 + 128 scans; sweep width of 7 ppm (2-9). A 90 0 
pulse of 10.1 Ils was used with a zq 30 program (30 0 pulse excitation). Four dummy scans were run 
before each experiment. The relaxation delay was 3 s and the acquisition time 4.68 s. Topspin was 
employed for data analyses.3 
The continuous variation method 
The continuous variation method has become known as Job's method, after the author of the 
original paper describing it.5 In the present study, proton NMR spectroscopy was used to draw Job 
plots for cyclodextrin host-guest reactions in solution. The reactions are of the form: 
aH+bG He 
where C = HaGb 
(1) 
The Job plot is a graph of some signal - here it is an NMR-derived signal, L100bs - that is a linear 
function of the concentration of the complex. With respect to our host-guest system, the signal is 
plotted against the molar ratio R = i~~ with[M] equal to the sum of the total concentrations of H 
and G, and X representing H or G. The resultant curve should reach a maximum at R = ~ and 
approach linearity immediately above and below this value.6 The dependent variable used in these 
experiments was L1oobs [X], where L100bs is the difference in observed chemical shift for a solution of 
the pure X and a solution where the host and guest are present. 
For a sample series of constant volume, the total molar concentration was kept constant while the 
molar ratio was varied stepwise. A 10 mM stock solution of each drug and partner cyclodextrin was 
prepared in OMSO or 020. A series of solutions was then prepared from these, usually 11, with 











Chapter 2: Experimental 
The association constant 
The association constant, K, is defined, from reaction equation (1) as: 
(2) 
Given that [HJr = [H] + a[e] and [GJr = [G] + b[e], where [HJr and [GJr are the total 
concentrations of Hand G, equation (2) may be expressed as: 
(3) 
If a, b = 1 as would be established from a Job plot, equation (3) becomes: 
K = [CI 
([H\t-a[C])([GIT-b[C]) 
(4) 
With reference to the earlier comment about Job' s method, the observed chemical shift Oobs is taken 
as a linear function of [e] where Oobs is defined as the weighted average chemical shift for the free 
guest o[ and complexed guest Dc simultaneously present in a given solution. It may be expressed as : 
o - [Glof+[Cloc 
obs - [GIT 
(5) 
Since [GJr = [G] + [e], equation (5) may also be expressed as: 
o = [Glof+([GIT - [G])Oc = ED + [GIT-[GI o 
obs [GIT [GIT 'f [GIT C 
And if = [~~, then: 











Chapter 2: Experimental 
As [G] ~ 0, z ~ 0 such that Oobs ~ oc . When [G] = [Gh or [Gh » [Hh then z ~ 1 and 
OobS ~ of (similarly proven for the host) . Furthermore, if it is defined that !J.o = of - Oobs and 
!J.oc = of - oc, then : 
!J.O (X) = [C] !J.o (X) 
obs [Xh c 
where X = H, G for a 1:1 complex. 
substituting the above result into equation (4) gives: 
[X]f (!J.o~~~t - [Xh!J.o~~~!J.oY) ([M] + ~) + [Hh[Gh (!J.oy) ) 2 = 0 
where [M ] = [Hh + [Gh 
And solving equation (7) for !J.O~~~ gives: 
(7) 
(8) 
The ratio !J.oobs/ !J.oc will always be less than 1, so only negative solutions of equation (8) are 
considered . For a set of n samples in an experiment, there will be n equations and only two 
independent variables that may be solved by taking the experimental Lloobs values as reference .
7 
ConstEQ and ConstEQV 
The association constant was derived with the aid of CONSTEQ.7 The program evaluates data 
obtained from the continuous variation experiment by non-linear least-squares fitting analysis 
according to equation (7), which, without approximations, correlates the total concentrations of 
host and guest with the chemical shift difference. During each step of the program's iterative fitting 
procedure, a quadratic equation is used to determine the direction of the search and the loss error 
function, E, is calculated according to the following equation: 
E = ~ . ·(LlO (i,j) - Llo (i,j) )2 
L...l ,j obs calc 
i: sample number, j :proton index 
E is the sum of squares of the deviations between the experimental and predicted values. The f itting 
procedure reaches convergence when the difference between two consecutive E-values is less than 










calculation to give a single representative K value but the procedure may only be used for systems 
with a host-guest stoichiometry of 1:1. 
ConstEQV, a modified version of ConstEQ, is used when the data from standard experiments do not 
result in convergence. In this case a second set of experiments is required, where the guest 
concentration is fixed and the host concentration varied so that the molar ratio varies from zero to 
values in excess of 10. So, when using ConstEQ, [M] remains constant, while for ConstEQV it varies. 
Isothermal Titration Calorimetry 
Isothermal titration calorimetry (ITe) is a technique that involves measuring tiny amounts of heat 
associated with a Ill-scale titration. Used to characterise the interactions between molecules in 
solution, the technique is commonly employed in the analysis of biological systems, to measure the 
heat of enzyme-substrate binding.sln general, the instrument comprises a sample cell and reference 
cell, which are maintained at the same temperature. A thermoelectric device measures the power 
required to maintain the sample cell temperature. The integral of this power value is proportional to 
heat generated or released by the reaction taking place in the sample cel1.9 
ITC experiments were performed at 298 K using a Nano ITC2G (TA Instruments). Each titration 
comprised 28 injections of 10 /-ll cyclodextrin solution into the 1.4 cm3 reaction cell, which contained 
the API solution of known concentration, details of which are provided in the relevant sections. The 
first step of each experiment was to measure the heat of dilution for the CD solution, so that this 
could be accounted for when measuring the heat of binding for each API-cyclodextrin system. 
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Determination of the binding parameters 
The experiments in the present study were used to measure parameters of binding for cyclodextrin 
com plexes in solution. The output signal from the ITe instrument is the value of the electrical power 
required to maintain iJT = 0 for the sample and reference cells. Integration of this power value 
yields the heat change (flqd between consecutive injections i - 1 and i. Plotting [Llqli against [CD]r, 
CD T [G]r 
where [CDh and [Ch are the total cyclodextrin and guest concentrations, respectively, results in a 
titration curve from which the values of the binding parameters K, nand flHo can be determined. 
These values are extracted using a least-squares non-linear adjustment method based on the 
Wiseman isotherm (equation (9)).10,11,12 The parameter r is a composition variable (equation (10)), 
Vo is the total volume of the reaction solution and XR is the absolute value of the ratio [[GIlT. Using CD T 
equations (11) and (12) made it possible to calculate the entropy and Gibbs free energy changes. 
X-ray Diffraction Analysis 









PXRD analysis was used extensively in this study to verify the uniqueness of new forms. During co-
crystal and cyclodextrin inclusion complex screening, samples of powdered material were checked 
routinely. The PXRD data were collected at room temperature, so in some cases where experimental 
traces are compared with traces calculated from single crystal X-ray data that was collected at low 
temperature (100 or 173 K), the peaks in the experimental trace appear to be shifted to slightly 
lower 28 values. Two instruments were used for PXRD analysis. 
Most of the powder X-ray diffractograms were recorded using a Philips PW1120/00 X-ray generator. 










Monochromater Series 611/5 to produce CuKu] radiation (A = 1.5405981 A) at 20 mA and 40 kV. The 
PXRD patterns were recorded by a Huber Imaging Plate Camera 670. In cases of temperature-
controlled PXRD, a Huber High Temperature Controller HTC 9634 unit was used with capillary 
rotation device 670.2. Samples were manually ground and a small amount (ca. 5 mg) packed into No. 
14 Markrohrchen non-diffracting glass. In a few cases where capillary mounting was not possible, 
flat samples were prepared on Mylar® film. 
The second instrument, employed for only a few samples, was a PANalytical X'Pert PRO MPD (Multi-
Purpose Diffractometer) with X'Celerator detector and fixed divergence slits for the CuKu] radiation. 
Samples were placed on zero background silicon holders and loaded onto a reflection transmission 
spinner. 
Single-crystal X-ray diffraction 
All single crystals were mounted on a nylon loop and coated with Paratone oil. 13 Unit cell dimensions 
were determined on two instruments - a Nonius Kappa CCD (charge-coupled device) diffractometer 
and a Bruker KAPPA APEX II DUO single-crystal X-ray diffractometer. The Nonius Kappa CCD 
diffractometer, employing graphite-monochromated MoKa radiation (A = 0.71069A) generated by a 
Nonius FR590 generator (54 kV, 23 mA), was used only for unit cell determination. Unit cell 
refinement and data-reduction were performed using the programs DENZO and SCALEPACK.14 
Intensity data for all the structures reported herein were collected on the Bruker KAPPA APEX II DUO 
diffractometer. This instrument accommodates both Cu and Mo sources. In all structures reported 
here, Mo-Ku radiation, generated by a Bruker K780 generator (50 kV, 30 mA), was used. For unit cell 
refinement and data-reduction, the program SAl NTiS was used and corrections for absorption by the 
crystals containing sulphur were carried out with the program SADABS.16 Low temperature collection 
made use of a Cryostream cooler (Oxford Cryostreams UK) with N2 gas flowing at a rate of 20 cm 3 
min-i. Space group determinations were verified using the program XPREP,17 which also prepared 
the SHELXS-97 input files, required for structure solution. 
SHELXS-97 and SHELXD 
SHELXS-97i8 was employed for the structure solutions of those structures containing smaller 
molecules, particularly the salts and co-crystals. The program allows the user to solve structures by 
direct methods or by the Patterson method. In this study only direct methods were employed for 
the solution of small structures. 
SHELXD18 is used for systems with large numbers of atoms. The program employs a dual-space 
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this programme for cyclodextrin structures has been to use isomorphous replacement. Here, 
coordinates of the host are "borrowed" from an existing structure belonging to the same 
isostructural series. 
SHELXH-97 
The SHELXH-9718 software program employs full-matrix least-squares fitting to minimise the value of 
L w(Fl- F/)z. The agreement between the observed and calculated intensities of reflections is 
expressed as the residual indices Rl and wRz - equations (13) and (14) . The default scheme 
em ployed for the weighting, w, is given in equation (15), where P is given in equation (16) using a 
combination of Fa and Fe to reduce statistical bias. The 'Goodness of Fit' parameter S (equation (17)) 
is also based on F Z with n the number of reflections and p the total number of refined parameters. 
The over-determination ratio (nip) should be ~10 and S is expected to approach unity for well-
behaved models. 
P = max(O.FJ) + ZFE 
3 
1 







Structure solution and refinement procedures for each structure are explained in detail in the 
relevant chapters. 
LAYER19 generates and displays intensity data as simulated precession photographs, which are useful 
for determining space group symmetry. 
POV-RAy20 is a ray tracer program employed here for image generation based on the crystal structure 
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LAZY PULVERIX21 was used to generate calculated PXRD patterns based on atomic fractional 
coordinates, thermal parameters and space group data from the crystal structure model. These 
calculated patterns were compared with experimental patterns to identify phases and check 
homogeneity. 
X-Seed22 served as the graphical interface for SHELXH-97, LAYER, POV-RAY and LAZY PULVERIX. 
PLATON23 was used to determine bond angles, torsion angles and bond lengths as well as the 
parameters defining non-covalent interactions (e .g. hydrogen bonds, TT-TT stacking). Standard 
deviations accompanied all ofthe calculated parameters. 
The Cambridge Structural Database (CSD)24 was used to access relevant published structures, 
particularly those that incorporated the drugs that were the subject of this study. 
The final crystallographic data files are provided in the following formats: 
Extension Details 
.hkl reflection data 
.res SHELX co-ordinate data 
.cif crystallographic information 
Jet structure factor tables 
.lis Platon output 
.xl SHELX output 
.sup tabulated supplementary data 
Solubility Studies 
An excess amount of each co-crystal was weighed into a 20 cm3 amber screw-cap test tube. The test 
tubes were filled with MilliQ water, allowing some headspace for agitation, and then sealed. Five 
replicates of each sample were prepared. Each test tube was fixed to a rotating axis (54 rpm) and the 
axis submerged into a water bath (37°C ± 0.5 0c) . The test tubes were rotated for 24 h, after which 
they were kept in the water bath until sampling. Samples were filtered using 0.45 ~m filters. The 
concentrations of the filtered solutions were considered to be representative of the equilibrium 
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HPLC 
A Shimadzu (Kyoto, Japan) UFLC (LC-20AD) chromatographic system was utilised. The system 
consisted of a SIL-20AC auto-sampler fitted with a sampler cooler, a UV!VIS Photodiode Array 
detector (SPD-M20A) and a LC-20AD solvent delivery module. The software used was LabSolutions 
(LC Solutions v1.21 SP1, Shimadzu). The HPLC was equipped with a 150 x 4.6 mm Luna C18 column 
which contained 5 11m packing. The flow rate was set to 1.0 cm3 minot, with the column temperature 
maintained at 35°C. The injection volume was set to be 1 ilL and the wavelength was set to 220 nm. 
A mobile phase containing 0.025 M ammonium phosphate buffer and acetonitrile (4:1) was used. 
The 0.025 M ammonium phosphate buffer (ACE Chemicals, BIN: 12698) was prepared by dissolving, 
in a volumetric flask, 2.88 g of the salt in distilled water to make an 800 cm 3 solution. The pH was 
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Chapter 3: Nevirapine 
Chapter 3: Nevirapine 
Introduction 
Nevirapine exists as three polymorphs according to a recent patent.1 PXRD analysis confirmed that 
the material with which we had been supplied was the polymorph referred to in the patent as 
Form II. A number of solvates of nevirapine have been reported, including five containing ethyl 
acetate, dichloromethane, toluene, water and l,4-dioxane, as well as a series of linear alcohols.2,3 An 
isostructural series was identified, wherein a variety of solvents was included in channels parallel to 
the a-axis. At the time of writing, only very limited discussion of attempted cyclodextrin inclusion of 
nevirapine existed in literature.4 
In the single crystal structures of free nevirapine and several solvates, the nevi rapine dimer 
(Figure 1), hydrogen bonded by the common amide-amide synthon is often present. Figure 2 shows 
the most relevant supra molecular synthons for the present study. These are common and were used 
as part of the selection criteria for co-formers in the production of nevirapine co-crystals. A variety 
of carboxylic acids and amides was chosen, among others (e.g. piperazine and saccharin) with less 
common functional groups. 




























Chapter 3: Nevlrapine 
Existing co-crystals 
Co-crystals of nevirapine have been prepared previously, though quite recently in our laboratory.s 
The first was a 2:1 co-crystal of nevirapine and saccharin and the second a 1:1 nevirapine-rac-tartaric 
acid co-crystal. The co-crystals were prepared by conventional slow evaporation, with single crystal 
X-ray structures determined for both. Attempts were made at preparing the saccharin co-crystal by 
co-grinding (dry and liquid-assisted) but these failed . 
Thermal stability is an important property that may be manipulated by co-crystal modification . 
These existing co-crystals were determined to have onsets of melting of 223°C for nevirapine-
saccharin and 228°C for nevirapine-rac-tartaric acid . The first melts at a temperature lower than 
both component melting points, while the melting point of the second is below that of the API- and 
above the co-former melting point. 
The co-crystals were subjected to dissolution rate testing and solubility testing. Both properties were 
enhanced with reference to the native API and stoichiometric physical mixtures. The nevirapine-
saccharin co-crystal showed a 20 % enhanced dissolution rate with respect to the physical mixture, 
while the drug equilibrium solubility was 46 times higher in the presence of one molar equivalent of 
the co-former. The dissolution rate of the nevirapine-rac-tartaric acid co-crystal was 10 % greater 
than that of the physical mixture and the equilibrium solubility of the drug was enhanced 16-fold by 
two molar equivalents of rac-tartaric acid. 
Present study 
During co-crystallisation attempts in the present study, slow evaporation from solutions of acetone 
and acetonitrile produced crystals with identical unit cell dimensions to those of the isostructural 
solvate series/ suggesting yet more isostructural solvates but because solvatomorphism was not 
within the scope of this research, these species were not further studied . 
Three novel co-crystals were identified via screening, prepared and analysed by various methods. 
Crystals were grown from solution and their structures determined using single crystal XRD. 
Cyclodextrin inclusion was attempted with I3-CD, V-CD, DIMEB and TRIMEB with no success. 
Reported preparation methods for a I3-CD complex were repeated but these yielded only physical 
mixtures. 
Co-crystal Screening 
Co-crystal screening was carried out by the methods explained previously (Chapter 2). The results of 
dry co-grinding and liquid-aSSisted co-grinding (LAG) were used to guide the slow evaporation 
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chloroform. The screening process is summarised below along with a list of the co-formers that 
produced hits i.e. potential co-crystals. There were several independent hits; however, the only co-
crystals that could be produced reliably were those that incorporated glutaric acid, salicylic acid and 
maleic acid . 
Chloroform produced promising results during LAG experiments, so a number of slow evaporation 
experiments were carried out using chloroform as solvent. Where the solubility was too high, a non-
polar solvent was incorporated into the solution, successfully producing crystals in some cases. 
In the interest of achieving a high-throughput rate, the co-precipitation experiments were only 
analysed where single crystals were achieved . In other words, the variety of other outcomes like 
mixed powders, fine crystal clusters and gels were not analysed. Indeed this means that some 
experiments may have yielded co-crystals or a mixture of products that included a co-crystal that 
may have escaped detection, but to do an extensive analysis for each experiment would have 
drastically reduced the throughput rate. 
The table below contains representative results from the dry co-grinding stage of co-crystal 
screening. None of the experiments conducted during this stage yielded a pure co-crystal product 
and there was only one case - that of the experiment with sorbic acid - in which a partial phase 
transformation occurred. 
Table 1: Co-formers and experimental outcomes for the dry co-grinding stage of co-crystal screening of nevirapine; all 
experiments employed a 1:1 molar ratio. 
Co-former Product 
Fumaric acid Physical mixture 
Glutaric acid Physical mixture 
L-Malic acid Physical mixture 
Maleic acid Physical mixture 
Sorbic acid New phase + physical mixture 
Methanol and chloroform were the main solvents utilised for the LAG stage of co-crystal screening, 
where in general a 1:1 molar mixture of co-former and API was ground in the presence of the 
solvent for 10 min. Table 2 shows a representative set of experiments with their outcomes. The 
three co-crystals to be discussed further are highlighted in blue. Chloroform was superior to 
methanol in facilitating the reaction of nevirapine with glutaric acid, while for the experiment with 
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Table 2: Co-formers, solvents and experimental outcomes for the liquid-assisted co-grinding stage of co-crystal screening 
of nevirapine; all experiments employed a 1:1 molar ratio. 
Co-former Solvent Product* 
Adipic acid Chloroform New phase + adipic acid 
Ascorbic acid Chloroform Physical mixture 
Glutaric acid 
Chloroform Co-crystal 
Methanol Co-crystal + physical mixture 
Maleic acid Chloroform Co-crystal 
Malonic acid Chloroform New phase 
Isonicotinamide Chloroform Physical mixture 
Nicotinamide Chloroform Physical mixture 
Propionamide Chloroform New phase 
Salicylic acid Chloroform Co-crystal + nevi rapine 
Sorbic acid 
Methanol New phase + physical mixture 
Chloroform New phase + sorbic acid 
Succinic acid Chloroform Physical mixture 
Uracil Chloroform New phase + physical mixture 
*Where the result is "co-crystal" the new phase was fully characterised later. In other cases where the PXRD result 
suggested potential co-crystallisation, the term "new phase" has been used. 
The slow evaporation stage of screening was informed by the results from LAG experiments but a 
number additional solvents were employed and where warranted, co-formers that had produced no 
hits during either of the previous stages of screening were still included. Table 3 contains a set of 
representative results, showing that only pure chloroform and a 50:50 v/v mixture of chloroform 
and hexane yielded co-crystals. 
Table 3: Co-formers, solvents, molar ratio and experimental outcomes for the slow evaporation stage of co-crystal 
screening of nevirapine. 
Co-former Solvent Molar ratio Product 
Glutaric acid Chloroform-hexane* 1:1 Co-crystal 
Maleic acid Chloroform 1:1 Co-crystal 
Chloroform 1:1 No crystal 
Propionamide Chloroform-hexane* 1:1 No crystal 
t-Amyl alcohol 1:1 No crystal 
Salicylic acid 
Chloroform-hexane* 1:1 Co-crystal 
Chloroform-hexane* 2:1 Co-crystal 
Sorbic acid 
Methanol 1:1 Solvate 
Chloroform 1:1 No crystal 
*50:50 v/v 
A summary of the results of co-crystal screening with nevirapine is provided in Table 4. Chloroform 
was used most extensively during the LAG stage of screening because it produced the best results 
during the initial experiments. More comprehensive lists of the co-crystal screening experiments are 
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Table 4: Summary of co-crystal screening outcomes. 
Method Co-formers Hits Pure co-crystal 
Dry co-grinding 6 1 0 
Chloroform LAG 30 13 3 
Methanol LAG 8 2 0 
Slow evaporation 25 3 2 
NVPMLE: nevirapine-maleic acid 1:1 co-crystal 
The co-crystal was produced by liquid-assisted grinding with chloroform, maintaining dampness with 
regular solvent addition. During screening, chloroform-assisted grinding yielded powdered co-
crystal. In producing a larger amount, some difficulties arose in confirming the purity of the prepared 
co-crystal. This issue will be discussed further in the section on thermal analysis but here it involved 
the curious recurring appearance of a small endotherm at the melting point of nevirapine, 
suggesting some uncomplexed nevirapine in the batch of NVPMLE. A larger amount was produced 
by grinding nevirapine (22 mg, 0.08 mmol) and maleic acid (10 mg, 0.08 mmol) in the presence of a 
few drops of chloroform for 15 min. The resultant powder dried quickly under ambient conditions. 
A few small crystals were produced by dissolving, with constant stirring, equimolar (0.07 mmol) 
amounts of nevirapine (19 mg) and maleic acid (8 mg) in 3 cm 3 chloroform at 40 °C. The solubility 
was poor but the suspension was stirred for 30 min and the undissolved material filtered off using a 
0.45 ~m microfilter. Allowing the solution to evaporate to dryness produced, in addition to 
powdered material, small irregular plates, one of which was used for single crystal XRD data-
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Identification 
The initial screening experiment involved grinding a small equimolar mixture of nevirapine and 
maleic acid for 10 min adding chloroform dropwise to keep the powder moist. After drying at room 
temperature, which required only a few minutes the sample was analysed by PXRD. The traces in 
Figure 3 show that the product of the grinding experiment is clearly a new phase. Its PXRD trace 
does not resemble either of the component traces. There are coincident peaks, so it was not clear 
whether or not there were indeed traces of either component remaining in the sample and indeed 
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Figure 3: PXRD trace of NVPMLE compared with the traces of free nevirapine and free maleic acid. 
Thermal analysis 
Prior to thermal analysis it was important to consider the melting points of the free components. 
DSC analysis (Figure 4) confirmed that the pure nevirapine melted at 244-249 °c and the pure maleic 
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HSM 
HSM analysis of NVPMLE was conducted with powdered material as larger crystals were not readily 
available. The sample was heated at a rate of 10 K min-1 The representative HSM photographs in 
Figure 5 show what appears as partial melting that begins at 202 °C and a final complete melt that 
occurs at 220-245 0c. At no point between 202 and 210 °C does the entire sample become liquid, so 
either the sample consists of two separate phases or the sample is initially one phase but the 
recrystallisation of the higher-melting species appears to be concurrent with the melt of the co-
crystal. 
Incidentally, the second melt concurred with the melting point of free nevirapine, suggesting that 
t he sample contained a new phase (potential co-crystal) and some excess nevirapine. 
202°C 
220°C 245°C 
Figure 5: Representative HSM photographs of NVPMlE. 
DSC and TGA 
Analysis using DSC (Figure 6) provided confirmation of co-crystal formation in that the accurately 
determined melting point (onset 185°C) of the new phase is unique - it differs significantly from the 
melting points of each of the components. Curiously, there was a reproducible endotherm at the 
melting point of nevirapine despite accurate weighing of the 1:1 starting materials. The possibility 
that nevirapine was in slight excess was ruled out because initially PXRD analysis (refer again to 
Figure 3) and later single crystal XRD investigation had suggested 1:1 stoichiometry. 
TGA (Figure 7) also showed the decomposition of maleic acid at the co-crystal melting point. The 
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30.4 % expected for 1:1 co-crystal stoichiometry. There was no apparent mass loss at lower 






















Figure 6: DSC trace for NVPMlE. 
100 150 200 
Temperature (0C) 
Figure 7: TGA trace for NVPMlE. 
200 250 300 
250 300 350 
It was necessary to conduct temperature-controlled PXRD to investigate the repeated occurrence in 
DSC traces of the endotherm in the nevirapine melting range. This would provide some identification 
of the sol id phase responsible for the endotherm. 
Temperature-controlled PXRD 
The recurrence of a melt peak that indicated the presence of free nevirapine was puzzling since 
there were no signs of this phase in the room temperature PXRD trace. This phenomenon persisted 
even when the preparative procedure for NVPMLE was repeated using an analytical balance (with a 
precision of 0.01 mg) to weigh the starting reagents. An investigation carried out by temperature-
controlled PXRD analysis revealed the simultaneous recrystallisation of free nevirapine during the 
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diminished and new peaks are appearing. At 200 O( the PXRD trace of NVPMLE is identical to that of 
pure nevirapine at room temperature. It is apparent now that as the co-crystal melts, the nevirapine 
molecules are free to hydrogen bond in their original arrangement (as in the bulk), while the maleic 
acid molecules remain molten and are subsequently vaporised. Because both the co-crystal melt and 
nevirapine recrystallisation occur simultaneously in the range 170-200 O( and the enthalpy of 
recrystallisation is much smaller than the enthalpy of melting, no recrystallisation exotherm is 
evident in this region of the DS( trace and the later melt at 240 O( can be attributed to free 
nevirapine that had been liberated from the co-crystal phase. 
> -'iii 
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Figure 8: PXRD traces of NVPMLE recorded in the range 21-220 ·C and compared with the trace for the nevirapine bulk 
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Single crystal X-ray analysis 
Data-collection and space group determination 
The chloroform solution produced only a few irregular plate-like crystals when allowed to evaporate 
to dryness. The best of these was selected for single crystal XRD analysis. The single crystal 
diffraction data for this crystal, as for all subsequent crystals in this chapter, were collected on a 
Bruker APEX DUO II four-circle diffractometer. The unit cell parameters, crystal system and space 
group P21 / n (alternative setting of P2dc) were determined from the X-ray diffraction data. The 
space group was confirmed using the program LAYER/ which provided evidence of the following 
reflection conditions: hkl: none; hal: h + l = 2n; aka : k = 2n. 
Structure solution and refinement 
SHELXS-978 was employed for the structure solution of NVPMLE. The asymmetric unit contains one 
API and one co-former molecule, of which the positions of all non-hydrogen atoms were determined 
by direct methods. These atoms were assigned and refined isotropically on F2 in SHELXH-97 .8 After 
confirming acceptable isotropic temperature factors, the atoms were refined anisotropically. 
Hydrogen atom positions were evident in the difference Fourier map. These were placed in idealised 
positions by means of a riding model. Particular attention was paid to the amide- and carboxylic acid 
groups. It was confirmed, unambiguously, via the difference electron density map that the carboxylic 
acid groups had retained their acidic protons and that the amide group in turn had remained 
unprotonated. The c-o bond distances (Table 5) of the carboxylic acid groups provided further 
confirmation. Each hydrogen atom was assigned an isotropic temperature factor of 1.2 times (1.5 for 
methyl hydrogens) that of its parent atom. Table 6 lists the crystal data and refinement parameters. 
Table 5: (-0 bond distances for the NVPMLE maleic acid molecule 
Bond Distance (A) 
C23-021 (single) 1.326 (2) 
C23-022 (double) 1.223 (2) 
C26-027 (double) 1.207 (2) 
C26-028 (single) 1.329 (2) 
0 0-., 24 
22" 23/ ~25 
/ \ 
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Table 6: Data-collection and refinement parameters for NVPMlE. 
Formula unit (ClsHl4N40) (C4H40 4) 
Formula mass (g morl ) 382.37 
Crystal system Monoclinic 
Space group P2dn 
a{A) 7.4001(5) 
b (A) 10.4599(7) 
c (A) 23.256(2) 
an 90 
~ (O) 98.968(1) 
Y (O) 90 
Volume (A3) 1778.1(2) 
Z 4 
DensitYcalc (g cm-3) 1.428 
F{OOO) 800 
~(MoKa) (mm-l ) 0.106 
Crystal size (mm3) 0.12 x 0.11 x 0.03 
Temperature (K) 100(2) 
Range scanned e (O) 2.14-26.46 
Index ranges h: -9, 9; k: -13, 13; 1:-29, 29 
<p and w scan angle n 0.5 
Total number of frames 1454 
Dx{mm) 40 
Total number of reflections collected 18372 
Number of unique reflections 3653 
Number of reflections with I > 20(1) 2773 
Number of least-squares parameters 257 
Rint 0.0477 
S 1.032 
Rl (I > 20(1)) 0.0413 
Number of reflections omitted 2 
WR2 0.0942 
Weighting scheme parameters a = 0.0424, b = 1.0228 
{Mo)mean < 0.001 
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Molecular structure 
The asymmetric unit (ASU), illustrated in Figure 9, consists of one nevirapine molecule and one 
maleic acid molecule, hydrogen bonded by the expected amide-carboxylic acid synthon C (Figure 2) . 
The maleic acid molecule does not display intramolecular hydrogen bonding and the nevirapine 
molecule is not engaged in the self-association common in the set of known nevirapine-containing 
crystal structures (see Figure 1). 
028 
Figure 9: ASU of NVPMlE. Thermal ellipsoids are drawn at the 50 % probability level, while hydrogen atoms are 
presented as spheres of arbitrary radii. 
Hydrogen bonding 
The hydrogen bonding motif links one nevirapine molecule and one maleic acid molecule in a cyclic 
arrangement as represented in Figure 10. At the centre of this motif is a crystallographic centre of 
inversion. The amide-carboxylic acid synthon associates the two molecules of the asymmetric unit, 
while the pyridine nitrogen N13 is engaged in N-H .. ·O hydrogen bonding with a carboxylic acid group 
of the inversion-related maleic acid molecule. Full details of these hydrogen bonds as well as those 
of several C-H .. ·O and C-H .. ·N hydrogen bonds are listed in Table 7. 
There is also IT-IT stacking in the a-direction between the C3-7C16 pyridine rings of inversion-related 
nevirapine molecules, as illustrated in Figure 11. The bonding distances of 3.875(1) and 3.671(1) A 
between centroids in this case are typical of strong IT-IT interactions. The shorter of these, where the 












Figure 10: View normal to the plane (1 0 -4). Only the most 
relevant hydrogen atoms are shown. 
Table 7: Hydrogen bond parameters for NVPMLE. 
D-H"'A D-H (A) H···A (A) 
N2-H2 .. ·022 0.88 1.97 
021-H21 .. ·08 0.84 1.77 
028-H28"'N13 0.84 1.94 
C11-Hll .. ·08 0.95 2.58 
C14-H14 .. ·022 0.95 2.56 
C17-H17B .. ·027 0.98 2.43 
C24-H24"'08 0.95 2.39 
C25-H25 .. ·N12 0.95 2.44 
Molecular geometry 
Chapter 3: Nevirapine 
Figure 11: n-stacking in the a-direction (N13 ring). View 
down the b-axis with hydrogen atoms omitted. 
D···A (A) D-H ... A (0) Symmetry code 
2.821(2) 162 X, y, z 
2.607(2) 174 x, y, z 
2.748(2) 162 i-x, 1-y, -z 
3.345(2) 138 5/2-x, 1/2+y, 1/2-z 
3.376(2) 144 i -x, 1-y, -z 
3.343(3) 154 l+x, y, z 
3.302(2) 162 3/2-x, -1/2+y, 1/2-z 
3.341(2) 158 -l+x, -l+y, Z 
The so-called 'butterfly angle' is the angle between the mean planes of the two nevirapine pyridine 
rings. It is taken as a measure of the extent to which the molecule as a whole is curved and is closely 
related to the puckering of the central 7-membered ring. In NVPMLE, the butterfly angle is 55.9(1)0. 
The amide group is almost planar with a C3-N2-Cl-C7 torsion angle of 13.2(3)0. 
The maleic acid molecule has its carboxylic acid groups oriented orthogonally with respect to one 
another, which is not a general occurrence for th is co-former. Of the many known structures 
containing this molecule only one displays the same geometry for maleic acid.9 The angle between 
mean planes drawn through each carboxylic acid group (021-C23-022 and 027-C26-028) is 89.6(2)0. 
The relevant torsion angles are 0.0{3t for 022-C23-C24-C25 and 89.4{3t for 027-C26-C25-C24. 
Crystal packing 
The hydrogen bonding motif (Figure 10) is present at the oc and ob faces of the unit cell. Figure 12 
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along the b-axis. The diagram also shows clearly the two-fold screw axis that runs parallel to the b-
axis, while the n-glide plane is perpendicular to it. 
Figure 12: View along the a-axis of NVPMLE. 
Comparative PXRD 
In Figure 13 the experimental pattern for NVPMLE and calculated pattern from single crystal X-ray 
diffraction data are compared. Note that the single crystal used to generate the calculated pattern 
was grown by slow evaporation, while the experimental pattern was recorded using a sample 
prepared by liquid-assisted grinding. This is because the slow evaporation method yielded the co-
crystal along with other phases, while the liquid-assisted grinding method produced the pure co-
crystal. Nevertheless, the similarity of these PXRD patterns provides assurance that the crystal 
selected for single crystal XRD data-collection was representative of the material used for other 
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Figure 13: Comparison of experimental and calculated PXRD traces for NVPMLE. 
40 
With regard to the above PXRD comparison, the sample used for single-crystal X-ray data collection 
was at a lower temperature (100 K) than the sample used to record the experimental PXRD trace 
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28 values. This applies to analogous figures elsewhere in this thesis, since all single crystal X-ray data 
were collected at 100 or 173 K. 
NVPGL T: nevirapine-glutaric acid 1:1 co-crystal 
It was possible to prepare the co-crystal NVPGLT by liquid-assisted co-grinding and by slow 
evaporation from solution. Preparation by liquid-assisted co-grinding required a few drops of 
chloroform, which was replenished regularly to maintain a moist consistency. An equimolar 
(0.075 mmol) mixture of nevirapine (20 mg) and glutaric acid (10 mg) was co-ground for 20 min and 
allowed to dry. 
Single crystals were prepared by combining 0.11 mmol each of nevirapine (30 mg) and glutaric acid 
(15 mg) by grinding with a few drops of chloroform for 2 min. The powder was dissolved in a 50:50 
v/v chloroform:hexane mixture at 40°C by stirring for 30 min. This solution was filtered while hot 
and allowed to cool spontaneously at room temperature. Crystals formed after four days of slow 
evaporation. Subsequently, it was determined that pre-grinding is unnecessary. The co-precipitation 
method essentially requires equimolar amounts of nevirapine and glutaric acid dissolved by stirring 
at approximately 40°C in a 50:50 v/v chloroform:hexane solution and allowed to evaporate slowly. 
Identification 
Initial screening by 10 min of liquid-assisted co-grinding with chloroform produced a hit for 
nevirapine-glutaric acid in 1:1 molar ratio. The PXRD comparison in Figure 14 shows the unique trace 
of the co-ground product as compared with traces for the pure starting reagents. There are no peaks 
in the product trace that suggest excess amounts of either component. 
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Thermal analysis 
The starting materials were analysed by Dse to determine experimental melting points for 
comparison with thermal data for the co-crystal. The melting point of nevirapine was as for the 
previous example and glutaric acid melting occurred at 96-101 0c. 
HSM 
The hot stage temperature was ramped from room temperature at a rate of 10 K min-1. The HSM 
photographs in Figure 15 revealed an onset of melting at 145°C. There is sign of partial melting and 
immediately thereafter, the crystal becomes opaque. A second, final melting step revealed smaller 
crystallites that were not visible due to the crystal opacity. The recrystallisation of these after the 
initial melt was only observable upon magnification (Figure 16). 
Figure 15: Representative HSM photographs of NVPGlT. 
Figure 16: Formation of new crystallites. Magnified HSM photograph at 148°C. 
TGAand OSC 
Analysis by DSe (Figure 17) revealed the unique co-crystal melting point with onset 137 °e and peak 
minimum at 140 °e along with immediate recrystallisation that is evident in the Dse trace. A second 
very broad melting point of the new phase was apparent at 185-220 0c. 
The TGA profile (Figure 18) shows a weight loss of 31.2 ± 1.5 % (n = 2) at 110-195 °e , corresponding 
to the degradation of glutaric acid for a 1:1 co-crystal (theoretical value: 33 .2 %), while the 
remaining mass (nevirapine) degrades directly thereafter. There is clearly no included solvent 
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60 80 100 120 140 160 180 200 220 240 260 
Temperature (DC) 
Figure 17: DSC trace for NVPGLT. 
50 70 90 110 130 150 170 190 210 230 250 270 290 310 330 
Temperature (DC) 
Figure 18: TGA trace for NVPGL T. 
Temperature-controlled PXRD 
PXRD patterns were determined at room temperature and 150°C (Figure 19) to determine what 
phase is present after the melt of the co-crystal at 137°C and subsequent recrystallisation. Clearly, 
at 150°C nevirapine has recrystallised and there is no trace of solid co-crystal or pure glutaric acid . 
So, as in the case of NVPMLE, after the melting of the co-crystal and near-simultaneous degradation 
of the co-former, nevirapine with its much higher melting point is free to recrystallise as the original, 
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Figure 19: PXRD patterns of NVPGLT recorded at room temperature and 150 ·C. The uppermost pattern was derived 
from our nevirapine bulk, the starting material from which the co-crystal was prepared. 
NMR spectroscopy 
Proton NMR spectroscopy provided further confirmation that the stoichiometric ratio in the 
NVPGLT co-crystal is indeed 1:1. The sample for proton NMR analysis was taken from a batch of 
crystals prepared by slow evaporation. A representative set of data is provided in Table 8 and further 
details are provided in the appendix. 
Table 8: Selected proton NMR signals used for the confirmation of the NVPGLT co-crystal stoichiometry. 
Assignment (, (ppm) Integral Normalised integral 
CH (aromatic, nevirapine) 8.57 1.0* 1 
CH (aromatic, nevirapine) 8.23 1.1 1 
CH2 (glutaric acid) 2.01 2.2 1 
*Reference integral 
Single crystal X-ray analysis 
Data-collection and space group determination 
One of the thick plate-like crystals was selected from the chloroform-hexane mother liquor. Data-
collection was carried out on the same diffractometer as for NVPMLE. The unit cell parameters, 
crystal system and space group were determined from diffraction data. Only inversion symmetry 
was evident and there were no systematic absences. Comparing the experimental 1£2 - 11 value of 
0.982 with the theoretical value of 0.968 for centrosymmetric structures confirmed that the space 
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Structure solution and refinement 
SHELXS-978 was employed for the structure solution of NVPGLT. The asymmetric unit contains one 
API and one co-former molecule, of which the positions of all non-hydrogen atoms were determined 
by direct methods. These atoms were assigned and refined isotropically on F2 in SHELXH-97.8 After 
conf irming acceptable isotropic temperature factors, the atoms were refined anisotropically. 
Hydrogen atom positions were evident in the difference Fourier map. These were placed in idealised 
positions by means of a riding model. Again, particular attention was paid to the amide and 
carboxylic acid groups to check whether or not proton transfer had taken place. The carboxylic acid 
protons were clearly evident in the difference map, and the c-o bond distances (Table 9) confirmed 
that these groups had not been deprotonated. The amide, in turn, did not show evidence of 
ionisation. Each hydrogen atom was assigned an isotropic temperature factor of 1.2 times (1.5 for 
methyl hydrogens) that of its parent atom. The data-collection and refinement parameters are listed 
in Table 10. 
Table 9: c-o bond distances for the glutaric acid molecule of NVPGL T. 
Bond Distance (A) 
C23-021 (single) 1.323 (2) 
C23-022 (double) 1.206 (2) 
C27-028 (double) 1.216 (2) 
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Table 10: Data-collection and refinement parameters for NVPGLT. 
Formula unit (ClsH14N40) (CSHg0 4) 
Formula mass (g morl ) 398.42 
Crystal system Triclinic 
Space group Pi 
a (A) 7.363(4) 
b (A) 12.292(6) 
c(A) 12.305(6) 
an 118.571(8) 
~ (0) 90.144(9) 
Y (0) 98.023(8) 
Volume (A3) 965.5(8) 
Z 2 
DensitYcalc (g cm-3) 1.370 
F(OOO) 420 
~(MoKa) (mm-l) 0.100 
Crystal size (mm3) 0.28> 0.26 > 0.21 
Temperature (K) 100(2) 
Range scanned 8 (0) 1.89-26.37 
Index ranges h: -9, 9; k: -15, 15; I: -15, 15 
<t> and w scan angle n 0.5 
Total number of frames 3777 
Dx(mm) 50 
Total number of reflections collected 22292 
Number of unique reflections 3906 
Number of reflections with I > 2a(l) 2999 
Number of least-squares parameters 266 
Rint 0.0477 
S 1.032 
Rl (I> 2a(I)) 0.0334 
Number of reflections omitted 9 
WR2 0.0798 
Weighting scheme parameters a = 0.0365, b = 0.3527 
(LVa)mean < 0.001 
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Molecular structure 
The asymmetric unit (Figure 20) com p rises one nevirapine molecule and one molecule of glutaric 
acid. As with the previous co-crystal, which also incorporated a dicarboxylic acid, the API and co-
former hydrogen bond via the predic ted supra molecular synthon C (see Figure 2). It is significant 
that here too, the predicted interaction between drug and partner molecule has replaced the 
generally robust amide-amide self-association of nevirapine. 
Figure 20: Asymmetric unit of NVPGL T. Thermal ellipsoids are drawn at the SO % probability level, while hydrogen atoms 
are presented as spheres of arbitrary radi i. 
Hydrogen bonding 
A representative hydrogen bonding motif is shown in Figure 21. It comprises two nevirapine 
molecules and two glutaric acid mole cules hydrogen bonded in the sequence NVP-GLT-GLT-NVP. 
Synthon C (see Figure 2) links nevirapin e molecules with glutaric acid and synthon B links the glutaric 
acid molecules in the middle, across a crystallographic centre of inversion. These four-molecule 
discrete units display typical hydrogen bonding interactions. It is significant that the amide-amide 
interaction of the nevirapine dimer is s uperseded by hydrogen bonding with the carboxylic acid. The 
pyridine nitrogens N12 and N13 do no t participate in strong hydrogen bonding, in contrast to what 
occurs in NVPMLE, where these atoms play an important directing role . 
In Figure 22 it can be seen that there are IT-stacking interactions along the a-axis and as with 
NVPMLE, the nevirapine molecules are positioned so that they interlock. The butterfly shape of 
nevirapine is essential, so the molecu les are forced to fit by being offset. The successive TT-stacked 
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Hydrogen bond parameters are provided in Table 11. The longest hydrogen bond is a C-H···N bond of 
distance 3.5 A and the strongest interactions are, as expected, N-H ·· ·O and O-H·· ·O hydrogen bonds. 
Figure 21: The primary hydrogen bonding motif, as viewed Figure 22: A view down the b-axis of n-stacking of the N13 
down the c-axis. Only the most relevant hydrogen atoms ring in the a-direction. 
are shown. 
Table 11: Hydrogen bond parameters for NVPGLT. 
D-H""A D-H (A) H"""A (A) D"""A (A) D-H"""A (0) Symmetry code 
N2-H2·· ·022 0.88 2.19 3.047(2) 163 x, y, z 
021-H21···08 0.84 1.76 2.597(2) 173 x, y, z 
029-H29···028 0.84 1.82 2.654(2) 176 3-x, 1-y, -z 
C10-H10···08 0.95 2.58 3.103(3) 115 -x, 1-y, 1-z 
C14-H14· ··022 0.95 2.56 3.353(3) 141 1-x, -y, -z 
C20-H20A···N12 0.99 2.55 3.475(3) 156 -x, -y, 1-z 
Molecular geometry 
The butterfly angle in NVPGLT is 55.9(1)0 and the torsion angle for the amide group is 6.7(2)". The 
glutaric acid molecules adopt a nearly planar conformation with a crystallographic centre of 
inversion at the centre of the carboxylic acid-carboxylic acid hydrogen bond. 
Crystal Packing 
Nevirapine molecules pack in rows along the a-axis, assisted by the non stacking interactions that 
were discussed earlier and illustrated in Figure 22 . In Figure 23 it can be seen that the glutaric acid 
molecules, which are dimerically hydrogen bonded, are also arranged in rows parallel to the a-axis. 
The rows of nevirapine molecules interact with these adjacent rows of glutaric acid dimers by 
hydrogen bonding that is staggered in the c-direct ion (Figure 24). Rows of the four-molecule 
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Figure 23: Packing of NVPGLT, viewed down the c-axis. Glutaric acid molecules are shown in different colours to 
distinguish between those in the foreground (yellow) and background (purple). 
Figure 24: Packing of NVPGLT viewed down the a-axis. 
Comparative PXRD 
PXRD was used to identify the new form as a potential co-crystal during an early stage of screening. 
SCXRD confirmed that this form was indeed a co-crystal and comparison of the computed pattern 
from SCXRD data with the experimental pattern from liquid-assisted co-grinding confirmed that the 
forms produced by both preparation methods are identical. The PXRD comparison is presented in 
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liquid-assisted grinding represents a quick and simple alternative preparative method that requires 
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Figure 25: Experimental and calculated PXRD traces for NVPGL T. 
NVPSLI: nevirapine-salicylic acid 2:1 co-crystal 
40 
The nevirapine-salicylic acid co-crystal (NVPSLI) is similar to NVPMLE and NVPGLT in that it may be 
prepared by simple slow evaporation and liquid-assisted co-grinding methods involving chloroform. 
A 2:1 mixture of the API (30 mg, 0.11 mmol) and co-former (8 mg, 0.056 mmol) were dissolved in a 
50:50 v/v chloroform-hexane mixture at ~40 °c and allowed to spontaneously cool to yield single 
crystals by slow evaporation. The crystals formed over a period of approximately four days. 
The co-crystal could also be produced by liquid-assisted co-grinding (LAG) using a few drops of 
chloroform that were constantly replenished to keep the mixture damp. 20 mg of nevirapine 
(0.075 mmol) and 5 mg salicylic acid (0.038 mmol) were combined. Kneading for 10 min in the 
presence of chloroform and allowing drying resulted in the co-crystal powder. 
Identification 
The NVPSLI co-crystal was identified during screening by chloroform LAG. The initial screening 
experiment involved grinding a 1:1 mixture of 10 mg nevirapine and a one molar equivalent of 
salicylic acid in the presence of chloroform . The result was a new phase with excess nevirapine 
identified in the PXRD pattern. The experiment was repeated with a 2:1 mixture, the result of which 
is illustrated in Figure 26. Clearly, the product of LAG represents a unique phase and contains little or 
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Figure 23: Packing of NVPGLT, viewed down the c-axis. Glutaric acid molecules are shown in different colours to 
distinguish between those in the foreground (yellow) and background (purple). 
Figure 24: Packing of NVPGLT viewed down the a-axis. 
Comparative PXRD 
PXRD was used to identify the new form as a potential co-crystal during an early stage of screening. 
SCXRD confirmed that this form was indeed a co-crystal and comparison of the computed pattern 
from SCXRD data with the experimental pattern from liquid-assisted co-grinding confirmed that the 
forms produced by both preparation methods are identical. The PXRD comparison is presented in 
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Figure 26: PXRD comparison showing the uniqueness of NVPSLI as compared with its starting reagents. 
Thermal analysis 
HSM 
The HSM photographs in Figure 27, recorded periodically while the temperature was ramped at a 
rate of 10 K min-1, showed no signs of bubbling at low temperature that would have suggested the 
presence of included solvent. The analysis revealed the melt of the co-crystal with nearly 
simultaneous recrystallisation of an unidentified phase. The HSM photograph taken at 225 O( clearly 
shows the formation of tiny crystallites along the edges of what was originally the co-crystal. The 
photograph taken at 230 O( has been magnified in Figure 28 to show the new crystallites. 
Temperature-controlled PXRD was again conducted to identify the recrystallised phase. 
180°C 225 °c 
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Figure 28: Formation of new crystallites. Magnified photograph recorded at 230°C. 
DSC and TGA 
The DS( trace of NVPSLI (Figure 29) shows that the melting onset occurs at 203 O( with peak 
maximum at 204°C. Thereafter, there is an erratic endotherm in the temperature range 215-240 0c. 
The TGA analysis represented in Figure 30 confirms that no included solvent is present in NVPSLI, as 
was determined by hot stage microscopy. The thermogram further confirms the stoichiometry of the 
co-crystal- the mass loss of 20.55 ± 0.05 % (n = 2) corresponds with the loss of one molar equivalent 
of salicylic acid in a co-crystal of stoichiometric ratio 2:1. This experimental value is precisely the 
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Figure 30: TGA trace for NVPSlI. 
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250 300 
A PXRD pattern collected at 210°C (Figure 31) reveals that NVPSLI transforms to pure nevirapine in 
the same phase as the bulk material that was used as one of the starting reagents. Upon melting of 
t he co-crystal, the nevirapine molecules are free to self-associate and reform the original 
t hermodynamically stable phase, as occurs for both of the co-crystals previously discussed here. 
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Figure 31: Temperature-controlled PXRD comparison of NVPSlI at 21°C and 210 ·C. An experimental trace for the 
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NMR spectroscopy 
Proton NMR spectroscopy was conducted on a sample of a few NVPSLI crystals grown from solution. 
The results confirmed the expected stoichiometry of 2:1 as suggested by PXRD evidence. 
Representative proton signals are summarised in Table 12 and more comprehensive details of the 
spectrum are available in the appendix. 
Table 12: Selected signals from the proton NMR spectrum of NVPSLI confirming 2:1 stoichiometry. 
Assignment 6 (ppm) Integral Normalised integral 
CH (aromatic, nevirapine) 8.49 2.1 2 
CH (aromatic, salicylic acid) 7.88 1.0* 1 
CH (aromatic, salicylic acid) 7.42 1.0 1 
CH (cyclopropyl, nevirapine) 3.71 2.1 2 
*Reference integral 
Single crystal X-ray analysis 
Data-collection and space group determination 
The thick plates were removed from their chloroform/hexane mother liquor onto a microscope 
slide. One was selected, placed in Paratone oil and the intensity data collected. The unit cell 
parameters, crystal system and space group were determined from the diffraction data, which were 
collected on the same diffractometer as for the two aforementioned co-crystals. There were no 
systematic absences and the diffraction data showed evidence of inversion symmetry only. The 
expected value of 1£2 - 11 is 0.968 for centrosymmetric structures and 0.736 for non-
centrosymmetric structures. The experimental value of 1.195 for NVPSLI confirmed that the space 
group is not PI but PI. 
Structure solution and refinement 
SHELXS-978 was employed for the structure solution of NVPSLI. The asymmetric unit contains two 
API molecules and one co-former molecule. The positions of all non-hydrogen atoms of the 
nevirapine molecules were determined by direct methods. These atoms were assigned and refined 
isotropically on F2 using SHELXH-97.8 After confirming acceptable isotropic temperature factors, the 
atoms were refined anisotropically. All hydrogen atom positions were evident in the difference 
Fourier map and the fact that no additional peaks appeared near the amide groups suggested that 
neither of these had been protonated, evidence that no acid-base reaction had taken place. All of 
the hydrogens were placed in idealised positions by means of a riding model. Each hydrogen atom 













The salicylic acid molecule is disordered over two orientations and was modelled accordingly. The 
major component A has a refined site occupancy of 0.739(3). Component A was modelled according 
to the difference Fourier map with all of the non-hydrogen atoms appearing as large electron 
density difference peaks. The atoms bonded with realistic interatomic distances and proposed bond 
angles, resembling the salicylic acid molecule. All atoms of this component were first refined 
isotropically. Upon confirmation of acceptable isotropic temperature factors, the atoms were 
refined anisotropically and exhibited refined Uiso-values of 0.031 N or less. Importantly, the c-o 
bond lengths of the carboxylic acid differed significantly (1.238 and 1.329 A) and the hydrogen atom 
of this group was identified in the electron density difference map, which confirmed that no proton 
transfer had occurred. In the case of component B (s.o.f. = 0.261(3)), all of the atoms were modelled 
isotropically. The substituents on the ring were allowed to refine freely but the benzene ring 
geometry was poor and required an AFIX 66 command, which was justified because the ring is 
required to be planar and have standard bond distances and angles, as exhibited by component A. 
All hydrogen atoms of both disordered components were placed using the same method as used for 
the nevirapine molecules. The high residual electron density difference peak of 1.30 e A-3 is located 
at the centre of the disordered salicylic acid molecules. It is an artefact that appears because of the 
large concentration of electron density represented by the benzene ring, which is disordered in the 
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Table 13: Data-collection and refinement parameters for NVPSLI 
Formula unit 2(C1SH14N40) (C7H60 3) 
Formula mass (g morl ) 670.72 
Crystal system Triclinic 
Space group Pi 
a (A) 11.155(1) 
b (A) 12.619(2) 
c (A) 13.464(2) 
a (0) 113.374(2) 
~n 99.133(2) 
y (0) 107.324(2) 
Volume (A3) 1575.8(3) 
Z 2 
OensitYcalc (g cm·3) 1.414 
F(OOO) 704 
Il(MoKa) (mm-l ) 0.097 
Crystal size (mm3) 0.35 x 0.14 x 0.05 
Temperature (K) 100(2) 
Range scanned e (0) 2.91-28.14 
Index ranges h: -14,14; k: -16,16; I: -17,17 
<p and w scan angle (0) 0.5 
Total number of frames 2030 
Ox (mm) 40 
Total number of reflections collected 23138 
Number of unique reflections 7552 
Number of reflections with I > 2a(l) 5331 
Number of least-squares parameters 474 
Rint 0.0296 
S 1.042 
Rl (I > 2a(I)) 0.0664 
Number of reflections omitted 23 
WR2 0.1851 
Weighting scheme parameters a = 0.1248, b = 0.6966 
(LVa)mean < 0.001 
~p excursions (e A"3) 1.298, -0.432 
Molecular structure 
The asymmetric unit consists of two crystallographically independent nevirapine molecules, denoted 
A and 8 for convenience, along with one salicylic acid molecule, which is disordered over two 
orientations. As can be seen in Figure 33 the two positions of the salicylic acid molecule are related 
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Figure 32: Asymmetric unit of NVP5L1. Thermal ellipsoids are drawn at the SO % probability level, while hydrogen atoms 
and disordered guest atoms are shown as spheres of arbitrary radii. 
0298 
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An overlay of the two nevirapine molecules of the asymmetric unit in Figure 34 shows that the 
molecules are puckered in opposite directions. The slight kink in the cyclopropyl substituent of 
nevirapine molecule A is confirmation that the two are not quite mirror images of one another. 
Figure 34: Overlay of the two nevi rapine molecules of the asymmetric unit. Atoms Cl, N2 and N5 are overlayed. 
Molecule A is displayed in red and B in blue. 
Hydrogen bonding 
Note the hydrogen bonding within the asymmetric unit that is illustrated in Figure 35. The salicylic 
acid molecule is internally hydrogen bonded - the hydroxyl group donating towards the carbonyl 
oxygen of the carboxylic acid. An example of the supra molecular synthon D (see Figure 2) is 
observable - the hydroxyl of the carboxylic acid in turn donates a hydrogen atom to the pyridine 
nitrogen N13 of nevirapine molecule A. The pyridine nitrogens of nevirapine molecule B are not 
hydrogen bonded. The two crystallographically independent nevirapine molecules are hydrogen 
bonded via synthon A to form the typical dimer. Parameters for the most important hydrogen bonds 
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Table 14: Hydrogen bond parameters for NVPSll. 
D-H .. ·A D-H (A) H .. ·A (A) D .. ·A (A) D-H"'A (0) Symmetry code 
N2A-H2A .. ·08B 0.88 2.05 2.924(2) 170 x,y,z 
N2B-H2B"'08A 0.88 2.05 2.921(2) 169 x,y,z 
027 A-H27 A .. ·029A 0.84 1.84 2.579(3) 145 x,y,z 
030A-H30A"'N13A 0.84 1.86 2.688(3) 168 x,y,z 
C14A-H14A .. ·08B 0.95 2.57 3.433(3) 152 1-x,1-y,1-z 
C17A-H17A .. ·029A 0.98 2.55 3.212(3) 125 1-x,1-y,1-z 
C17B-H17F"'08A 0.98 2.60 3.448(3) 145 x,y,z 
C18A-H18A"'030A 1.00 2.48 3.160(3) 125 x,y,z 
C19B-H19C· .. 027A 0.99 2.50 3.416(3) 155 1-x,1-y,1-z 
030B-H30B .. ·N13A 0.84 2.12 2.941(16) 167 x,y,z 
027B-H27B,,·029B 0.84 1.84 2.461(18) 142 x,y,z 
C19A-H19B"'027B 0.99 2.53 3.378(11) 143 1-x,1-y,1-z 
Multiple IT-IT stacking interactions further stabilise the structure. Note in Figure 36 that infinite 
chains of nevirapine molecules - as seen in both NVPMLE and NVPGLT - are shown on the right, 
while on the left is a discrete three-membered motif comprising one salicylic acid molecule 
'sandwiched' between the N12 pyridine rings of two unrelated nevirapine molecules. For the 
interaction represented on the left, only the major component of the co-former is shown. For this 
major orientation, the distance between the centroids of the nevirapine molecule A and the co-
former is shorter than the nevirapine B-salicylic acid distance. The average of these is 3.82 A. For the 
minor position of the co-former, the nevirapine A-salicylic acid distance is still the shorter, while the 
distance between centroids of nevirapine B and the salicylic acid molecule is slightly greater than 4 
A, which is large for this type of interaction. The average of these two is 3.83 A. With regard to the 
'IT-stacking on the right in Figure 36, the mean distance between centroids is 3.63 A. 
b 
\ a 
NeVir.Pi~ - '7 
c 
Figure 36: TT-TT stacking in NVPSll . View of the ac-plane on the left (with only the major disordered component shown) 
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Table 15: Parameters for n-stacking interactions in NVPSLI. Cg is the centre of gravity (centroid) of a given ring. 
Ring# Atoms Interaction* Cgl· .. CgJ 
Cgll. CgJ l. Symmetry 
distance* distance code 
1 C6A-7N12A Cg1"'Cg5 3.655(2) 3.654 3.579 1-x, 1-y, -z 
2 C4A-7N13A Cg1"'Cg6 3.546(6) 3.531 3.324 1-x, 1-y,-z 
3 C6B-7N12B Cg2 .. ·Cg2 3.909(1) 3.448 3.448 1-x, 1-y, 1-z 
4 C4BN-713B Cg2 .. ·Cg4 3.630(1) 3.507 3.536 l+x,y,z 
5 C21A-7C26A Cg3 .. ·Cg5 3.988(2) 3.578 3.479 1-x, 1-y, 1-z 
6 C21B-7C26B Cg3 .. ·Cg6 4.116(6) 3.692 3.738 1-x, 1-y, 1-z 
Cg4" 'Cg2 3.630(1) 3.536 3.507 -l+x,y,z 
Cg4 .. ·Cg4 3.712(1) 3.393 3.393 -x, 2-y, 1-z 
Cg5 .. ·Cg1 3.655(2) 3.579 3.654 1-x, 1-y,-z 
Cg5 .. ·Cg3 3.988(2) 3.479 3.578 1-x, 1-y, 1-z 
Cg6".C-,\1 3.546(6) 3.324 3.531 1-x, 1-y, -z 
Cg6"'Cg3 4.116(6) 3.738 3.692 1-x, 1-y, 1-z 
*The length of the line drawn between Cgl and CgJ normal to the mean plane of the atoms of ring I 
Molecular geometry 
The nevirapine butterfly angle is 58.2(1)° for molecule A and 59.4(1)° for B. The amide torsion angles 
(C3-N2-Cl-C7) are 5.2(3)" and -7.3(3)" for A and B respectively. Given that the nevirapine dimer is 
present in NVPSLI but not in NVPMLE or NVPGLT, it is interesting to note that in this case the 
butterfly angles for both independent nevirapine molecules are greater than for the previous two 
co-crystals. The amide groups here are similarly planar, so it is the amide function of NVPMLE that is 
the most twisted with a torsion angle of 13.2°. 
Crystal packing 
NVPSLI displays a crystal packing arrangement that is similar to the one exhibited by the toluene 
solvate of nevirapine reported by Caira et 01.2 and referred to briefly at the start of this chapter. 
Representations of NVPSLI and the toluene solvate are shown in Figure 37 and Figure 38 
respectively, viewed in different orientations to best illustrate their resemblance . This similarity in 
packing calls into question the validity of the distinction between co-crystals and solvates. A co-
crystal is comprised of components that are all solids at room temperature, while a solvate contain 
molecules of the solvent from which the crystals were grown. While this distinction has been 
accepted for the purpose of this study (see Chapter 1), it is noteworthy that both the solvate and co-
crystal in question incorporate 'guest' molecules of similar size. In the case of NVPSLI, while there 
are hydrogen bonds between API and co-former, the sal icylic acid molecules clearly occupy channels 
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interactions are 'host-host' interactions forming the typical nevirapine amide-amide dimer. It is 
difficult to accept that the two species belong to different classes. 
Figure 37: View down the line [110) of the NVPSLI co-crystal. Only the major disordered component is shown. 
Figure 38: View down [100) of the nevirapine toluene solvate. This image is reproduced from reference 2. 
Comparative PXRD 
The comparison below shows that the experimental pattern of the co-crystal obtained by liquid-
assisted co-grinding matches the calculated trace from the diffraction data. This provides assurance 
that the crystal chosen for SCXRD represents the sample of NVPSLI that was used for other analyses. 






















5 10 15 
--Experimental 
--Calcu lated 
20 25 30 35 
Figure 39: Comparison of experimental and calculated PXRD traces for NVPSLl. 
Solubility Studies 
40 
The three co-crystals described above were subjected to solubility tests in the hope that one or 
more would show enhanced solubility over the nevirapine raw materia l. An excess amount of each 
co-crystal was weighed into 20 cm3 test tubes. These were filled with MilliQ water (leaving a small 
amount of air to facilitate agitation), sealed and placed in a solubility bath. The bath was set at a 
temperature of 37 °C and the test tubes were agitated for 24 h. A UV spectroscopic method was 
attempted according to the method described by Stieger et al. lO However, shifting of the Amax of 
nevirapine occurred in all cases, making the calibration curve invalid . It was thought that, based on 
existing evidence of shifting of the peak in acidic medium, the acidity of the co-formers in solution 
caused the complication. An HPLC method, as described in Chapter 2, was employed instead. 
Calibration curves were constructed for all three co-crystals. An amount of co-crystal was weighed 
and made to volume using HPLC grade methanol. Regression lines of r2 = 0.998524, r2 = 0.999653 
and r2 = 0.999943 were obtained for nevirapine in NVPMLE, NVPGLT and NVPSLI, respectively. 
The values for the equilibrium solubility at 37 °c in water are provided in Table 16. The solubility 
ratio is See /S[ree where S[ree is the solubility of anhydrous nevirapine and S ec the solubility of 
nevirapine for the co-crystal. Clearly, the NVPGLT and NVPSLI co-crystals showed only a minor 
enhancement in solubility but the NVPMLE showed the greatest increase - 5.3 times. This compares 
favourably with reported results where co-crystallisation has produced increases and decreases in 
equilibrium solubility.ll Itraconazole co-crystals12 had enhancements of 4-20 times in 0.1 M HCI but 
more impressive results have also been shown. For example, Good and co-workers reported 2-152 
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Table 16: Results of solubility determination at 37°C in water for the nevirapine standard and three co-crystals. 
Form Nevirapine solubility (mg cm3) Solubility ratio 
Nevirapine standard lO 0.0976 ± 0.0017 1 
NVPMLE 0.515 ± 0.033 5.3 
NVPGLT 0.115 ± 0.003 1.2 
NVPSLI 0.110 ± 0.010 1.1 
Co-crystal Comparison 
Interestingly, all of the co-crystals reported here were reliably prepared by LAG and/or slow 
evaporation from solution and were identified as potential co-crystals during the LAG stage of co-
crystal screening. This suggests solvent-assisted co-grinding is a quick method (as little as 5 minutes 
to reach complete conversion) for finding a potential nevirapine co-crystal. The method certainly 
allows for a large variety of solvents and a high co-former throughput rate, and involves very small 
amounts of sample (~1O mg) that may even be recoverable, depending on the method of sample 
preparation employed for PXRD analysis. 
For convenience the abbreviations NVSC and NVTIA, as assigned by Samsodien will be used here in 
reference to that author's nevirapine-saccharin and nevirapine-rac-tartaric acid co-crystals. 5 These 
were described briefly in the introduction to this chapter. It is noteworthy that all of the successfully 
employed co-formers in the present study possessed carboxylic acid groups and none of the amides 
- except propionamide - provided potential evidence of co-crystallisation. Of all the known 
nevirapine co-crystals, only NVSC does not incorporate a carboxylic acid . 
Table 17 provides a summary of relevant parameters related to the five nevirapine co-crystals. 
NVPMLE has the highest solubility ratio with respect to anhydrous nevirapine and NVTIA is the most 
thermally stable. 
Table 17: Properties of the nevi rapine co-crystals. 
Co-crystal Stoichiometry 
Melting onset 
Solubility ratio Method of preparation (0C) 
NVPMLE 1:1 185 5.3 LAG 
NVPGLT 1:1 137 1.2 LAG/slow evaporation 
NVPSLI 2:1 203 1.1 LAG/slow evaporation 
NVSC 2:1 223 1.4* Slow evaporation 
NVTIA 1:1 228 1.2* Slow evaporation 
·Estimated based on the percentage dissolution after 3 hours, according to Samsodien.
5 
Interestingly, the dicarboxylic acids (maleic acid and glutaric acid) were able to prevent the 
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bonding to form a four-molecule motif. NVTTA also exhibits amide-carboxylic acid hydrogen bonding 
(synthon C in Figure 2), where the typical nevirapine self-association does not occur.s In the case of 
NVPSLI, the salicylic acid co-former behaves similarly to the solvent molecule toluene, by occupying 
channels in the crystal. It may be that the preferred intramolecular hydrogen bonding of salicylic 
acid reduces its electron donating potential to the extent that it is unable to compete with the 
amide-amide interaction of the API dimer. 
All three of the co-crystals studied herein displayed melting points somewhere between those of the 
co-former and API. In general this is a common result but not predictable. There have been cases of 
co-crystals having melting points below, within or above the melting range ofthe starting reagents.ll 
The co-crystals NVSC and NVTTAs were not shown to exhibit the recrystallisation of nevirapine as 
was described here. Instead, after melting, these co-crystals decomposed. The thermal behaviour of 
these co-crystals in the temperature range between melting and final degradation warrants further 
investigation, given that all three of the co-crystals described in the present study displayed a 
common phenomenon. 
Cyclodextrin Inclusion 
There have been reports of ~-CD, randomly methylated-~-CD (RAMEB) and hydroxyl-propyl-~-CD 
(HP-~-CD) inclusion complexes of nevirapine with accompanying solubility studies.4 However, the 
PXRD evidence upon which the conclusions of complexation are based is not convincing. 
Here we report a repetition of the experiment from literature along with a number of other 
attempts at inclusion of nevirapine in ~- and y-CD by liquid-assisted kneading and co-precipitation by 
slow-cooling. The kneading experiments summarised in Table 18 all involved kneading in the 
presence of MilliQ water (enough to maintain a wet paste) for 45 min. The products of kneading 
were analysed by PXRD while still moist. The co-precipitation experiments (Table 19) entailed 
dissolving ~15 mg of the co-former and one molar equivalent of j3-CD or V-CD in water, stirring for 
approximately 24 h at a temperature of 60°C. Thereafter the solutions were filtered and allowed to 
cool slowly in a vacuum flask. 
Table 18: Solvent-assisted kneading experiments. 
Cyclodextrin Molar ratio Solvent 
j3-CD 1:1 H2O 
j3-CD 1:1 30% ethanol in water (v/v) 
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Table 19: Co-precipitation experiments by slow cooling. 
Cyclodextrin Molar ratio Solvent 
~-CD 1:1 H2O 
~-CD 1:1 30% ethanol in water (v/v) 
V-CD 1:1 H2O 
V-CD 1:1 30% ethanol in water (v/v) 
All of the attempts at cvclodextrin inclusion of nevirapine failed . In particular, even the reported 
method for preparation of a nevirapine-~-CD complex by methanol-assisted kneading yielded only a 
physical mixture. The comparison of PXRD traces in Figure 40 confirm this result and that the same 
occurred in the presence of water. Evidently, the authors of the paper in which the methanol-based 
method was used misinterpreted their PXRD data . 
--Water, 45 min 
- Methanol, 45 min 
--Nevirapine 
-~-CD 
5 10 15 20 25 30 
Figure 40: PXRO comparison showing traces of the products of water-assisted kneading and methanol-assisted kneading, 
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Figure 41 shows that for V-CD as well, kneading in the presence of water produces merely a physical 
mixture of drug and cyclodextrin. 
--Water, 45 min 
-- Nevirapine 
--V-CD 
5 10 15 20 25 30 
Figure 41: PXRD comparison showing traces of the product of water-assisted kneading as well as traces of the pure API 
and V-CD (computed) 
Solution studies included experiments using isothermal titration calorimetry (ITC) and proton NMR 
spectroscopy. The results thereof further supported the solid-state experimental evidence that a 
[3-CD complex was unlikely to have been produced by the method described in literature. ITC was 
performed on nevirapine-[3-CD and nevirapine-y-CD systems in 30 % ethanol in water (v/v) and the 
results were haphazard. There was no consistent indication of complexation. 
The NMR experiments were conducted in d6-DMSO because of the exceptionally low aqueous 
solubility of nevirapine. No significant differences in chemical shifts were observed for either the 
cyclodextrin protons or nevi rapine protons in the initial equimolar test for solutions of nevi rapine 
with [3-CD and V-CD. The implication is that under these conditions, there was little or no interaction 
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Chapter 4: Efavirenz 
Introduction 
There are several efavirenz polymorphs described in literature. Herein we will refer mostly to Form 1 
and Form ~ with reference to two reported polymorphs. There are also reported co-crystals and 
solvates. There have been several patents claiming novel polymorphs, and X-ray structures have 
been published for four polymorphs, one hydrate, two solvates and two non-pharmaceutical co-
crystals. References to these studies are provided below. 
Tiekink et 01. published the first known crystal structure of efavirenz in 2009.1 Having compared its 
calculated PXRD trace with the traces of known polymorphs as they appear in patents, Mahapatrah 
and co-workers determined that it does not correspond with any ofthe patented forms of the drug.2 
Form 1, the first efavirenz polymorph patented by the DuPont Pharmaceutical Company/ is 
accepted to be the most thermodynamically favourable form of the drug. Each of the other four 
polymorphs (Forms 2, 3, 4 and 5) described in this particular patent can be converted to Form 1. A 
number of patent applications followed this original one, claiming several novel polymorphs.4,s,6 
There are also methods for the preparation of an amorphous phase. 7 The bulk efavirenz (as 
purchased) with which the present study was conducted corresponds with Form 1. Figure 1 shows 
the PXRD comparison that confirms this. 
5 10 15 20 25 30 
Figure 1: PXRD of the efavirenz bulk (as purchased and used in the present study; blue trace) and Form 1 as it appears in 










Ravikumar and Sridhar reported X-ray structures for two forms - a monohydrate and a polymorph.8 
The polymorph corresponds with Form ~, which was patented by the company Ranbaxy 
La boratories. 6 
There are also reported solvates and co-crystals. Mahapatra and co-workers have determined X-ray 
structures of two related polymorphs and two related cyclohexane solvates. Both pairs are 
interconvertible by temperature-induced single-crystal to single-crystal phase transformations. One 
of the polymorphs has been shown to be the thermodynamically stable Form 1. In addition, the 
same group determined X-ray crystallographic structures of two non-pharmaceutical co-crystals with 
the partner molecules l,4-cyclohexanedione and 4,4' -bipyridine.2 
Present study 
During the co-crystal screening process in this study, it became evident that liquid-assisted grinding 
(LAG) of efavirenz with THF and ethanol resulted in phase transitions. One of the polymorphs 
isolated has been identified as Form ~ (the structure determined by Ravikumars group), while the 
other did not match reported forms. Attempts were made to recover single crystals of these forms 
by recrystallisation from various solvents but these were unsuccessful. 
Cyclodextrin inclusion studies involved attempts at complexation using standard kneading methods 
and co-precipitation by slow cooling. A reported method for complex formation was investigated. 
Furthermore, the solution behaviour of efavirenz in the presence of various cyclodextrins was 
studied. The results were not conducive to full characterisation of the inclusion behaviour but 
qualitative conclusions could be drawn about the nature and relative strengths of the interactions. 
Co-crystal Screening 
A summary of co-crystal screening results is presented in Table 1. There were two hits in the co-
crystal screening stage that involved solvent-assisted co-grinding with tetrahydrofuran (THF). DSC 
analysis was conducted on these potential co-crystals but in each case the analysis revealed several 
thermal events, an indication that the product contained a mixture of phases. So, it was not possible 
to prepare any efavirenz co-crystals by dry- or liquid-assisted co-grinding. 
Fourteen different co-formers were used during the slow evaporation stage of screening. Despite 
the large variety of solvents and solvent mixtures employed, no crystals were yielded; only 
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Table 1: Summary of the results of efavirenz co-crystal screening. 
Method Co-formers Hits Pure co-crystal 
Dry co-grinding 18 0 0 
Tetrahydrofuran LAG 19 2 0 
Ethanol LAG 7 0 0 
Slow evaporation 14 0 0 
As mentioned above, during the co-crystal screening process, it became evident that liquid-assisted 
grinding with THF and ethanol resulted in phase transformations of the efavirenz component. One of 
the polymorphs has been identified as a known polymorphic form (Form 13), while the other was 
unidentifiable . With regard to the unidentified form, TGA revealed the likelihood of included solvent. 
Form J3 by Liquid-assisted Grinding 
There were occurrences of phase transformation with regard to the efavirenz component during a 
number of co-crystallisation attempts by solvent-assisted co-grinding with ethanol. Except in the 
cases of possible co-crystallisation and no change, efavirenz (Form 1) was transformed to Form ~ 
during grinding with ethanol. The refined method involved grinding efavirenz with a few drops of 
ethanol using a pestle and mortar for at least 10 min and allowing the resultant material to dry. The 
PXRD traces in Figure 2 confirm that the product of this LAG preparation is in fact Form 13. Previous 
descriptions of preparative methods for Form 13 have not incorporated grinding or solvent-assisted 
grinding. Even the most recent patent application (2009)9 describes only solution-based methods 
involving seeding and freeze-drying. Thus, the method described here represents a new, rapid 
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Figure 2: PXRO comparison of the product of ethanol liquid-assisted grinding (experimental) and Form 13 (calculated 
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Solvate by liquid-assisted Grinding 
The second form of efavirenz, prepared by LAG using THF, is a solvate. Its PXRD pattern is not similar 
to any reported patterns, which makes it difficult to identify as a known form. To check whether this 
was an unsolvated polymorph or a solvate, the sample was subjected to TGA beyond its melting 
point. 
The TGA experiment was conducted between room temperature and 300 o( at a heating rate of 
5 K min-1. The TGA trace (Figure 3) exhibits a relatively large mass loss at low temperature (~40 0c) 
suggesting the loss of THF or water. THF is the more likely of these two candidates because of its 
lower boiling point (66 0c) but, given that desolvation may occur well below or above the solvent 
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Figure 3: TGA trace of EFV solvate prepared by THF liquid-assisted grinding_ 
The solvent mass loss determined from TGA is ~12%, which implies a host-guest ratio of 1:0.6 if THF 
is included; however, it is unwise to make firm assertions about stoichiometry because of the nature 
of the preparation method . Liquid-assisted grinding leaves the sample inherently prone to both 
surface adsorption and desolvation, meaning the TGA will likely reflect a mass loss that is in excess 
(where the sample is still dam p) or smaller (because of drying to the point of partial desolvation) 
than the actual stoichiometric value. In addition, the solvent loss occurs at a low temperature, so the 
solvent molecules are proba bly loosely held within the crystal. Solvent loss under ambient 
conditions may also result in a misleading va lue from TGA. 
Temperature-controlled PXRD 
Variable temperature PXRD a nalysis was carried out to investigate the desolvation process. PXRD 
patterns were determined at r oom temperature, 40, 80 and 120 0c. The comparison of patterns in 
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so lvate to the thermodynamically stable Form 1 of efavirenz, the bulk material from which the 
solvate was initially prepared .This result is consistent with the TGA trace, where the maximum rate 
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Figure 4: Variable temperature PXRD patterns for the efavirenz solvate prepared by THF liquid-assisted grinding. 
Temperatures are in °C. 
Cyclodextrin Inclusion 
There are reports of cyclodextrin inclusion complexes of efavirenz with (3-CD and derivatised 
cyclodextrins. In particular, Sathigari and co-workers have described complexes of efavirenz with (3-
CD, hydroxypropyl-(3-CD (HP-(3-CD) and randomly methylated (3-CD (RAMEB). l1 
Solid-state experiments involved attempted complexation by simple 1:1 mole ratio kneading 
experiments in the presence of water and ethanol. NMR spectroscopy was used to study the 
behaviour of efavirenz-cyclodextrin systems in solution. Here, all of the cyclodextrins used by 
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Solid-state studies 
Table 2 and Table 3 summarise the attempts at cyclodextrin inclusion by kneading and co-
precipitation, respectively. None of these experiments produced convincing evidence of 
complexation. 
Table 2: Solvent-assisted kneading experiments 
Cyclodextrin Mole ratio Solvent Method 
~-CD 1:1 H2O 45 min knead 
~-CD 1:1 50 % ethanol in water (v/v) 45 min knead 
V-CD 1:1 H2O 45 min knead 
Table 3: Co-precipitation experiments 
Cyclodextrin Mole ratio Solvent Method 
~-CD 1:1 H2O Slow cooling from 60°C 
~-CD 1:1 30 % ethanol in water (v/v) Slow cooling from 60°C 
V-CD 1:1 H2O Slow cooling from 60 °c 
V-CD 1:1 30 % ethanol in water (v/v) Slow cooling from 60°C 
DIMEB 1:1 H2O Recrystallisation at 60°C 
TRIMEB 1:1 H2O Recrystallisation at 60°C 
The kneading experiments conducted with EFV and ~-CD yielded only physical mixtures of the 
starting components, as evidenced by PXRD comparisons in Figure 5. Displayed are experimental 
traces of A, the product of 1:1 kneading in the presence of water and B, the product of 1:1 kneading 
in the presence of 50 % ethanol in water (v/v). 
Both kneading experiments were carried out for 45 min and the products sampled while still a wet 
paste, so as to ensure an accurate PXRD representation. Allowing the sample to dry completely may 
result in a different crystal form, as crystalline solvent is liberated. One of the kneading experiments 
was conducted according to the method described by Sathigari's group except that the kneading 
time was increased to 45 min for continuity and to be sure that adequate time was provided for 
complete conversion . Our results did not agree with those reported in the paper. 
With reference to the PXRD traces in Figure 5, it is clear that the product A is merely a physical 
mixture of the starting reagents, while the kneaded material B is a physical mixture containing at 
least pure ~-CD . The balance of the material represented by B may consist of some polymorph of 
efavirenz, an efavirenz solvate and/or a small amount of complexed efavirenz; it cannot be said for 
certain which . What is clear is that this method does not appear to be a reliable one for the 
preparation of an efavirenz-~-CD complex and the PXRD evidence is not by itself sufficient to 
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transitions when ground in the presence of some solvents. This accounts for the prominence of pure 
~-CD peaks with the simultaneous shrinkage of, in particular, the largest efavirenz peak at 28 ~ 6° . 
5 10 15 20 25 30 
--Water, 45 min 
--50% ethanol in 
water (v/v), 45 min 
--Efavirenz 
-~-CD 
Figure 5: PXRO comparison for I3-CO kneading experiments. 
Similarly, with V-CD, the kneading method produced only a physical mixture of host and guest. Here, 
only a single V-CD kneading experiment was conducted, since no reported methods existed . The 
method employed was kneading, in the presence of water, of an equimolar mixture of efavirenz and 
V-CD. The resultant material was sampled while still a wet paste and analysed using PXRD. The traces 
compared in Figure 6 show clearly that the product of kneading is a physical mixture of the host and 
guest - the trace shows only peaks represented in the traces of the pure components. 
--Water, 45 min 
--Efavirenz 
--y-CD 
5 10 15 20 25 30 
Figure 6: PXRO comparison for V-CO kneading experiment. 
Solution studies 
The solution behaviour of efavirenz in the presence of cyclodextrins was investigated. Because of the 
extemely low aqueous solubility of the drug, its solution behaviour in water could not be studied by 
NMR spectroscopy. The concentration required was 10 mM (3.2 mg cm-3), while the solubility of 
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experiments were carried out in d6-DMSO with the 1:1 molar ratio tests providing an initial 
indication of the extent of interaction between the efavirenz and cyclodextrin molecules. Again the 
interactions between the drug and CD appear to be weak and difficult to characterise . The chemical 
shift variations in all of the experiments did not allow for the determination of useful Job plots. Note 
that the choice of CDs was informed by the evidence of complexation with ~-CD, HP-~-CD and 
RAMEB that had been published previously.ll 
Initially, tests were conducted for equimolar solutions of the drug and cyclodextrin to determine 
which systems showed signs of strong interaction between the host and guest. This involved the 
preparation of 10 mM stock solutions of both efavirenz and the cyclodextrins. For the 1:1 test, the 
solutions were mixed in equal volume, stirred for a period of 24 h and sampled . 
These preliminary tests would inform the decision about which systems to include in the set of 
continuous variation experiments. A shortened version of the results is given in Table 4. Only the 
chemically induced shifts (CISs), tJ.0, for the protons H1, H2 and H3 of efavirenz are shown because 
the values for these three were greatest. The CISs for the rest of the efavirenz protons were 
negligible. We were also able to determine CISs for the protons of ~-CD and V-CD. Overall, the CISs 
were greatest for y-CD, HP-~-CD and RAMEB, so it was decided to carry out full continuous variation 
experiments with these three. 
Table 4: CISs for efavirenz protons H1, H2 and H3, which showed the greatest deviat ions during tests that involved a 
host-guest molar ratio of 1. 
Cyclodextrin tJ.6(Hl) (ppm) 
~-CD 1.10 x 10-3 
V-CD -7.40 x 10-3 
HP-~-CD -1.01 x 10-2 
RAMEB -6.70 x 10-3 
tJ.6(H2) (ppm) 
8.00 X 10-4 
-7 .70 X 10-3 
-1.13 10-2 
-8.30 X 10-3 
tJ.6(H3) (ppm) 
2.00 X 10-4 
-6.70 X 10-3 
-9.30 x 10-3 




Figure 7 presents the data for continuous variation experiments carried out with the three 
cyclodextrins that showed the greatest absolute CISs during preliminary tests. For a system that 
forms an inclusion complex in solution, plotting tJ.o·[Xl * against the ratio 
R = [Xl/([Hlt+[Glt), as described in Chapter 2 should produce a relatively smooth Job plot with a 
maximum where R is equal to the stoichiometric ratio of the complex. However, the results for the 
efavirenz-cyclodextrin systems are erratic. They suggest that there is some interaction, the strength 
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of which generally increases as the value of R is increased. However the dramatic decreases at 
R = 0.5 for y-CD, R = 0.5 for HP-~-CD and R = 0.9 for RAMEB imply complicated interactions with 
potentially multiple modes of weak complexation. 
0.08 0.05 
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Figure 7: Results of continuous variation experiments w ith efavirenz and V-CD, HP-j3-CD and RAMEB. The data obtained 
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The NMR peaks of the HP-~-CD and RAMEB protons could not be easily followed because of 
overlapping within the spectrum but the V-CD proton signals could be tracked. The CISs for the OH2 
and OH3 protons (Figure 8) of V-CD were the greatest during preliminary tests but for ratios of 0 to 1 
in steps of 0.1, the values of 66·[V-CDl for these protons followed a similarly erratic pattern as for 
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Figure 8: Results of the continuous variation experiment with efavirenz and V-CD. The data obtained for V-CD protons 
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Chapter 5: Zidovudine 
I ntrod uction 
In 1987 zidovudine, or azidothymidine (AZT), became the first drug approved for AIDS therapy. l It is 
a chiral drug which is still employed, in combination therapy, as a nucleoside reverse transcriptase 
inhibitor against HIV-1 infection. This API has a modest aqueous solubility of 25 mg cm-3, a low 
melting point of 106-112 °c and is basic with a pKa of 9.7.2,3 Represented in the figure below, the 
molecule possesses potential hydrogen bond donor/acceptor groups that have been highlighted. 
Figure 1: Zidovudine with potential hydrogen bonding groups highlighted. 
The single crystal structure of zidovudine has been reported by at least three different groups4,S,6 
and a number of structures of derivatives have been determinedY There were no other polymorphs 
of zidovudine reported, nor solvates of zidovudine known at the time of writing. Only two co-crystals 
of zidovudine are known - one with lamivudine and another with 2,4,6-trinitropyrimidine, a co-
former which is not pharmaceutically relevant.9 Thus, while this drug has been in use for at least 30 
years, it does not appear to have been the target of many attempts at supra molecular modification. 
Included in this chapter are details of co-crystal screening experiments with GRAS compounds and 
attempts at cyclodextrin inclusion. A new form, namely a novel ~-CD complex has been discovered. 
Details of its preparation, analysis and the determination of its single crystal structure are presented. 
Co-crystal Screening 
Limited screening experiments were conducted with zidovudine. A representative selection of co-
formers was used for dry co-grinding and liquid-assisted co-grinding (LAG) with ethanol. All mixtures 
for the co-grinding experiments were prepared in 1:1 molar ratio and co-ground for 10 min. Table 1 
below provides a summary of the results of the screening experiments, showing that two hits were 
obtained. The set of nine co-formers employed were selected for variety in functional groups, 
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Table 1: Summary of the results of grinding experiments from co-crystal screening of zidovudine. 
Method Co-formers· Hits 
Dry co-grinding 9 1 
Ethanol LAG 9 1 
*The nine co-formers are glutaric acid; isonicotinamide; maleic acid ; L-malic acid; oxalic acid dihydrate; piperazine; 
propionamide; saccharin and L-ta rta ric acid. 
The first two stages of screening produced hits only with saccharin but from PXRD analysis it was 
evident that the resultant material was not a pure phase but a mixture of the possible co-crystal and 
zidovudine. Ten slow evaporation experiments, with 1:1 molar ratio and employing a different 
solvent or solvent mixture in each case, were subsequently conducted with saccharin as co-former. 
These experiments yielded no hits. 
Cyclodextrin Inclusion 
Attempts were made at preparing complexes of zidovudine with ~-CD and y-CD, as well as with the 
derivatised cyclodextrins DIMEB and TRIMEB. A number of standard methods were employed 
including kneading, co-precipitation by slow cooling and co-precipitation at elevated temperature, 
the results of which are summarised in Table 2. 
Table 2: Summary of experimental results for attempted cyclodextrin inclusion of zidovudine. 
Cyclodextrin Method Result 
~-CD 30 min water-assisted kneading Complex crystals 
~-CD Slow cooling Physical mixture 
V-CD 30 min water-assisted kneading Powdered complex 
V-CD Slow cooling V-CD crystals 
DIMEB Elevated temperature DIMEB crystals 
TRIMEB Elevated temperature No crystals 
Co-precipitation by slow cooling produced an inclusion complex of zidovudine with ~-CD, while only 
pure host crystals resulted from the co-precipitation experiments with V-CD. Kneading in the 
presence of water, on the other hand yielded a V-CD complex and a zidovudine-~-CD physical 
mixture. The slow cooling experiments entailed dissolving 20-30 mg zidovudine and one molar 
equivalent of V-CD or ~-CD in 0.8-1 cm3 Milli-Q water at elevated temperature . The resultant 
solutions were filtered while hot and allowed to cool slowly in a vacuum flask over a period of 2-3 
days. The kneading experiments were carried out by mixing ~10 mg of zidovudine with one molar 
equivalent of ~-CD or V-CD and kneading for 30 min. Water was added to ma intain a wet paste-like 
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The solubilities of the derivatised cyclodextrins DIMEB and TRIMEB are inversely related to 
temperature. At room temperature and below, both are highly water-soluble and at around 60°C 
thei r solubilities are much lower. Inclusion attempts with these potential hosts were carried out by 
dissolving ~20 mg zidovudine and one molar equivalent of TRIMEB or DIMEB in 5 cm3 MiIIiQ water, 
with the vials suspended in an ice bath. The suspensions were stirred for 24 h, after which they were 
filtered while still cold, placed in an oven preset to 60°C and allowed to slowly crystallise . The 
experiments with these cyclodextrins did not yield any complexes. 
J3-Cyclodextrin Inclusion Complex 
Preparation of the complex 
Single crystals of the zidovudine-p-CD complex (ZIDj3CD) were grown - with great difficulty - by slow 
cooling. A saturated solution of 138 mg (0.11 mmol) ~-CD and 29 mg (0.11 mmol) zidovudine was 
prepared by dissolving at 60°C in water while stirring for 6 h. Thereafter the solution was filtered 
while hot and placed in a covered vacuum flask and allowed to cool over a period of 3 days. This 
method did not reliably produce the complex, with the host often crystallising as the free hydrate. 
Only high concentrations (typically ~ 0.14 mmol cm·3) yielded crystals of the inclusion complex. 
Kneading with ~-CD in an attempt to produce the same complex was unsuccessful. Only a physical 
mixture resulted after 30 min of kneading. This was verified by the absence of new peaks in the 
PXRD pattern. 
NMR spectroscopy 
Proton NMR spectroscopic analysis of (Figure 2) ZIDj3CD crystals grown by the slow cooling method 
revealed a host-guest stoichiometry of 1:1. As can be seen in Figure 2, the zidovudine HI and H2 
proton signals at 7.59 and 6.14 ppm integrate for 1.00 and LOS, respectively while the ~-CD HI 
proton signal at 5.04 ppm has an integral value of 6.83, which correlates with the predicted value of 
7 for a 1:1 complex. The minor deviation from the theoretical value is attributed to a small excess of 
zidovudine. As mentioned earlier, the complex crystallised only at very high concentrations, where 
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I 
L it_ 7.0 6.5 5.5 ppm ~~( 
Figure 2: Partial proton NMR spectrum confirming 1:1 stoichiometry of the ZIOPCO complex. 
Thermal analysis 
HSM 
A sample of the tiny ZID(3CD crystals was heated at a rate of 10 K min·1 during HSM analysis. The 
representative photographs in Figure 3 reveal important thermal events. At 60°C the crystals begin 
to show signs of damage and at 85 °c, the crystals are clearly cracked . At 110 °c, bubbles appear 
indicating the loss of water vapour. Degradation becomes visible at approximately 240°C and the 
sample is at an advanced stage of decomposition at 270 °c, where the crystals have turned dark 
brown. The numerous bubbles that are visible at 270°C are likely not solvent but a volatile product 
of the complex degradation. 
270°C 
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TGA and DSC 
Refer to the traces in Figure 4, both of which were generated by a temperature program with a 
heating rate of 10 K min-1. In the TGA trace, the initial mass loss, attributed to dehydration, was 
determined as 9.6 ± 0.1 % (n = 2), which implies a molar equivalent of 8.3 water molecules per mole 
of host/guest. Thereafter, the sample mass remains constant until the onset of the first stage of 
decomposition at 190°C. A second, more rapid stage of decomposition begins at 260 0c. 
The DSC thermogram exhibits a number of noteworthy features. The first endotherm, occurring at 
35-140 °c with peak minimum at 59°C is the one associated with the water loss. At 190-285 °c, a 
large, broad exotherm with a peak maximum of 243°C is observed. This exotherm coincides with the 
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Figure 4: TGA (red) and DSC (blue) thermograms for ZIDI3CD. 
Considering the evidence from all three thermal analytical techniques, it is clear that 8.3 water 
molecules per unit of the complex are lost from room temperature to "'140 °c and that the complex 










Single crystal X-ray diffraction 
Data-collection and space group determination 
Data were collected on a Bruker KAPPA APEX II DUO diffractometer. One of the tiny block-like 
crystals was selected from the vial and placed on a slide in Paratone oil to prevent dehydration. This 
was done quickly and carefully to ensure that the data collected were representative of the fully 
hydrated complex. X-ray diffraction data gave the unit cell dimensions and Laue symmetry of 21m, 
characteristic of the monoclinic crystal system. The following reflections conditions were identified 
in XPREp lO: hkl: h + k = 2n; (hOl: h = 2n), and these were confirmed using the program LAYER. ll 
Thus, the space group options were C2, Cm or C2/m. The space group C2 was chosen because ~-CD 
is known to be chiral, so the existence of mirror planes is impossible. 
Structure solution and refinement 
The unit cell dimensions of ZIDPCD were compared with those of known ~-CD complexes that 
crystallise in the space group C2. The one with the closest matching unit cell dimensions was used to 
solve the ZID~CD structure by isormorphous replacement, using the coordinates of non-hydrogen 
atoms of the host molecule only. After refinement using SHELXH-97/2 disorder was identified at the 
06 positions of the ~-CD rings A2, A4 and A7 (labels in Figure 5). All three were treated as disordered 
over two positions and the minor components of these oxygen atoms were labelled 07 A2, 07 A4 and 
07A7. The C6-06 and C6-07 bond lengths in these disordered cases were constrained to 1.40 A 
using a DFIX instruction with 0 = 0.01 A. After refinement, the major components 06A2, 06A4 and 
06A7 had site-occupancy factors of 0.71(2), 0.72(2) and 0.77(2), respectively. Hydrogen atoms of the 
host were placed in idealised positions for those hydrogens directly bonded to carbon atoms and an 
AFIX 83 instruction (hydrogen bond searching) was employed to place the hydrogens of the hydroxyl 
groups. The hydrogen atom positions of hydroxyl groups were inspected for potential hydrogen 
bonding that had not been accounted for by the riding model, and transformations carried out 
where necessary. Each hydrogen atom was assigned an isotropic temperature factor of 1.2 times 
that of its parent atom. Even after the entire host molecule had been modelled, the coordinates of 
the guest molecule could not be identified due to the very low values of difference electron density 
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Table 3: Data-collection and refinement parameters for ZIDj3CD. 
Formula unit (C42H7003S) (ClOH13NS04) 7.24{H2O) 
Form ula mass (g morl ) 1532.67 
Crystal system Monoclinic 
Space group C2 
a (A) 19.103(4) 
b (A) 24.550(5) 
c (A) 15.797(3) 
a (O) 90 
~ (O) 109.522(4) 
Y (O) 90 
Volume (A3) 6982(3) 
Z 4 
DensitYcalc (g cm-3) 1.463 
Il{MoKa) (mm-l ) 0.130 
F{OOO) 3270 
Crystal size (mm3) 0.25 x 0.26 x 0.36 
Temperature (K) 173 
Range scanned e (O) 1.67-26.70 
Index ranges h: -24, 22; k: -30, 30; I: -19,19 
ct> and w scan angle (O) 0.5 
Total number of frames 1052 
Dx{mm) 40 
Total number of reflections collected 23372 
Number of unique reflections 14413 
Number of reflections with I > 2cr{l) 9431 
Number of least-squares parameters 741 
Rint 0.0278 
S 1.478 
Rl (I > 2cr{I)) 0.1357 
Number of reflections omitted 12 
WR2 0.3683 
Weighting scheme parameters a = 0.2 
{Ll/cr)mean < 0.001 
~p excursions (e A-3) 0.755, -0.573 
The positions of three water molecules with full site-occupancy were identified and those oxygen 
atoms placed accordingly, while the disordered waters were placed systematically in order of the 
size of their difference electron density peaks. Based on the relatively high Uiso-values of the host 
atoms and the three water molecules with full site-occupancy, the Uiso-values of the disordered 
oxygen atoms were fixed at 0.1 A2 and the individual site-occupancy values treated as variables. The 
refined values for site occupancy and isotropic thermal parameters are provided in Table 4. In total, 
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Table 4: Parameters for the water sites of ZID~CD. 
Atom s.o.f. Uiso (A2) Atom s.o.f. Uiso (A2) Atom s.o.f. Uiso (A2) 
01W 1 0.075 06W 0.51 0.10 OllW 0.18 0.10 
02W 1 0.079 07W 0.52 0.10 012W 0.35 0.10 
03W 1 0.091 08W 0.35 0.10 013W 0.37 0.10 
04W 0.68 0.10 09W 0.29 0.10 014W 0.13 0.10 
05W 0.44 0.10 010W 0.38 0.10 015W 0.34 0.10 
After the final refinement the Goodness of Fit value (5) and weighted R-factor, which are available in 
Table 3, remained high. This is attributed to the high degree of disorder within the structure. The 
entire guest molecule, several water molecules as well as hydroxyl groups of the host are all 
disordered . 
Molecular structure 
The asymmetric unit, shown in Figure 5 contains one ~-CD molecule and 7.2 water molecules, some 
of which are disordered over multiple positions. The guest molecule could not be modelled and so 
does not appear in the image. 
. A2 
Figure 5: ASU of ZID~CD. Hydrogens atoms have been omitted for clarity. 
Figure 6 shows the electron density in the cavity of the host. These peaks appear in the difference 
Fourier map with a maximum value of only 0.71 e A-3. In the figure it can be seen that relative atom 
positions do not resemble those of a zidovudine molecule, which is evidence that the guest may be 
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Figure 6: Stereodiagram showing the electron density in the host cavity. 
Crystal packing 
As mentioned earlier, the structure of ZID~CD belongs to an isostructural series with space group 
and unit cell dimensions of a ~ 19 A, b ~ 24.5 A, c ~ 16 A, 13 ~ 109°. Channel-type packing, the likes of 
which is seen in this isostructural series, has been described extensively in the Iiterature.13,14,15 As 
expected, the host molecules of ZID~CD form dimers that are stacked one above the other along the 
c-axis, with a small degree of lateral shifting, making it possible for a guest molecule to be in a 
position anywhere along the length of a channel. The interplanar angle between the tail-to-tail 
cyclodextrins of adjacent dimers is 1.440 and the lateral shift between these two host molecules is 
2.52 A. 
The diagrams in Figure 7 show packing as viewed down the b-axis, illustrating clearly the twofold axis 
of rotation that runs parallel to the b-axis and highlighting an individual dimer, as well as two 
adjacent dimer layers. 
Figure 7: Packing of ZIDI3CD as viewed down the b-axis. On the left, a single dimer is highlighted in green and on the right 
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In Figure 8, a stereoview down the c-axis is provided, displaying the channels within which the guest 
molecules are included. It is apparent that there are also water molecules present in the channels. 
These water molecules are 09W and OlOW. 
.-Jb 
o 
Figure 8: Stereoview down the c-axis, showing the packing of ZIDI3CD. 
Host-host hydrogen bonding 
The heptagonal geometry of the host molecule is reinforced by a belt of intramolecular 02H .. ·03 
hydrogen bonds at the secondary rim. These "flip-flop type" hydrogen bonds are a common 
occurrence, observable in most known ~-CD structures.16 Then, the principal hydrogen bonds that 
secure the dimer are intermolecular 02-H .. ·03' hydrogen bonds, which are illustrated in Figure 9. 
The author is aware that the 0-3 .. ·H03' hydrogen bonds are also important and that all of these 
interactions are of the 'flip-flop' type.13 The hydrogen bond seeking model that was used to place 
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Figure 9: Stereoview down the b-axis showing hydrogen bonding that links the two cyclodextrins of the ZIDI3CD dimer. 
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Table 5 provides a summary of the hydrogen bonds that involve host molecules only. Details are 
given for three sets of hydrogen bonding interactions - intramolecular hydrogen bonds; 
intermolecular bonds that occur between molecules of the same dimer and intermolecular bonds 
between molecules of adjacent dimers, that is, within the same layer. There are no hydrogen bonds 
that directly connect molecules of adjacent layers of the dimer. 
Table 5: A summary of ZID~CD host-host hydrogen bonds and relevant parameters. 
Interaction Type Number 
Mean D· .. A Mean bond 
distance (A)* angle (0) 
Intramolecular 02-H···03 7 2.81 153 
Intermolecular 02-H···03' 4 3.08 146 
(within dimer) 03-H···03 ' 3 2.80 170 
Intermolecular 06-H···06' 1 2.88 172 
(within layer) C2-H ·· ·03' 2 3.34 163 
*The mean esd for all bond lengths is 0.01 A 
Hydrogen bonds involving water 
The water molecules that are distributed over 15 sites are hydrogen bonded with each other, the 
host (and presumably the guest molecule). Parameters of the principal hydrogen bonds that have a 
host hydroxyl group behaving as the donor and a water molecule as the acceptor are given in 
Table 6. 
Table 6: Parameters for interactions where a water molecule is the hydrogen bond acceptor. 
Hydrogen bond D-H (A) D···A (A) D-H •.. A (0) Symmetry code 
06AI-H6Al···0l W 0.84 2.787(1) 172 x,y,z 
02A6-H2A6···02W 0.84 2.655(9) 117 x,y,z 
06A3-H6A3·· ·03W 0.84 2.748(1) 167 x,y,z 
06A 7 -H6A 7 ···06W 0.84 2.80(3) 151 x,y,z 
07A7-H7A7···06W 0.84 2.52(3) 171 x,y,z 
06A6-H6A6···08W 0.84 2.96(3) 166 x,y,z 
06A4-H6A4·· ·08W 0.84 2.81(3) 151 l-x,y,-z 
06A2-H6A2 ···08W 0.84 2.84(3) 164 1/2-x,y-l/2,-z 
07 A4-H7 A4···09W 0.84 2.93(3) 155 x,y,z 
02A2-H2A2 ·· ·013W 0.84 2.76(3) 122 x,y,z 
07A2-H7A2·· ·015W 0.84 2.52(3) 148 x,y,z 
There are 23 close contacts between water molecules and oxygen atoms of the host with distances 
in the range 2.61-3.21 A and a mean distance of 2.93 A. There are 8 close contacts between adjacent 
water molecules with a distance range of 2.71-3.16 A. The mean distance for the set of water-water 
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The water molecules that are found in the interstitial cavity are represented in 
Figure 10. The magnified portion of the diagram has the water molecules on the left labelled . Those 
on the right of the diagram are related to the labelled atoms by a twofold symmetry axis running 
vertically through the middle of the image. Atoms 09W and OlOW are positioned in the channels, 
09W near the primary rim and OlOW at the head-to-head interface of the dimer. 09W is in close 
contact with one of the host hydroxyl groups so it may be acting as bridge between host and guest, 
while OlOW is not in close contact with any host molecules, so may be interacting with the 
disordered guest only. 
OlOW n 
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Figure 10: Diagram highlighting the positions of water molecules in the interstitial space. The twofold axis runs vertically 
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Host molecular geometry 
Table 7 provides parameters (defined in Chapter 1) that describe the conformation of the host 
molecule. The I-values are the lengths of the sides of the 04-polygon, r is the centroid-04 distance, 
<I> the torsion angle 04(n-2)-04(n-1)-04(n)-04(n+1) and d the deviation of each atom from the 04 
mean plane. Also provided are the distances between consecutive inter-glucose hydroxyls of the 
secondary rim, D3 , and the tilt angles ' I and ' 2. The glucose residues are all found to be in the usual 
4C1 chair conformation The primary hydroxyl groups that have full site-occupancy are all in the (-)-
gauche conformation. All of the three disordered primary hydroxyl groups have their major 
components in the (-)-gauche conformation and minor components in the (+)-gauche conformation. 
Figure 11 is a graphical representation of the pseudo heptagonal symmetry of the host. The 
predicted polygon angle for a regular heptagon is 128.6° and the maximum deviation from this value 
for the current host is -2.6°. 
Table 7: Geometrical parameters for the host molecule of ZIDj3CD. 
Residue I (A) r (A) d (A) 4> (0) D3 (A) tl (0) t2 (0) 
A1 4.315 5.028 -0.007(4) 1.4 2.892(7) 7.0(2) 8.5(1) 
A2 4.459 4.954 -0.023(5) 0.4 2.832(9) 12.5(3) 14.5(2) 
A3 4.335 5.087 0.021(5) -1.5 2.787(1) 9.4(2) 11.6(3) 
A4 4.396 5.088 0.002(4) 1.0 2.859(9) 7.2(3) 8.3(3) 
A5 4.298 4.978 -0.003(4) -0.5 2.756(7) 3.4(2) 4.6(2) 
A6 4.443 4.974 -0.021(4) 1.2 2.753(9) 9.6(2) 9.7(1) 
A7 4.350 5.147 0.032(4) -2.1 2.779(9) 12.5(2) 13.2(1) 
04A5 
04A7 
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Comparative PXRD 
Figure 12 provides a comparison of the experimental PXRO trace of ZIDPCD with the computed PXRO 
trace derived from the single crystal structure. The dominant peaks in the computed pattern match 
those in the experimental trace. Beyond ~13° there are only very low intensity peaks in the 
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Figure 12: Experimental and calculated PXRD traces of ZID!3CD. 
The experimental trace of ZIDPCD was also compared with the computed traces for the structures 
with CSO reference codes ZUZXOH and AJUVEG.17 ZUZXOH is the structure from which coordinates 
of the host were 'borrowed' for the isomorphous replacement structure solution of ZlDpCD. AJUVEG 
is a structure from the same isostructural series, where the guest has been modelled . The peaks 
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Figure 13: Experimental PXRD trace of ZID!3CD compared with the calculated traces for the reported structures with CSD 
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Solution-state NMR spectroscopy 
Continuous variation experiments (see Chapter 2) were conducted to characterise zidovudine-~-CD 
com plexation in solution, with proton NMR spectroscopy used to track changes in chemical shifts 
due to complexation. Stock solutions of concentration 10 mM were prepared of zidovudine and 
~-CD in D20 . These solutions were mixed to a constant volume of 2 cm
3 to give a series of 11 
samples, each with R in the range 0-1, where R = [X]/([H]t+[G]t) . For each of the samples, a proton 
NMR spectrum was collected and the chemically induced shifts (CISs) of the host and guest protons 
determined. The resultant Job plots are illustrated in Figure 14. The CIS, 110, multiplied by the 
host/guest concentration [X] is plotted against R. For the zidovudine protons, significant shifting was 
observed for three protons, while for the host protons, only H3 exhibited shifting. Overall, the CISs 
were very small, which is indicative of weak complexation. 
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The program ConstEQ18 was used for an initial determination of the association constant but the 
fitting procedure did not converge. An additional continuous variation experiment was carried out 
where the concentration of zidovudine was fixed at 0.5 mM and the ~-CD concentration varied from 
o to 12.5 mM so that the R values for the data set had a range of 0-25. Using this new dataset, the 
association constant was determined in ConstEQV (see Chapter 2), applying the regression analysis 
to the set of IJ.{j values for the zidovudine proton H2 (diagram in Figure 14). The results of these 
calculations are provided in Table 8. E is the error loss function and r is the correlation coefficient. 
The magnitude of IJ.{j·(X) reached a maximum at R = 0.5 for all four Job plots, which indicates that the 
stoichiometry in solution is 1:1. The association constant of 15.47 is extremely small, suggesting only 
very weak interaction between the host and guest. Given that the H3 host protons were shifted the 
most in the original continuous variation experiment, the interaction most likely occurs at the 
secondary rim. 
Table 8: Binding parameters for ZIDjiCD in solution determined using ConstEQV. 
K 15.47 
E 1.52 x 10'6 
r 0.9994 
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y-Cyclodextrin Inclusion Complex 
An inclusion complex (ZIDyCD) of zidovudine with V-CD was prepared bV kneading. All of the 
attempts to produce the complex bV co-precipitation and slow cooling failed. These experiments 
yielded only crystals of the free host. The successful preparation method entailed 12 mg (0.045 
mmol) of zidovudine and 64 mg (0.045 mmol) of V-CD, combined in a mortar. The mixture was 
kneaded for 30 min, adding drops of MilliQ water periodically to maintain a wet paste-like 
consistency. 
Comparative PXRD 
The material obtained from kneading was subjected to PXRD analysis and the resultant trace 
compared directly with a trace representing the most common known packing arrangement for V-CD 
complexes (Figure 15). Since the major features of both patterns are identical, it can be deduced 
that the ZIDyCD complex is of the channel-type, crystallising in the space group P421 2. 
5 10 15 20 
--ZIDyCD from 30 min 
kneading 
--Known V-CD complex 
25 30 
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Chapter 6: Lamivudine 
Chapter 6: Lamivudine 
Introduction 
Lamivudine (2R,55 enantiomer) is a chiral drug. At 70 mg cm-3, the aqueous solubility of lamivudine is 
far greater than those of nevirapine and efavirenz. Still, an improvement in solubility is desirable. In 
addition there are other physicochemical properties like thermal stability, hardness and 
compressibility that may be enhanced in some way by supra molecular modification. Thus, 
lamivudine was subjected to various attempts at preparing novel co-crystals and cyclodextrin 
inclusion complexes, with the expectation that the experiments might result in these desired forms 
or new polymorphs, hydrates, solvates or salts. 
Existing forms 
Crystal structures have been reported for pure lamivudine and two lamivudine hydrates. The first of 
these hydrates has five lamivudine molecules in the asymmetric unit and a lamivudine-water ratio of 
5:1, grown from water, methanol and other aqueous alcohols.l The second is a hemihydrate, the 
preparation conditions of which have not been described . Tetragonal crystals of the solvent-free 
lamivudine can be grown from dry ethanol, n-propanol and some mixtures of these with non-polar 
solvents.2 For convenience, the nomenclature in Table 1 will be used in reference to these forms. 
Table 1: Common forms of lamivudine. 
Label Description Reference 
Form I 0.2-hydrate 1 
Form II Anhydrous, tetragonal crystals 1 
Form III Hemihydrate 2 
Lamivudine salts and co-crystals have been reported in the literature. The salts are lamivudine 
maleate, lamivudine saccharinate and lamivudine 3,5-dinitrosalicylate while the co-crystal is a 
monohydrated lamivudine-zidovudine co-crystal. There is also a description of a "co-crystal" with 4-
quinoline, which by definition in this thesis is a solvateY 
A complex of lamivudine with ~-CD has been claimed by Lloret Perez and co-worker.5 The patent 
describes preparation by kneading of at least 0.5 molar equivalents of a cyclodextrin (primarily ~-CD 
but other cyclodextrins are encompassed by the patent) with one molar equivalent of lamivudine. A 
PXRD trace (see Figure 31 in this chapter) was provided as evidence of the patented form . At the 
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Present study 
It was confirmed that the bulk material that we were using was the reported anhydrous Form II by 
comparing the PXRD pattern of our starting material with those of the known forms. The same batch 
was tested for purity by NMR analysis and DSC (to confirm melting point) . Both tests were consistent 
with a high degree of purity of the starting material. 
The present study reveals six novel pharmaceutically acceptable, mUlti-component molecular 
crystals, two of which are cyclodextrin inclusion complexes. Note that the term 'multi-component 
molecular crystal' is employed here in reference to co-crystals and salts. Two pharmaceutical salts 
were analysed by single crystal X-ray diffraction to determine their crystal structures. Of the 
cyclodextrin complexes, only that with ~-CD could be prepared as single crystals and the X-ray 
structure solved . The y-CD complex of lamivudine could only be produced by kneading. 
Co-crystal Screening 
Again, co-formers were chosen on the basis of hydrogen bonding groups that could potentially form 
robust synthons with lamivudine. The lamivudine molecule possesses a number of features that 
suggest it would be well-suited to this type of modification. Its molecular structure is presented 
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Figure 1: Lamivudine with potential hydrogen bonding groups highlighted. 
Having encountered salt forms of this API in the literature, it was important to consider the pKa of 
the co-former. In general, co-formers were not excluded on the basis of an unfavourable pKa value 
but emphasis was certainly placed on those with more suitable pKa constants during the screening 
process. 
The outcomes of co-crystal screening with lamivudine are summarised in Table 2. Several hits 
resulted from the initial dry co-grinding experiments, so this method was employed extensively. A 











Chapter 6: Lamivudine 
formers of a variety of pKa constants in attempts to produce co-crystals as opposed to salts. 
Nevertheless, novel salts were identified and studied . 
Table 2: Summary of lamivudine co-crystal screening experiments and their outcomes. 
Method Co-formers Hits Pure salt/co-crystal 
Dry co-grinding 30 10 4 
Ethanol LAG 3 0 0 
Slow evaporation 10 4 4 
A number of our attempts to grow lamivudine co-crystal and salt single crystals produced single 
crystals of the host in reported Forms I and II. Form II crystallised when a mixture of ethanol and 
propanol with less polar solvents like pentane, hexane or cyclohexane was used. None of our 
experiments yielded crystals of Form III, the hemihydrate. 
LAMSUC: product of reaction between lamivudine and succinic 
acid 
Preparation of the reaction product 
A new phase, referred to here as LAMSUC is produced when combining lamivudine with succinic 
acid by co-precipitation or dry co-grinding. One reliable method of preparation involved 22 mg 
(0.096 mmol) lamivudine and 11 mg (0.093 mmol) succinic acid dissolved in 1.5 cm3 1-propanol at 
~40 0c. The resultant solution was allowed to cool spontaneously to room temperature and slowly 
evaporate. Fibrous crystals appeared after approximately 10 days. 
Identification 
LAMSUC was identified during the dry co-grinding screening stage. A small equimolar mixture of 
lamivudine and succinic acid was co-ground for 5 min and the resultant material subjected to PXRD 
analysis. In Figure 2 it can be seen that the product of co-grinding is not a physical mixture of starting 
reagents. Some peaks in the trace for LAMSUC appear to coincide with peaks in the pure lamivudine 
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Figure 2: The PXRD trace of LAMSUC compared with traces of free succinic acid and lamivudine. 
The products obtained from dry co-grinding and slow evaporation were compared by PXRD analysis 
(Figure 3) to confirm that they represented the same phase. Indeed it can be seen that the peaks of 
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Figure 3: PXRD Comparison showing LAMSUC produced by dry co-grinding and slow evaporation. 
Thermal analysis 
HSM 
A clump of LAMSUC crystallites was heated at a rate of 10 K min-1 during HSM analysis. The selected 
photographs in Figure 4 show the loss of solvent vapour, onset of melting, the melted product and 
discolouration at the onset of degradation. The onset of melting at 131 O( coincides with the initial 
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from neat co-grinding, it may be deduced that the solvent that is incorporated is water. Atmospheric 
water vapour is incorporated during the dry co-grinding process. 
190°C 
Figure 4: Representative HSM photographs for lAMSUC. 
TGA and DSC 
The DS( and TGA traces in Figure 5 were recorded using a sample obtained by slow evaporation and 
show what appears to be a two-step loss of solvent. The first stage of solvent loss occurs over a 
broad range of 60-120 0c. The sample was dried very well on filter paper but it is still possible that 
this initial mass loss relates to solvent adsorbed on the crystallite surfaces. The second mass loss is 
sharper at onset 123 O( with peak minimum 124°C. This event occurred identically for samples 
obtained from two slow evaporation experiments that employed different solvents (ethanol and 1-
propanol) with different boiling points, which is further evidence that the solvent present in 
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NMR spectroscopy 
Proton NMR spectroscopy was used to determine the stoichiometry of LAMSUC. The sample for 
analysis was taken from a batch prepared by slow evaporation from i-propanol. The resultant 
spectrum, an abbreviated summary of which is provided in Table 3, suggests a lamivudine-succinic 
acid stoichiometric ratio of 1:1. 
Table 3 Summary of the NMR data used to determine the stoichiometry of LAMSUC. 
Assignment 6 (ppm) Integral Normalised integral 
CH (aromatic, lamivudine) 7.79 1.0* 1 
CH (aromatic, lamivudine) 5.74 1.0 1 
2 x Clli (succinic acid) 2.41 4.0 1 
*Reference Integral 
FTIR spectroscopy 
Single crystal X-ray diffraction could not be performed because the fibrous crystals were not large 
enough . Infrared spectroscopy (Figure 6) was employed in determining whether LAMSUC was a salt 
or co-crystal; in other words, to determine whether or not an acid-base reaction had taken place 
during the formation of this new phase. It can be seen that there are prominent peaks, associated 
with carbonyl stretching, at 1713 and 1651 cm-l . The absence of a strong carboxylate peak at around 
1500 cm-l suggests that no acid-base reaction took place in the formation of LAMSUC. Thus, the IR 
spectrum indicates the species is most likely a co-crystal and not a salt but further investigation is 
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LAMGLT: product of reaction between lamivudine and glutaric acid 
Preparation of the reaction product 
LAMGLT was grown by slow evaporation from an acetonitrile solution. The solution was prepared by 
dissolving, at ~40 0(, 23 mg (0.10 mmol) lamivudine and 13 mg (0.098 mmol) glutaric acid in 2 cm3 of 
the solvent. Slow cooling, another solution-based method, was employed in an effort to grow larger 
crystals suitable for single crystal XRD analysis. However, even with slow cooling the crystalline 
material produced was extremely fine. The slow cooling preparation was carried out over a period of 
three days with the solution cooled from a temperature of ~60 0c. 
Identification 
The lamivudine-glutaric acid reaction product was identified during the dry co-grinding stage of 
screening. In 1:1 molar ratio, lamivudine and glutaric acid were co-ground for 5 minutes. After only a 
few minutes of grinding, the consistency of the mixture changed - the co-ground material became 
sticky and quite difficult to remove from the mortar. PXRD analysis (Figure 7) indicated that a 
reaction had taken place since the product of co-grinding was not a physical mixture of the starting 
reagents. A later PXRD comparison with the product obtained by slow evaporation 
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Figure 7: Comparison of the PXRD traces of the product of dry co-grinding (5 min), LAMGl T prepared by slow 
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Thermal analysis 
HSM 
A clump of the fine, thread-like crystals of LAMGLT was analysed by hot stage microscopy. The 
crystals were heated at a rate of 10 K min-I. The photographs in Figure 8 provide evidence of melting 
at an onset temperature of 137 0(, The melting point is very sharp - the crystals are completely 
melted at 138 0(, 
Figure 8: Representative photographs for the HSM analysis of LAMGLT. 
DSC and TGA 
The samples used for DSC and TG analysis were prepared by slow evaporation. DSC (Figure 9) 
revealed melting at onset 127.3 °c with a peak minimum at 129.0 0 (, The hot stage does not heat 
efficiently at its centre, which accounts for the deviation between values obtained by the two 
different methods. The melting point determined by DSC analysis is far more accurate. This 
sharpness of the melting endotherm and the fact that no other thermal events are evident is an 
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TGA (Figure 10) confirmed the absence of included solvent and showed that the sample begins to 










Figure 10: TGA trace for LAMGLT. 
A sample of LAMGLT prepared by slow evaporation was removed from the mother liquor and dried 
on filter paper before being dissolved in CDCI3 and analysed by proton NMR spectrocopy. The results 
of the experiment were used to determine the stoichiometry of the reaction product, which is 1:1 
according to the representative set of data provided in Table 4. 
Table 4: Selected proton NMR signals for LAMGLT confirming 1:1 stoichiometry. 
Assignment 6 (ppm) Integral Normalised integral 
CH (aromatic, lamivudine) 7.80 1.0* 1 
CH (cytosine, lamivudine) 6.21 0.9 1 
2 x CH 2 (glutaric acid) 2.25 3.8 1 
C!::h (glutaric acid) 1.73 1.9 1 
*Reference integral 
FTIR spectroscopy 
The infrared spectrum of LAMGLT (Figure 11) provided evidence of salt formation. The existence of a 
peak at 1539 cm'l, characteristic of a carboxylate stretch suggests that at least one of the acidic 
protons of the glutaric acid molecules has been transferred to the API. The absorption peak at 
1674 cm'l is evidence that a carbonyl group is still present. This information does not allow us to 
predict the precise extent of proton transfer, given the existence of a C=O function on the 
lamivudine molecule and the density of peaks in this region of interest, but it can be deduced that at 
least one acid-base reaction has taken place. Thus, LAMGLT is most probably a salt and not a co-
crystal. 
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Figure 11: FTIR spectra of LAMGLT, Glutaric acid and Lamivudine. 
LAMOXL: lamivudine-oxalic acid salt 
Preparation of the salt 
The lamivudine-oxalic acid 2:1 salt LAMOXL was prepared by co-precipitation from a solution of 
0.11 mmol (25 mg) lamivudine and 0.055 mmol (7 mg) oxalic acid dihydrate in 1 cm 3 of 50:50 v/v 
ethanol in water. The solution was prepared by dissolving the starting reagents at 50°C with 
continuous stirring. It was allowed to cool spontaneously and slowly evaporate. Crystals of the salt 
formed within one day. The salt could also be prepared by slow evaporation from a solution of 50:50 
v/v 1-propanol in water. 
Grinding experiments did not produce LAMOXL. The product of different co-grinding experiments 
was affected by the reagent stoichiometry, the solvent added and period of grinding. Thus, these 
were not investigated further. All of the material used for analysis was prepared by the reliable slow 
evaporation method described above. 
Identification 
The initial screening experiment that suggested the potential existence of a lamivudine-oxalic acid 
co-crystal or salt involved neat co-grinding of a small equimolar mixture of lamivudine and oxalic 
acid dihydrate. Figure 12 contains the PXRD trace of the resultant material compared with traces for 
the starting reagents. The pattern for the material obtained from co-grinding exhibits peaks that are 
represented in the traces for the starting reagents, indicating that it is a mixture of phases that 
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extended and the molar ratio varied in the hope of finding a method that produced a quantitative 
conversion to the new phase, but in each case PXRD and thermal analysis revealed that the product 
was a mixture of forms. Nevertheless, this initial set of tests suggested a co-crystal or salt of 
lamivudine could be prepared using oxalic acid as the partner molecule. 
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Figure 12: PXRD trace of co-ground lamivudine and oxalic acid dihydrate. The product trace is compared here with traces 
of the pure starting reagents. 
Thermal analysis 
HSM 
The hot stage microscope is used to observe thermal events directly. A large portion of one of the 
LAMOXL crystals was cut for the analysis. Representative photographs are shown in 
Figure 13 for the onset of melting, start of degradation and the further degradation. The first sign of 
melting occurs at 210°C. Thereafter, at approximately 216 °c the crystal becomes discoloured and 
bubbles begin to form rapidly. Bubbles are most often associated with the loss of solvent vapour but 
the high temperature at which they are released from LAMOXL suggests the gas is more likely a 
product of degradation. 
210°C 216°C 
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OSC and TGA 
DSC analysis (Figure 14) provided confirmation of the purity of the co-crystal, since no heat transfer 
was apparent that could be associated with melting of the pure co-former or free AP I. The unique 
melting point of the product is much higher than for both starting components, an expected result 
of salt formation. The sum of electrostatic interactions of the salt product is evidently greater than 
the sum of hydrogen bonding interactions that exist within the crystal structures of the free 
components. After melting, a broad endotherm occurs. It is related to the onset of degradation . 
The TGA trace (Figure 15) exhibits a two-step degradation in the range 200-300 0c. The fractions do 
not correlate well with, for example the loss of oxalic acid only, or one molar equivalent of 
lamivudine. The degradation process is thus assumed to be complex and neither the two-step mass 
loss nor the broad endotherm in the DSC trace related to degradation can be explained by complete 
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Figure 14: DSC trace for LAMOXL. 
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In summary, the melting point of the new species is significantly higher than the melting points of 
both free components. The degradation is a complex two-step process, the onset of which produces 
a broad endotherm in the DSC trace immediately after melting. The second step of degradation 
could not be observed using HSM or DSC but TGA revealed that it begins at ~250 °C. 
Single crystal X-ray diffraction 
Data-collection and space group determination 
Data were collected on a Bruker KAPPA APEX II DUO diffractometer. The striated rectangular rod 
crystals grew as large aggregates. Having placed a sample under Paratone oil to prevent the loss of 
potentially included solvent, a suitable portion was cut for analysis. X-ray diffraction data gave the 
unit cell dimensions and Laue symmetry mmm, characteristic of the orthorhombic crystal system. 
Using the program XPREp6 the space group was determined as P21 21 21 . The program LAYER
7 was 
employed to confirm this assignment - the following systematic absences were observed: 
hkl: none; hOO: h = 2n + 1; OkO: k = 2n + 1; OOl: l = 2n + 1. 
Structure solution and refinement 
SHELXS-978 was employed for the structure solution of LAMOXl. The asymmetric unit contains two 
lamivudine ions and one oxalate ion. Following their location, non-hydrogen atoms were assigned 
and refined isotropically on F2 in SHELXH-97.8 Upon confirming acceptable isotropic temperature 
factors, the atoms were refined anisotropically. It was clearly evident from the difference Fourier 
map that the oxalic acid had been deprotonated to yield a dicarboxylate ion, while each lamivudine 
molecule had been protonated at the N3-position. Measuring the carboxylate c-o distances, which 
were significantly alike with an average value of 1.256 A, provided further confirmation of the acid-
base reaction. Hydrogen atoms were placed by means of a riding model, except for those of the 
primary amines (position N8), which were placed directly, according to peak positions in the 
difference Fourier map. The N-H distances of these two groups (at N8) were constrained at 0.88 A 
using a DFIX instruction with a = 0.01 A. After refinement, the N-H distances ranged from 0.875 to 
0.885 A and each of the hydrogen atoms had a temperature factor in the range 0.032-0.048 A2. Each 
hydrogen atom placed using a riding model was assigned an isotropic temperature factor of 1.2 
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Table 5: Data-collection and refinement parameters for LAMOXL. 
Formula unit 2(CsH12N303S+) (C2O/) 
Formula mass (g morl ) 548.55 
Crystal system Orthorhombic 
Space group P21 21 21 
a (A) 6.6768(5) 
b(A) 9.1379(7) 
c (A) 37.688(3) 
a (0) 90 
~ (0) 90 
Y (0) 90 
Volume (A3) 2299.4(3) 
Z 4 
Densitycalc (g cm-3) 1.585 
~(MoKa) (mm-l ) 0.301 
F(OOO) 1144 
Crystal size (mm3) 0.20 x 0.18 x 0.10 
Temperature (K) 173(2) 
Range scanned e (0) 1.89-26.37 
Index ranges h: -9, 9; k: -15,15; 1:-15, 15 
<p and w scan angle n 0.5 
Total number of frames 1520 
Dx(mm) 48 
Total number of reflections collected 22292 
Number of unique reflections 3906 
Number of reflections with I > 2cr(l) 2999 
Number of least-squares parameters 343 
Rint 0.0391 
S 1.020 
Rl (I > 2cr(I)) 0.0413 
Number of reflections omitted 4 
wR2 0.0835 
Weighting scheme parameters a = 0.0427, b = 0.2685 
(Ll/cr) mean <0.001 
6p excursions (e A-3) 0.301, -0.274 
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M olecular structure 
The asymmetric unit consists of one oxalate ion of formal charge 2- and two crystallographically 
independent lamivudine cations. Both lamivudine ions in the asymmetric unit possess a proton that 
has been fully transferred to the nitrogen atom N3. 
Figure 16: Asymmetric unit of LAMOXl 
The deprotonation of both carboxylic acid groups is consistent with the tentative model that predicts 
salt or co-crystal formation based on the ~pKa of API and partner molecule, but only because the 
~pKa values for the present systems fall within the range 0 < ~pKa < 3 where the model predicts that 
either a co-crystal or a salt will form. In the case of oxalic acid, the values are pKal=1.3 and pKa2=4.1. 
The pKa of lamivudine is 4.3, so the values of ~pKa with respect to both proton transfer steps are 3.0 
and 0.2. The list of c-o bond distances in Table 6 for the oxalate ion confirms that both carboxylic 
acid groups were deprotonated . 
Table 6: Coo bond distances for the oxalate ion of LAMOXl. 
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Hydrogen bonding 
There are no strong hydrogen bonds between adjacent lamivudine molecules. Within the 
framework, lamivudine ions are linked only via oxalate ions. The parameters for all of the hydrogen 
bonding interactions are provided in Table 7. The mean bond length for O-H···O hydrogen bonds is 
2.80 A, while the average of the N-H···O hydrogen bond distances is 2.88 A. Short D···A distances are 
observed, as expected, for the charge-assisted hydrogen bonds. For example, N8B-H8D···016 has a 
hydrogen bond length of 2.655{2} A. The only hydrogen bonds between adjacent lamivudine 
molecules are C-H· ··O and N-H···O interactions, the longest of which is the C14A-H14B···015B 
hydrogen bond of 3.433{2} A. 
Table 7: Hydrogen bond parameters for LAMOXL 
D-H···A D-H (A) H···A (A) D···A (A) D-H ..• A (0) Symmetry code 
N3A-H3A···020 0.88 1.96 2.841{2} 176 -l+x,y,z 
N3B-H3B···017 0.88 2.04 2.858{2} 155 x,y,z 
N8A-H8A···021 0.87{2} 2.00{2} 2.823{2} 158{2} -l+x,y,z 
N8A-H8B···016 0.875{1} 2.21{2} 2.779{2} 122{2} x,y,z 
N8A-H8B···020 0.875{1} 2.22{1} 3.063{2} 163{2} x,y,z 
N8B-H8C···017 0.886{1} 2.41{1} 3.249{2} 158{2} -l+x,y,z 
N8B-H8C···021 0.886{1} 2.17{2} 2.801{2} 128{2} -l+x,y,z 
N8B-H8D···016 0.88{2} 1.78{2} 2.655{2} 173{2} x,y,z 
015A-H15A···021 0.84 2.00 2.837{2} 171 -1/2+x,3/2-y,l-z 
015B-H15B·· ·017 0.84 1.98 2.771{2} 157 1-x,-1/2+y,l/2-z 
C5A-H5A· ··07 A 0.95 2.27 2.985{2} 132 l+x,y,z 
C5B-H5B"'07B 0.95 2.47 3.108{2} 125 -l+x,y,z 
C6B-H6B···07B 0.95 2.55 3.155{2} 122 -l+x,y,z 
C13B-H13C···015B 0.99 2.37 3.234{2} 146 l+x,y,z 
C13B-H13D···OlOB 0.99 2.41 3.298{2} 149 1-x,l/2+y,l/2-z 
C14A-H14B···015B 0.99 2.56 3.433{2} 147 1/2-x,l-y,l/2+z 
Each oxalate ion is directly hydrogen bonded with six lamivudine cations {Figure 17}. The N-H···O 
hydrogen bonds are illustrated separately from the O-H···O hydrogen bonds for clarity. The oxygen 
atoms 016, 020 engage in bifurcated hydrogen bonds while 017 and 021 are involved in trifurcated 
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-- --------~ 
0 17 ./····. 0 21 . . .... -
Figure 17: Hydrogen bonding of the oxalate ion. N-H"'O hydrogen bonds are shown on the left and O-H"'O hydrogen 
bonds are illustrated on the right. 
Crystal packing 
The similarity between the packing of LAMOXL and the two previously reported salts of lamivudine 
can be seen in comparing Figure 18 with the packing diagrams from a recent paper4 that have been 
reproduced in Figure 19. The zig-zag arrangement is common to all three but in the case of LAMOXL, 
the lamivudine molecules are not stacked directly above one another. 
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lamivudine maleate 
lamivudine saccharinate 
Figure 19: View of the be-face of the maleate and saccharinate salts, reproduced from reference 4. 
Molecular geometry 
Given that the pyrimidine fragment of lamivudine is necessarily virtually planar, predictably, the 
main geometrical differences in the two crystallographically-independent lamivudine ions of the 
asymmetric unit exist with respect to the five-membered cytosine ring. Puckering analysis was 
carried out according to the methods described by Kilpatrick et 01.11 and Cremer and Pople.12 With 
respect to ion A the maximum amplitude and phase angle are q2 = 0.429(2) A and 4>2 = 338.8(2)0 
respectively, while for ion B, q2 = 0.527(2) A and 4>2 = 169.8(2)0. The overlay on the left (cytosine 
fragments overlapping) also illustrates the difference in the orientation of the N1-C9 bond . The 
perpendicular distance between C9 and the mean plane of the pyrimidine ring is -0.187 A and 
0.226 A for ions A and B respectively. The hydroxyl group orientations are also markedly different. 
Figure 20: Overlay of independent lamivudine ions of the asymmetric unit. Ion A is presented in red, while B is in blue. 
128 
On the left, the ions have been positioned so that the pyrimidine rings are overlapping, while on the right, the 
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Comparative PXRD 
It was not possible to produce LAMOXL by dry or liquid-assisted co-grinding. Multiple dry co-grinding 
experiments were attempted with different molar ratios and periods of grinding. The experimental 
patterns of the dry grinding products are shown to differ from that of LAMOXL (prepared by slow 
evaporation) in Figure 21. The product compositions are complex and inconsistent between 
experiments. The product of the 5 min grinding method exhibits peaks that correlate with those in 
the uppermost pattern (20 min grinding) and the trace of LAMOXL, implying that there are similar 
phases present. Based on these PXRD data there are very likely other salt forms that may be 
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Figure 21: The products of dry co-grinding experiments (molar ratios and periods of grinding) are compared with the 
PXRD trace of LAMOXL prepared by slow evaporation. 
The experimental PXRD trace for LAMOXL is presented along with the computed pattern in Figure 22 
to show that upon mild grinding this salt form is stable and to confirm that the PXRD trace can be 
used for identification. It also provides assurance that the crystal selected for single crystal X-ray 
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-- Experimental 
--Calculated 
5 10 15 20 25 30 35 40 
Figure 22: Comparison of experimental and calculated PXRD patterns for LAMOXL. 
LAMMLI: lamivudine-malic acid salt 
Preparation of the salt 
A mixture of 0.087 mmol lamivudine (20 mg) and 0.089 mmol L-malic acid (12 mg) was pre-ground 
for 15 minutes and then dissolved in 1 cm 3 of ethanol at ~40 °c while stirring. The solution was then 
carefully filtered and allowed to cool spontaneously. The solvent was allowed to evaporate 
extremely slowly and crystals of LAMMLI appeared after approximately 7 days. 
Identification 
The screening experiment that revealed the new form was carried out by dry co-grinding a small 
equimolar mixture of lamivudine and L-malic acid for 5 min and analysing the product using PXRD. In 
Figure 23 the PXRD trace of the reaction product is compared with those of the starting reagents to 
show that the reaction product represents a new phase and does not appear to contain excess 
lamivudine or L-malic acid . 
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Thermal analysis 
TGAand OSC 
TG analysis, conducted in triplicate, revealed a solvent loss of 4.5 ± 0.2 % at onset 79 0c. After the 
desolvation event, the sample mass continues to decrease at a very slow rate until decomposition at 
approximately 140 0c. Initially the TGA programme that was used involved heating at 10 K min·1 but 
this rate did not allow resolution of the melting and decomposition events. A heating rate of 
1 K min-1 was required to achieve the necessary resolution. 
The DSC curve exhibits a single, exceptionally broad endotherm at 85-105 °c associated with 
melting. The onset of melting appears to be coincident with the solvent loss as seen in the TGA 
trace, the implication being that the crystal collapses (and begins to melt) precisely when the 
included solvent is expelled. 
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Figure 24: TGA (red) and DSC (blue) traces for LAMMLI. 
In summary, TG and DSC analyses revealed the presence of included solvent. Given that LAMMLI 
may be prepared by both co-precipitation and dry kneading, the solvent of crystallisation is most 
likely water, since water may be absorbed from the atmosphere in neat grinding experiments.13 The 
melting of LAMMLI occurs over a broad range at relatively low temperature. In fact the onset of 
melting occurs well below the melting points of both starting reagents. Decomposition occurs 
directly after melting and accelerates greatly at ~140 0c. 
HSM 
A sample of aggregated LAMMLI crystals was subjected to a 10 K min-1 heating using the HSM 
apparatus. Photos were taken to illustrate the only visible thermal event - melting. During HSM 
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included water, we expected to see the release of water but this is not evident for two important 
reasons. Subsequent analysis - the results of which are presented later in this chapter - showed that 
water is indeed the solvent of crystallisation. It represents a very small fraction of the total mass of 
LAMMLI - 4.5 ± 0.2 % as determined by thermogravimetry. Secondly, the collapse of the hydrate by 
melting occurs well below the boiling point of water. We are only able to observe the release of 
solvent as it is vaporised and forms bubbles in the silicone oil medium. 
Figure 25: Representative HSM photographs for LAMMLI. 
NMR spectroscopy 
A sample of LAMMLI crystals grown from solution was subjected to proton NMR spectroscopic 
analysis. The results indicated a lamivudine-malic acid stoichiometry of 1:1, which concurs with the 
PXRD evidence. An abbreviated set of data from the NMR spectrum is provided in Table 8. 
Table 8: Selected NMR signals used to confirm the stoichiometry of LAMMLI. 
Assignment 6 (ppm) Integral Normalised integral 
CH (aromatic, lamivudine) 7.81 1.0* 1 
CH (aromatic, lamivudine) 5.75 0.9 1 
CH (L-malic acid) 4.26 1.0 1 
*Reference integral 
Single crystal X-ray diffraction 
Data-collection and space group determination 
The needle-like crystals grew as aggregates. Having placed one under Paratone oil to prevent the 
loss of potentially included solvent, a suitable portion was cut for analysis. X-ray diffraction data 
were collected on a Bruker KAPPA APEX II DUO diffractometer. The data were used to determine the 
unit cell dimensions and identify the crystal system as being orthorhombic (Laue symmetry: mmm ). 
The space group P21 21 21 was determined using XPREP and confirmed using the program LAYER to 
observe the following systematic absences: hkl : none; hOO : h = 2n + 1; OkO: k = 2n + 1; 
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Structure solution and refinement 
SHELXS-97 was employed for the structure solution of LAMMLI. The asymmetric unit contains one 
lamivudine ion and one L-malate ion. Non-hydrogen atoms were located in the difference Fourier 
map, assigned, and refined isotropically on F2 in SHELXH-97. Upon confirming acceptable isotropic 
temperature factors, these atoms were refined anisotropically. Guided by peaks in the difference 
Fourier map, hydrogen atoms were placed by means of a riding model. Importantly, it was clearly 
evident from the difference Fourier map that the L-malic acid had been deprotonated, while the 
lamivudine had been protonated at the N3-position. Each hydrogen atom was assigned an isotropic 
temperature factor of 1.2 times that of its parent atom. The single water molecule in the asymmetric 
unit was identified by the large peak of the oxygen atom. Hydrogens of the water molecule were 
also evident in the difference Fourier map. These were placed according to peak positions and the 
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Table 9: Data-collection and refinement parameters for LAMMLI. 
Formula unit (CSH12N30 3S+) (C4HsOs-) (H2O) 
Formula mass (g morl ) 381.36 
Crystal system Orthorhombic 
Space group P2 1 21 21 
a (A) 5.1651(3) 
b (A) 16.9225(8) 
c(A) 17.7735(9) 
a (0) 90 
~ (0) 90 
Y (0) 90 
Volume (A3) 1553.5(1) 
Z 4 
DensitYcalc (g cm-3) 1.631 
I1(MoKa) (mm-l ) 0.266 
F(OOO) 800 
Crystal size (mm3) 0.17 x 0.10 x 0.07 
Temperature (K) 173(2) 
Range scanned 8 n 2.29-28.31 
Index ranges h: -9, 9; k: -13,13; 1:-29,29 
ct> and w scan angle n 0.5 
Total number of frames 1671 
Dx (mm) 40 
Total number of reflections collected 22453 
Number of unique reflections 3870 
Number of reflections with I > 20(1) 3512 
Number of least-squares parameters 246 
Rint 0.0404 
S 1.033 
Rl (I > 20(1)) 0.0293 
Number of reflections omitted 2 
WR2 0.0675 
Weighting scheme parameters a = 0.0378, b = 0.2294 
(LVo)mean <0.001 
flp excursions (e A-3) 0.251, -0.175 
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Molecular structure 
There are one lamivudine ion and one malate ion in the asymmetric unit. There is also one water 
molecule present. Referring back to the thermal analysis that showed a water content of 4.5 %, it 
can be seen that this correlates well with the theoretical value of 4.7 % based on the crystal 
structure. The standard deviation of 0.2 % and the low temperature of dehydration account for the 
small discrepancy between the experimental and theoretical values. 
The difference Fourier map clearly revealed the protonation of the lamivudine molecule at atom N3. 
The deprotonation of the dicarboxylic malic acid molecule at one end is consistent with the tentative 
model for the prediction of salt formation that was described in Chapter 1, given that 
pKa (L-malic acid) = 3.4, 5.2 and pKa (Iamivudine) = 4.3. The pKa of the more acidic carboxylic acid 
group results in a ilpKa value that is between zero and three but the value of ilpKa with respect to 
the second carboxylic acid group is less than zero. Thus, the model correctly predicts that the first 
carboxylic acid group mayor may not react (in this case it does) and that the second -(OOH group 




Figure 26: Asymmetric unit of lAMMlI. 
Hydrogen bonding 
The hydrogen bonding pattern is again complex (see Table 10 for hydrogen bond parameters), owing 
largely to the existence of the strongly electron-donating carboxylate group of the counterion. As 
expected, the O-H· ··O hydrogen bonds are numerous with an average D· ··A distance of 2.87 A and an 
angular range of 133-178°. There are three unique N-H···O hydrogen bonds with bonding angles 
158°, 175° and 179° and a mean D···A distance of 2.79 A, which is short because all three of these 
hydrogen bonds are charge-assisted. The three C-H···O hydrogen bonds are of mean bond distance 
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Table 10: Hydrogen bond parameters for LAMMLI. 
D·H···A D·H (A) H .. ·A (A) D .. ·A (A) D.H"'A (0) Symmetry code 
N3-H3 .. ·016 0.82{2} 1.87(2} 2.68(2} 175(2} 1/2+x,3/2-y,1-z 
N8-H8A .. ·017 0.88 1.91 2.79{2} 179 1/2+x,3/2-y,1-z 
N8-H8B .. ·017 0.88 2.05 2.886{2} 158 x,y,z 
015-H15 .. ·022 0.76{2} 2.20{2} 2.767{2} 133(2} -l+x,y,z 
015-H15 .. ·025 0.76{2} 2.42(2} 3.034{2} 139(2} -l+x,y,z 
023-H23 .. ·025 0.84 1.74 2.575{2} 178 x,y,z 
024-H24 .. ·023 0.93{3} 1.99{3} 2.911{2} 168(3} l +x,y,z 
025-H25A .. ·015 0.83(1} 2.45(2} 3.177{2} 147(3} x,y,z 
025-H25B .. ·016 0.83(2} 1.90(2} 2.725(2} 176(2} 1-x,1/2+y,3/2-z 
C6-H6 .. ·015 0.95 2.26 3.159(2} 157 x,y,z 
C14-H14A" '024 0,99 2.43 3.371(2} 159 1-x,l/2+y,3/2-z 
C19-H19B .. ·015 0.99 2.54 3.367(2} 141 1-x,-1/2+y,3/2-z 
Refer to Figure 27, which illustrates the hydrogen bonding pattern w ith respect to the malate ion. 
Malate ions are connected via the hydrogen bond 024-H,,·023. Furthermore, each malate ion is 
hydrogen bonded to three lamivudine ions and two water molecules. As in the case of LAMOXL, 
there are no hydrogen bonds that link adjacent API units. In other words, the hydrogen bond 
connections are all of the form malate-malate, malate-water or malate-Iamivudine. 
025 
016 
022 017 •• ~ •••••• N3 
./ .... ~
' '/ .. -{ ,-
Figure 27: Stereodiagram showing hydrogen bonding with respect to the malate ion. Irrelevant hydrogen atoms have 
been omitted for clarity. 
Crystal packing 
The 21 screw-axes that characterise the space group P2 1 21 21 are clearly visible in Figure 28. In the 
b-direction the lamivudine ions pack in an alternating head-to-head and tail-to-tail arrangement, 
while along the c-axis successive lamivudine ions are separated by a water molecule. Figure 29 
shows how the salt former and API pack in rows along the a-axis. Looking down the c-axis, the API 
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b 
.L, 
Figure 28: Crystal packing of lAMMLI. View down the a-axis. The only hydrogens shown are those of the water 
molecules. 
Figure 29: View down the c-axis. Alternate layers of the API are shown in different colours. Hydrogen atoms have been 
omitted for clarity. 
Molecular geometry 
The cytosine ring of the lamivudine ion (see Figure 26 for atom labels) is in the usual envelope 
conformation with 512 the flap atom. The puckering parameters are q2 = 0.489(1) A and c!>2 = 
168.1(2t. The torsion angles about the C11-C14 bond (at which the hydroxyl group is attached) are 
65.7(2t (010-C11-C14-015) and -54.9(2)° (512-C11-C14-015) and the angle between the mean 
planes of the six-membered and five-membered rings is 78.03(4)° . 
Comparative PXRD 
Below is a PXRD comparison showing that the sample of LAMMLI prepared by dry co-grinding and 
used for analysis was indeed identical to the sample from which the single crystal was selected for 
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crystal diffraction data were collected at 173 K, while the experimental trace was determined at 
room temperature . 
-- Experimental 
--Calculated 
5 10 15 20 25 30 35 40 
29° 
Figure 30: PXRD comparison of the experimental and calculated traces for LAMMLI. 
Cyclodextrin Inclusion 
P-CD and V-CD 
Lamivudine was reported to form a complex with ~-CD in a patent by Lloret Perez and co-worker.5 It 
was confirmed, in the present study, that the patented complex could be prepared by kneading for 
90 min in the presence of water. In addition, it was discovered that it is possible to produce a V-CD 
complex of lamivudine by a similar method . Slow cooling was employed in an attempt to grow single 
crystals of both of these native cyclodextrin complexes. Single crystals of the ~-CD complex were 
successfully prepared but the slow cooling experiments with V-CD yielded only powdered material. 
DIMEB and TRIMEB 
In the present study, attempts were made to complex lamivudine with DIMEB and TRIMEB. The 
experiments involved dissolving an equimolar mixture of the API and cyclodextrin in a water at low 
temperature (ice bath), while stirring for approximately 24 h. Subsequently the solutions were 
placed in an oven preset to 60°C and allowed to crystallise. The DIMEB experiments produced only 
pure DIMEB single crystals; the API remained in solution . Experiments with TRIMEB did not yield 
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p-Cyclodextrin Inclusion Complex 
Preparation of the complex 
The ~-CD complex LAM~CD was prepared by slow cooling and kneading in water. The slow cooling 
experiment involved heating a near-saturated solution of 110 mg (0.087 mmol) ~-CD and 20 mg 
(0.087 mmol) lamivudine to 60°C with simultaneous stirring for 24 h. Good single crystals were 
obtained only when a clear slow-cooled solution was allowed to slowly evaporate over a period of 
several weeks. Kneading a mixture of 44 mg ~-CD (0.035 mmol) and 8 mg lamivudine (0.035 mmol) 
with a small quantity of water for a minimum of 30 min produced the same complex. 
The complex prepared here by slow cooling and kneading was compared with that of the complex 
claimed by Lloret Perez and co-worker using PXRD analysis.s Observe the comparison of PXRD traces 
in Figure 31. Firstly, note that the products of both the slow cooling and kneading methods are 
identical. The method described in the aforementioned patent combined lamivudine with "at least 
about 0.5 molar equivalents of cyclodextrin" . Unfortunately the quality ofthe patent trace is low but 
according to the available evidence the complexes appear identical, since all of the dominant peaks 
in the patterns match. The LAM~CD PXRD trace was then compared with representative patterns for 
the known ~-CD isostructural series by the method that Caira has described .14 However, it did not 
match any of these, and thus appears to represent a novel ~-CD packing arrangement. 
L 
--Slow cooled 
-- Kneaded, 90 min 
5 10 15 20 25 30 
Figure 31: PXRD traces of the complex obtained by kneading and slow cooling (below) compared with the trace of the 
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Thermal analysis 
HSM 
A sample of LAMPCD crystals was heated at a rate of 10 K min-1 on the hot stage and representative 
photographs recorded . The first signs of bubbling, related to the loss of waters of crystallisation, 
appeared at 65 °C. At 260 o( the crystals began to decompose, indicated by the colour change from 
colourless to brown. Extensive decomposition at 295 o( can be seen by the dark brown colour of the 
crystals and the evolution of some gas that is likely a product of degradation. 
260°C 295 °C 
Figure 32: Representative HSM photographs for lAMi3CD. 
TGA and DSC 
The TGA and DS( traces appear in Figure 33. TGA revealed a two-step mass loss of 
10.9 ± 0.3 % (n = 2) associated with dehydration. The onset of dehydration is evident from the 
profile as a large mass loss beginning at 245 o( and accelerating rapidly at 310°C. The trace obtained 
from DS( analysis displayed a large endotherm at the start of the run and a second, smaller 
endotherm beginning immediately thereafter and ending at 135 °C. Both of these are related to 
dehydration, which is a two-step process as evidenced by the TGA trace. A third endotherm, 
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Figure 33: TGA (red) and DSC (blue) traces for LAMj3CD. 
NMR spectroscopy 
Proton NMR spectroscopy was used to determine the host-guest stoichiometry of the complex. A 
representative set of data used for calculation of the stoichiometry is listed in Table 11. Most often, 
J3-CD complexes with non-solvent guest molecules are found to have stoichiometries of 1:1 or 2:1; 
however, in this case 1:1.46 appeared to be the approximate host-guest stoichiometry. 
Table 11: Data from a proton NMR spectrum of LAMj3CD, used to determine the stoichiometry of the complex. 
Assignment 6 (ppm) Integral Normalised integral 
aromatic C.!:! (guest) 7.83 1.00* 1.46 
cytosine C.!:! (guest) 6.29 1.00 1.46 
7 x C.!:!l (host) 5.01 4.8 1 
* Reference integral 
The NMR experiment was repeated, this time with a crystal that had been grown from a highly 
concentrated solution of the pre-ground complex. The second experiment gave a similar result and, 
taking both experiments into account, the mean host-guest stoichiometry is 1:1.48 ± 0.05 (n = 2) . 
Single crystal X-ray diffraction 
Data-collection and space group determination 
One of the elongated plate-like crystals was removed from the aqueous mother liquor and placed 
directly into Paratone oil to prevent the loss of any waters of crystallisation . The data were collected 
using a Bruker KAPPA APEX II DUO diffractometer (details provided in Chapter 2). From the X-ray 
diffraction data, the unit cell dimensions were determined along with Laue symmetry, which was 
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hkl: none; hal: none; aka: k = 2n (confirmed using LAYER\ the space group options were P2 1 
and P2dm. Knowing that the structure could not be centrosymmetric because of the chiral nature 
of the host molecule, the space group P21 was chosen. 
Structure solution and refinement 
The initial structure solution was carried out using 5HELXD,8 which employs ab initio direct methods. 
All of the non-hydrogen atoms of the host molecule and a complexed guest molecule were identified 
and assigned . These were refined isotropically, resulting in reasonable temperature factors. These 
atoms were then modelled as anisotropic and refined to give temperature factors that indicated a 
low degree of thermal motion. In fact the highest Uiso value was 0.057(1) A2 for an 06 atom of the 
cyclodextrin, which is remarkably low for a group of this type. The next greatest electron density 
peaks were inspected for typical hydrogen bonding distances and, where appropriate, the oxygen 
atoms of water molecules were placed. Water molecules 01W-05W were placed with full site-
occupancy and refined isotropically. All five atoms exhibited relatively low temperature factors and 
were refined anisotropically to assist identification of the disordered waters. Atoms 06AW and 
06BW, and atoms 07AW and 07BW were initially assigned as disordered pairs. Later these were 
assigned the same global Uiso of 0.05 A2 as for the rest of the eight water positions that appeared to 
have partial site-occupancy. After isotropic refinement and settling of the site-occupancy factors, the 
temperature factors of 06AW, 06BW, 07AW, 07BW and 08W were again treated as variables and 
allowed to refine freely, while for the other seven disordered atoms, the temperature factors were 
treated as variables but the site-occupancies had to be fixed . The hydrogens of the host and guest 
molecules were placed in idealised positions. For the hydroxyl groups, a hydrogen bond searching 
model was employed. All of the hydrogens were refined isotropically with temperature factors set at 
1.2 times those of their parent atoms. The hydrogens of water atoms were not placed. 
All of the residual electron density in the interstitial spaces was treated as water because the 
connectivity of the electron density peaks did not resemble any portion of the lamivudine molecule. 
The TGA data were used as a guide for the modelling of these water molecules, so that their total 
number in the model (9.7) was in reasonable agreement with the predicted value of 9.3. The 
apparent absence of approximately half a guest molecule, as expected according to NMR 
spectroscopic evidence, is addressed in detail in a later section of this chapter. Nevertheless the final 
weighted R-factor, at 7 %, is excellent for a cyclodextrin inclusion complex and the Goodness of Fit 
parameter, 5, is very close to 1. The crystal data and refinement parameters are listed in Table 12 
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(Flack) parameter has been quoted but is largely irrelevant given that both ~-CD and lamivudine 
have known absolute configurations. 
Table 12: Data-collection and refinement parameters for LAM~CD. 
Formula unit (C42H7003S) (CgHllN30 3S) 9.66{H2O) 
Formula mass (g morl ) 1538.27 
Crystal system Monoclinic 
Space group P2 1 
a{A) 15.270(1) 
b (A) 10.1453(8) 
c{A) 23.746(2) 
a (a) 90 
~ (a) 100.250(2) 
y (a) 90 
Volume (A3) 3620.0(5) 
Z 2 
DensitYcalc (g cm-3) 1.411 
F{OOO) 1637 
Il{MoKa) (mm-l ) 0.153 
Crystal size (mm3) 0.36 x 0.11 x 0.07 
Temperature (K) 173(2) 
Range scanned e (a) 2.19-28.32 
Index ranges h: -20, 20; k: -13,13; I: -31, 31 
<p and w scan angle (a) 0.5 
Total number of frames 1500 
Dx{mm) 40 
Total number of reflections collected 41216 
Number of unique reflections 17977 
Number of reflections with I > 2a{l) 14434 
Number of least-squares parameters 927 
Rint 0.0421 
S 1.037 
Rl (I > 2a{I)) 0.0700 
Number of reflections omitted 1 
WR2 0.1860 
Weighting scheme parameters a = 0.1206, b = 3.1427 
{6!a)mean < 0.001 
t:.p excursions (e A-3) 1.032, -0.656 
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Table 13: Site-occupancy factors and thermal parameters for the LAMPCD water sites. 
Atom s.o.f. Uiso (A2) Atom s.o.f. Uiso (A2) 
01W 1 0.0277(8) 08W 0.55(2) 0.064(3) 
02W 1 0.038(1) 09AW 0.43 0.052(2) 
03W 1 0.065 (2) 09BW 0.33 0.051(3) 
04W 1 0.051(1) 09CW 0.23 0.059(5) 
05W 1 0.076(2) lOW 0.21 0.084(7) 
06AW 0.53(2) 0.066(4) llA 0.50 0.054(2) 
06BW 0.37(2) 0.065(5) llB 0.22 0.058(5) 
07AW 0.62(2) 0.058(3) llC 0.23 0.066(5) 
07BW 0.44(2) 0.078(5) 
Molecular structure 
The asymmetric unit is illustrated in Figure 34, showing clearly the mode of guest inclusion. The 
cytosine ring is inserted into the host cavity with its hydroxyl group at the secondary rim. The 
pyrimidine ring protrudes from the primary rim. The red spheres in the image represent the 17 




Figure 34: Stereodiagram showing the asymmetric unit of LAMPCD as viewed down the a-axis. Hydrogen atoms are 
omitted for clarity. 
The host and guest molecules are represented separately in Figure 35 to show the labelling of atoms 
and the relative sizes of thermal ellipsoids. The relatively small ellipsoids of the host atoms, as 
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Figure 35: The host and guest molecules of LAMPCD. Thermal ellipsoids are drawn at the 50% probability level and 
hydrogen atoms are drawn as spheres with arbitrary radii . 
Hydrogen bonding: host-host 
The host-host hydrogen bond parameters are summarised in Table 14. The primary intramolecular 
interactions of the host molecule form a hydrogen bonding 'belt' at the secondary rim (similarly to 
ZIOPCO). All of these hydrogen bonds are of the form 03An-H .. ·02A{n+1). It is important to mention 
here that the hydrogen bond seeking model cannot fully account for the 'flip-flop' hydrogen bonding 
of the secondary hydroxyls/s so in this regard the model may in some respects be unrealistic. Some 
artefacts may occur, like the fact that in this case 02A2-H appears not to have a hydrogen bond 
acceptor. The host geometry is such that 06An-H .. ·OSAn hydrogen bonds are also present. There are 
five C-H" 'O hydrogen bonds and three O-H .. ·O interactions linking adjacent host molecules. 
Table 14: A summary of host-host hydrogen bond parameters. 
Interaction Type Number 
Mean O"'A Mean bond 
distance (A) angle (0) 
Intramolecular 
03-H .. ·02 6 2.846(4) 164 
C6-H .. ·OS 3 3.324{S) 144 
06-H,,·02 ' 1 2.727(4) 149 
Intermolecular 
02-H .. ·03 ' 1 2.747(4) 131 
06-H .. ·06' 1 2.7SS(4) 167 
C-H"'O' S 3.403(4) lS4 
Hydrogen bonds between the host and guest 
The guest molecule is not merely included with in the cyclodextrin cavity, but rather plays a very 
important directing role through hydrogen bonding with the host atoms of adjacent complexes. 
There are five principal hydrogen bonds between the host and guest (Table lS), three of which are 
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bond angle is particularly low for this type of interaction but this is because the donor appears to 
interact with two acceptors - 07 and 03A5. 
Table 15: Parameters for the hydrogen bonds between the host and guest. 
Interaction Hydrogen bond H .. ·A (A) D .. ·A (A) D-H ... A (0) 
Symmetry 
code 
06A2-H26···015 1.94 2.743(4) 159 x,-l+y,z 
Host-guest 02A5-H2A5···07 2.04 2.709(4) 136 x, l +y,z 
C2A5-H20···N3 2.56 3.323(6) 132 x,l+y,z 
Guest-host 
N8-H8B···06A5 1.99 2.859(6) 169 1-x,-1/2Y,2-z 
015-H15·· ·03A2 1.95 2.743(4) 157 1-x,l/2+y,l-z 
Figure 36 and Figure 37 illustrate the host-guest O-H···O and N-H···O hydrogen bonds respectively. It 
can be seen that the interactions are complex - the host and guest are co-operatively responsible for 
the overall packing arrangement. It can be seen from the stereodiagrams that the monomeric 
complexes pack extremely close to one another in a herringbone arrangement. The ~-CD A2 residue 
is nearly inserted into the cavity of an adjacent host molecule at the secondary rim. 
03A2 
0 ...... 
· · · · 
Figure 36: An illustration of the O-H···O hydrogen bonds between the host and guest. Above is a stereodiagram and 
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Figure 37: An illustration of the guest-host N-H"'O hydrogen bond. Above is a stereodiagram and below, the most 
relevant atoms are magnified. 
Hydrogen bonds involving water 
There were 17 water molecule sites identified. Parameters for the 7 host-water and single guest-
water hydrogen bonds are listed in Table 16. Of the sites that have full occupancy, three are 
hydrogen bond acceptors where host atoms are the donors. OsW is the hydrogen bond acceptor for 
the only guest-water hydrogen bond. 03W is the only water molecule with full site-occupancy that is 
not directly hydrogen bonded with the host or guest. 
Table 16: Parameters for host-water and guest-water hydrogen bonds. 
D-H···A H···A (A) D···A (A) D-H"'A (0) Symmetry code 
02AI-H2Al···01W 2.31 3.071(4) 151 x,y,z 
N8-H8A···OsW 2.21 3.04s(8) 159 x,y,z 
06A3-H6A3···01 W 2.07 2.894(4) 169 x,y,z 
06A6-H28· ··06AW 2.08 2.68(1) 128 x,y,z 
06As-H6As···07 AW 2.20 2.832(9) 132 x,y,z 
06As-H6As·· ·07BW 1.80 2.s9(1) 156 x,y,z 
02A6-H2A6···06AW 2.38 3.01(1) 132 x,y,z 
02A6-H2A6···06BW 1.84 2.76(1) 171 x,l+y,z 
02A7-H2A7···02W 1.84 2.676(4) 174 x,y,z 
06A7-H6A7···04W 1.90 2.716{s) 164 x,y,z 
There are 11 close contacts between water molecules and host atoms. The distances of these 
contacts are in the range 2.72-3.15 A and their average value is 2.86 A. Eighteen close contacts 











Chapter 6: Lamivudine 
Water molecules 01W and 02W are of particular interest because both have unusually low 
temperature factors (0.028 and 0.038 A2 respectively). The reason for this is related to the hydrogen 
bonding of these two molecules. 01W is an acceptor of two host hydrogen bonds and is in close 
contact with two other host oxygen atoms. There is one host-water hydrogen bond for which 02W is 
the hydrogen bond acceptor. 02W is also in close contact with 04W and two other host oxygen 
atoms. Thus, it appears that both 01W and 02W are 'tethered' in at least four different directions, 
restricting their thermal motion. 
Molecular geometry 
The host molecule is distorted by the presence of the guest, particularly because of the extensive 
network of host-guest hydrogen bonds. The relevant geometrical parameters, as defined in 
Chapter 2, are listed in Table 17. Note in particular the large tilt angles - the maximum values of '(1 
and '(2 are 22.6 and 25.5° respectively. The reason for these large values may be that, as mentioned 
previously, the host molecules of LAMPCD pack very closely to one another, to the extent that the 
A2 glucopyranoside residue is practically inserted at the secondary rim of an adjacent cyclodextrin. 
The torsion angle <I> for residue A6 is large at -23.8° and the deviations (d) of 04 atoms from the 
mean plane of the 04 polygon are, on average, an order of magnitude greater than the 
corresponding values for the ZIBPCD structure. 
Table 17: Geometrical parameters for the I3-CO molecule of LAMI3CO. 
Residue I (A) r (A) d (A) a 4> (0) D3 (A) Tl (0) T2 (0) 
Al 4.427 4.970 0.301(2) 128.2 12.0 2.953(4) 22.20(7) 21.2(2) 
A2 4.402 5.046 0.053(2) 129.0 -7.1 2.914(4) 22.61(7) 25.5(2) 
A3 4.335 5.141 -0.297(2) 125.0 -7.8 2.808(4) 3.06(8) 7.7(2) 
A4 4.320 4.900 0.005(2) 130.6 5.1 2.946(4) 6.93(8) 8.6(1) 
A5 4.483 4.931 0.414(2) 129.4 16.4 2.702(4) 4.74(7) 6.5(3) 
A6 4.213 5.165 -0.301(2) 123.9 -23.8 2.755(4) 15.27(9) 20.5(2) 
A7 4.414 4.986 -0.175(2) 129.7 6.3 3.184(5) 1.95(8) 2.2(1) 
Figure 38 illustrates the large deviation from heptagonal symmetry of the LAMPCD host molecule by 
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04A6 
04A1 
Figure 38: Overlay of the 04 polygon of lAM/3CD and a regular heptagon. 
With regard to the guest molecule, the pyrimidine ring is nearly planar as usual, while the cytosine 
ring is puckered in the usual envelope conformation, with C9 the flap atom (Figure 35). The 
maximum amplitude, q2 = 0.421(4) A and the phase angle, 4>2 = 290.5(6t . The six-membered and 
five-membered rings are almost orthogonal to one another - the angle between the mean planes of 
these rings is 81.5(2)°. The torsion angles about the C11-C14 bond (about which the hydroxyl group 
may rotate) are -158.8(3)° (010-C11-C14-015) and 83.6(4)° (S12-C11-C14-015). 
Crystal packing 
Notice in Figure 39 how the herringbone crystal packing of LAM~CD is similar to the crystal packing 
in two other structures, which are referred to here according to their CSD16 reference codes -
POBRON, where the only guest molecules are water atoms and SUYLON, which is the structure of a 
monosubstituted cyclodextrin (6-deoxy-6-[(lR,2S)-2-hydroxyindan-1-yl]amino-l3-cyclodextrin) where 
the substituent is included within an adjacent molecule to form an infinite chain of tilted 
cyclodextrins stacked along the b-axis. In all three cases the packing arrangement may be classified 
as cage type. The cyclodextrins interlock to form 'herringbone' rows along the twofold screw-axis. It 
is particularly interesting that despite the similarities in packing, the nature of the complex in all 
three cases is very different. In the first case it is a hydrate, in the second a self-included complex 
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POBRON SUYLON 
LAMI3CD 
Figure 39: Diagram showing the similarity in packing arrangements between POBRON, SUYlON and lAMpCD. 
The space-filling models in Figure 40 show how the guest molecule of LAMpeD fills the cyclodextrin 
cavity and how the monomeric complex units interlock and stack along the b-axis. The image on the 
right illustrates particularly how adjacent host molecules are positioned so that there are virtually no 
voids between them . 
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The missing guest 
The single crystal X-ray model that has just been discussed accounts for 1:1 host-guest stoichiometry 
but NMR data indicated a stoichiometric ratio of 1:1.5 for LAMPCD. Figure 41 shows the interstitial 
channel with water molecules represented as green spheres and bonded where the interatomic 
distances are smaller than the sum of the van der Waals radii. It is clear that none of the bonded 
fragments resembles any portion of the lamivudine molecule. Most of the residual electron density 
(the maximum peak height is 1.03 e A-3) of this structure is located within the illustrated space. 
a '------_~ 
Figure 41: A view down the a-axis, showing the interstitial channel. Water molecules are represented as green spheres, 
bonded where the interatomic distance is smaller than the sum of the van der Waals radii . 
A set of putative water molecules with low site-occupancy factors was removed from the model to 
simulate a void where a partial lamivudine guest molecule might be located. The atoms removed 
were 09AW, 09BW, 09CW, 010W, 011A, 011B and 011e. All of these water molecules had site-
occupancy factors of less than 0.5 and none of them had been unequivocally identified as hydrogen 
bond acceptors. The hypothesis was that these oxygen atoms had accounted for density that in 
reality might represent the partial'missing guest' . 
The programme WebLab Viewer17 was used to simulate the channel and the guest molecule. Two 
layers of the complex were generated and the guest orientated longitudinally to the channel. The 
guest was further orientated so that it was roughly in the middle of the two complex layers i.e. so 
that no portion of the guest would protrude from the top or bottom of the simulated channel. 
Thereafter it was translated and rotated to find the best fit . Two conformations of the guest were 
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First, the conformation of the modelled guest of LAMpeD was tested (Figure 42, left) . It was possible 
to position the molecule such that the only close contact that formed was between an H atom of 
lamivudine (at C14) and water molecule 08W, which has a site-occupancy of 0.55. The 1.94 A 
contact represents a possible C-H .. ·O hydrogen bond. A second, more compact conformation of the 
lamivudine molecule was also tested (Figure 42, right). In this case it was possible to position the 
molecule within the channel without the occurrence of any close contacts. 
Figure 42: Weblab Viewer image of the simulated 'missing guest' in stick mode. 
In Figure 43, space-filling models illustrate how the simulated guest molecules of both 
conformations fill the interstitial channel. It is apparent that a guest molecule could well be present 
in this space and the available evidence suggests that such a molecule would exhibit low s.o.f.s for 
the individual atoms and may be disordered over multiple positions. 
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Comparative PXRD 
The PXRD traces in Figure 44 demonstrate the similarity between the experimental trace for 
LAMPCD and the trace computed from the single crystal X-ray structure. Despite some 
incompleteness of the structure - i.e. significant electron density unaccounted for and the problem 
of an un modelled partial guest - there is only one peak at 28 ~ 21 0 in the computed pattern that is 
not present in the experimental trace. The variations in intensity at low 28 values may be attributed 
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ITC 
ITC was performed on the lamivudine-~-CD system in solution. A 15 mM ~-CD solution was titrated 
against a 0.75 mM LAM solution at a temperature of 298 K. 10 f.1L aliquots were injected at 1.2 s 
intervals. The raw data are provided in Figure 45 and the integrated data from which the binding 
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Figure 45: Raw ITC data for lamivudine in the presence of I3-CO, 
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The binding parameters, determined directly from the ITC data, and calculated thermodynamic 
parameters are listed in Table 18. Chapter 2 contains the equations that were used to calculate tJ.So 
and tJ.Go. The stoichiometry in solution appears to be 1:1 (n = 1) and the association constant of 511 
suggests that the interactions between the host and guest are relatively weak in solution. The 
thermodynamic data imply that the inclusion reaction is both enthalpy- and entropy-driven. 




tJ.Ho (kJ morl ) -3.7(1) 
tJ.So (kJ K-l morl ) 0.039 
TtJ.So (kJ morl ) 11752 
tJ.Go (kJ morl ) -15452 
*The energy values without e.s.d.s were not directly measured but calculated using K and ~H 
Solution-state NMR Spectroscopy 
The lamivudine-~-CD system in solution was analysed by proton NMR spectroscopy and Job plots 
produced according to the method described in Chapter 2. Stock solutions of 10 mM were prepared 
of lamivudine and ~-CD in D20. These solutions were mixed to a constant volume of 2 cm
3 to give 
ratios in the range 0-1 with increments of 0.1, where the ratio is defined as R = [X]/([H]t+[G]t). 
Figure 47 shows the Job plots of tJ.o·[X] against R, where tJ.O is the induced chemical shift and [X] is 
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Figure 47: Job plots for lamivudine-I3-CO in 0 20. 
The results of the continuous variation experiment show that the average stoichiometry in solution 
is 1:1, but the fact that there are absolute maxima at R = 0.6 indicates that the system is intricate, 
with multiple modes of guest inclusion. Mostly, the H3 and HS protons of ~-CD experience the 
greatest increase in shielding, in which case the guest must penetrate at the secondary rim. The two 
dominant modes of inclusion are likely to involve: 
1. Insertion of the cytosine fragment at the secondary rim, resulting in greater shielding of 
lamivudine protons H4 and HS 
2. Insertion at the secondary rim, with the central portion of the lamivudine molecule 
(including protons H1 and H3) most affected 
Using ConstEQ18 as described in Chapter 2 with six protons of the lamivudine-~-CD complex in 
solution considered (two of the cyclodextrin and four of the drug), the association constant was 
determined. Table 19 provides K along with the error loss function (E) and the correlation coefficient 
(r). The 6.0 values for the relevant protons are provided for a possible 1:1 complex. Each of these 
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NMR spectroscopy is fairly small, but importantly, is similar to the value determined by a rather 
different method, lTC, where K = 511 (Table 15). These association constants imply that the host-
guest interactions are of moderate to weak strength. 
Table 19: Association parameters for lamivudine-j3-CO in 0 20 assuming 1:1 complexation. 
K 978.5 
E 3.33 X 10-4 
r 0.9947 
6oH3 (13-CD; ppm) 0.03950 
6oH5 (13-CD; ppm) 0.03348 
60Hl (LAM; ppm) 0.08167 
6oH3 (LAM; ppm) -0.02227 
6oH4 (LAM; ppm) 0.03864 
6oH5 (LAM; ppm) 0.06398 
y-Cyclodextrin Complex 
A lamivudine complex (LAMyCD) with V-CD was prepared by kneading and slow cooling. The 
kneading experiment involved 20 mg (0.087 mmol) lamivudine and 124 mg (0.087 mmol) V-CD. The 
reagents were mixed in a mortar and kneaded for a period of 30 min in the presence of a small 
amount of water. The slow cooling method was carried out by dissolving an equimolar (0.13 mmol) 
mixture of 30 mg lamivudine and 186 mg V-CD in 1 cm 3 water at a temperature of 50°C. The 
temperature was maintained and the solution stirred for approximately 6 h. Thereafter, the solution 
was passed through a 0.45 ~m microfilter and cooled slowly over a period of three days in a covered 
vacuum flask. Powdered LAMyCD was obtained . 
The slow cooling method is generally useful for growing larger crystals but in this case the product 
was always a powder. The complex was identified by PXRD analysis (Figure 48), which revealed that 
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Figure 48: PXRD comparison of traces for LAMyCD prepared by different methods and a calculated trace representing 
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Chapter 7: Conclusion 
A total of nine new pharmaceutical co-crystals, salts, and cyclodextrin inclusion complexes of the 
selected antiretroviral drugs were discovered by supramolecular methods and isolated. Single crystal 
X-ray structures were determined for seven of these. 
Co-crystal Screening 
Co-crystal screening was carried out with nevirapine, efavirenz, zidovudine and lamivudine. The 
methods employed were dry co-grinding, liquid-assisted co-grinding and co-precipitation by the 
well-known slow evaporation procedure. PXRD together with thermal analysis, specifically HSM, TGA 
and DSC analysis, were used to identify co-crystals and, where co-crystallisation had occurred, to 
determine whether a sample contained only the co-crystal or a mixture of phases. 
No co-crystals of efavirenz or zidovudine were isolated. Three co-crystals of nevirapine were 
prepared and these were labelled NVPMLE, NVPGLT and NVPSLI. For lamivudine, two novel 
pharmaceutical salts (LAMOXL and LAMMLI) and two other mUlti-component molecular crystals 
{LAMGLT and LAMSUq were obtained by co-crystal screening and isolated. Proton NMR 
spectroscopy, X-ray diffraction, and thermal analysis methods were used to characterise these new 
forms. Where single crystals were obtained, three-dimensional X-ray analysis was used to determine 
the crystal structures and where this was not possible, the powdered samples were analysed by FTIR 
spectroscopy to investigate whether these were salts or co-crystals. 
Cyclodextrin Inclusion 
Cyclodextrin inclusion was attempted with each of the APls using ~-CD, V-CD, DIMEB and TRIMEB. 
For the native cyclodextrins, attempts were made at preparing solid-state complexes by water-
assisted kneading and co-precipitation. PXRD analysis and the isostructural series method described 
by Caira 1 was employed extensively for the identification of complexes. 
There was no convincing evidence of complexation in any of the inclusion attempts with nevirapine 
and efavirenz. A lamivudine-~-CD complex (LAMpCD) was prepared by kneading in the presence of 
water and by slow cooling. Zidovudine was successfully included in ~-CD by slow cooling and the 
solid-state complex (ZIDPCD) isolated; however, kneading methods produced only physical mixtures. 
A V-CD inclusion complex of lamivudine was prepared by water-assisted kneading with but co-
precipitation attempts yielded only crystals of the pure host. Single crystals were obtained of 












For the derivatised cyclodextrins, only co-precipitation at elevated temperature (60°C) was 
attempted. All of the attempts at inclusion in DIMEB and TRIMEB were unsuccessful. The DIMEB 
experiments yielded only pure DIMEB crystals. In the case of the TRIMEB experiments, the solutions 
were not concentrated enough and did not crystallise after more than five months at 60°C. 
Cyclodextrin complexation in solution was also investigated. The continuous variation method was 
employed using proton NMR spectroscopy. For nevirapine, lamivudine and zidovudine, preliminary 
NMR test runs were carried out with ~-CD and V-CD. In the case of efavirenz, tests were conducted 
with ~-CD, V-CD, RAMEB and HP-~-CD, the derivatised CDs having been included because 
complexation with these had been reported by Sathigari and co-workers.2 Based on the preliminary 
tests, full continuous variation experiments were conducted for lamivudine with ~-CD, zidovudine 
with ~-CD, and efavirenz with V-CD, RAMEB and HP-~-CD. From the resultant data, association 
constants were determined for the lamivudine-~-CD and zidovudine-~-CD complexes, while for 
efavirenz, the data displayed no clear trends and were not conducive to carrying out the necessary 
calculations. ITC was employed for further characterisation of the inclusion behaviour of the 
lamivudine-~-CD complex in aqueous solution. 
Nevirapine 
The three new nevirapine co-crystals NVPMLE, NVPGLT and NVPSLI incorporate the carboxylic acids 
maleic acid, glutaric acid and salicylic acid, respectively. All three were prepared by liquid-assisted 
grinding, using chloroform as the solvent. This appears to be a very robust method. In scaling up 
from very small quantities of ~10 mg to larger quantities of ~10 g, only the duration of grinding and 
amount of solvent were increased appropriately. No other modifications to the preparative method 
were required. Furthermore, the co-crystallisation reaction was successful regardless of the pestle 
and mortar used - a small, smooth pestle and mortar were used for small batches, while large 
batches were prepared with a much bigger, textured pestle and mortar. 
NVPGLT and NVPSLI could be reliably prepared by slow evaporation from a 50:50 v/v 
chloroform:hexane solution. Crystals of NVPMLE were obtained by slow evaporation but the result 
was not reproducible. Using the single crystals obtained, the X-ray crystal structures of all three co-
crystals were determined with residual indices in the range 0.035 < Rl < 0.066 and Goodness of Fit 
parameters of 1.007 < 5 < 1.042, implying excellent correlation between the data and the respective 
models. 
Remarkably, nevirapine recrystallised upon melting of each of the co-crystals. It is a factor that 











commercialised. As in the cases where drugs have inadvertently undergone polymorphic phase 
transitions/ or transformed between anhydrous and hydrated forms, co-crystals of nevirapine may 
potentially revert to a mixture of free nevirapine and the co-former, especially if exposed to high 
temperature. 
The aqueous solubility of the co-crystals was investigated. Two of the co-crystals showed only 
modest solubility increases for nevirapine, a similar result as was observed in a previous study for 
the saccharin and rac-tartaric acid co-crystals of nevirapine.4 NVPMLE, on the other hand showed a 
fivefold drug solubility enhancement as compared with anhydrous nevirapine. 
Interestingly, there are distinct similarities between the NVPSLI co-crystal and a previously reported 
toluene solvate of nevirapine.5 Given that the salicylic acid and toluene molecules are of similar 
shape and size, to distinguish the two crystal forms as belonging to separate categories - one a 
solvate and the other a co-crystal - on the basis of one being a solid at room temperature and the 
other a liquid, seems illogical. As explained in Chapter 1, the definition of a co-crystal for the purpose 
of this dissertation includes the condition that the co-former be a solid at room temperature. 
However, the similarities between the crystal structure of NVPSLI and that of the nevirapine toluene 
solvate lend credence to Bond's assertion that the distinction between co-crystals and solvates is 
"contrived and inappropriate".6 
Efavirenz 
Though the experiments with efavirenz did not yield any co-crystals or cyclodextrin inclusion 
complexes, a known polymorph was prepared by liquid-assisted grinding and a solvate, also 
prepared by liquid-assisted grinding, was discovered. 
Form ~7 of efavirenz was prepared from Form 1 by a simple, 10 min liquid-assisted grinding 
procedure, using ethanol as the solvent. The most recent patent application (2009),8 claiming 
improved methods for the preparation of Form ~, describes the use of solution-based methods 
involving seeding and freeze-drying. Previous descriptions of preparative methods for Form ~ have 
not included any grinding or solvent-assisted grinding procedures. Thus, the method described in 
this thesis represents a novel procedure for converting efavirenz Form 1 to efavirenz Form ~. 
The drug-solvent stoichiometry of the solvate was determined to be 1:0.6 by TG analysis, assuming 
that the included solvent is THF. However, this is only a tentative conclusion because the solvate 
could be prepared only by liquid-assisted grinding and desolvation occurred at low temperature 
(~40 Qq. An accurate determination of stoichiometry would require the solvate to be prepared by a 










to minimise solvent loss. Temperature-controlled PXRD analysis revealed that upon desolvation, the 
solvate reverts to efavirenz Form 1, the phase from which it was prepared. 
Zidovudine 
ZIDPCD, a novel 1:1 zidovudine-~-CD complex was prepared and characterised. Single crystals were 
grown with great difficulty. The slow cooling method had a low degree of reproducibility, with most 
of the experiments resuting in crystals of the pure host. The complex crystallises in the space group 
C2 with unit cell dimensions that place it in the isostructural series 11.1 Its structure was determined 
by isomorphous replacement, using the coordinates of the structure with CSD reference code 
ZUZXOH. As is commonly the case with the C2 channel type structures of ~-CD inclusion complexes, 
the guest was highly disordered and could not be modelled. The crystal structure included 7.2 water 
molecules distributed over 15 positions and this was in reasonable agreement with the value of 8.3 
obtained from TG analysis, given the level of disorder present in the structure. 
The complexation between ~-CD and zidovudine in aqueous solution was investigated by NMR 
spectroscopy. The chemically induced shift values were very low and suggested only weak 
complexation. Job plots gave a host-guest stoichiometry of 1:1 and calculations using the program 
ConstEQ9 yielded an association constant of K = 15 which is very low and confirms that the host-
guest binding interaction in solution is extremely weak. This accounts for the difficulty with which 
crystals ofthe complex were obtained from solution. 
Lamivudine 
The two mUlti-component molecular crystals of lamivudine, LAMGLT and LAMSUC, were prepared 
using glutaric acid and succinic acid respectively. Both could be prepared by dry co-grinding and slow 
evaporation. Single crystals could not be grown, so the extent of ionisation could not be determined 
by single crystal X-ray diffraction analysis. FTIR evidence suggests that LAMGLT may be a salt and 
LAMSUC a co-crystal, but further investigation is required since the IR spectra were not conclusive. 
LAMOXL and LAMMLI, the two additional salts were prepared by slow evaporation and their single 
crystal structures determined. Both salt formers are carboxylic acids and both salts crystallise in the 
space group P21 21 2v as is the case for the previously reported saccharinate and maleate salts.
lO
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However, only LAMOXL shows some similarities in crystal packing when compared with these 
previously reported forms. 
As in the case of ZIDPCD, the LAMPCD single crystals were not easily obtained. The crystals of the 
complex formed only at very high reagent concentrations. The single crystal X-ray structure was 











yielded a host-guest stoichiometry of 1:1.5 but only one guest molecule (that included in the host 
cavity) could be modelled using the single crystal X-ray data. After the host-guest complex was 
modelled, all of the residual electron density difference peaks were treated as water molecules. 
These were modelled as such, using TG analysis as a guide for the number of expected water 
molecules. Nevertheless, an investigation using the program WebLab Viewer12 revealed that the 
space occupied by dubious water molecules is large enough to accommodate a lamivudine molecule, 
which is probably disordered over multiple positions, such that it appears in the Fourier difference 
map as a diffuse scattering of low electron density peaks. 
The LAM~CD structure represents a novel packing arrangement for native ~-CD inclusion complexes. 
It is most similar to the structures of the series containing free hydrated ~-CD, and may be 
considered a variation thereof, with elongation of the c-axis. In comparing with the modified CDs as 
well, the structure of LAM~CD is most similar to the crystal structure of a monosubstituted ~-CD 
with CSD reference code SUYLON13,14 but of course the two cannot be isostructural. The crystal 
packing of LAM~CD is highly dependent on a complex set of at least five host-guest hydrogen 
bonding interactions. The host is significantly distorted from its usually pseudo-heptagonal 
symmetry. In particular, some of the tilt angles t1 and t2 are very large (> 20°) because of the 
intricate host-guest hydrogen bonding. Adjacent complex units pack very closely, with the A2 
residue of one host molecule nearly inserted at the secondary rim of another. 
The lamivudine-~CD complex was analysed in aqueous solution by proton NMR spectroscopy and 
ITe. The Job plots from continuous variation experiments indicate a host-guest stoichiometry of 1:1 
but there are consistent abnormalities in the curves that suggest the interactions in solution are 
much more complicated than conventional guest inclusion. The association constants determined 
from continuous variation and ITC differ, which is not uncommon/5 but both suggest moderate to 
weak binding. From continuous variation, K = 979 and from lTC, K = 511. 
Suggestions for Future Work 
To date, five nevirapine co-crystals have been discovered. Given the 2000+ food additives and 
pharmaceutical excipients16 that may be potential co-formers, as well as the dramatic influence that 
different solvents may have on the success rate of screening experiments, additional screening will 
surely yield more co-crystals. The saccharin and rac-tartaric acid co-crystals of nevirapine were 
shown to have enhanced nevirapine dissolution rates as compared with physical mixtures of the 











The inclusion complex ZIOPCO was not investigated by ITe. While the association constant has 
already been determined by proton NMR spectroscopy, analysis of the system by ITe could provide 
validation of the conclusion that the host-guest binding in solution is extremely weak. 
LAMGLT, LAMSUC, LAMOXL and LAMMLI should also be tested to determine whether these exhibit 
improved lamivudine solubility and dissolution rates. Further analytical investigation of LAMGLT and 
LAMSUC is required to confirm whether these are in fact a salt and a co-crystal respectively. 
Alternatively, other solvents or solvent combinations could be employed in an effort to grow larger 
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